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Large bowel cancer, or colorectal cancer (CRC) is the third most common cause of 
cancer worldwide and the fourth biggest cause of cancer mortality. Twin studies have 
shown that the heritable contribution is ~35%, with ~5% of cases due to rare, high-
penetrance mutations. In the last decade, the use of genome-wide association studies 
on large, well-characterised case-control cohorts of CRC has facilitated the 
identification of over 25 common genetic variants that carry with them an increased 
predisposition to colorectal cancer, invoking the common-disease common variant 
paradigm. As almost all of these variants lie within non-coding regions, the 
underlying causal mechanism is to-date poorly understood for the majority of these 
loci, and it is thought that they mediate risk by influencing gene expression levels.  
To test this hypothesis, an agnostic approach that utilises expression quantitative trait 
loci (eQTL) analysis was first carried on 115 normal colorectal mucosa samples and 
59 peripheral blood mononuclear cells (PBMC). As these heritable variation on gene 
expression are likely to be subtle, there is a strong emphasis on the technical 
methodology to minimise experimentally-induced non-biological variations, 
including the extraction of high-quality RNA from primary tissue, the selection and 
validation of reference genes for normalisation of gene expression quantification, as 
well as internal validation of the samples and data processing. Thereafter, the 
association between the 25 CRC risk variants and the expression of their cis-genes 
were examined systematically, demonstrating that ten of these variants are also 
tissue-specific eQTLs. This intermediate phenotype strongly suggests that they 
confer risk, at least in part, by modifying regulatory mechanisms. One of the best 
eQTL associations (Xp22.2) is investigated in further detail to reveal a novel indel 
polymorphism (Indel24) at the distal promoter region of target gene SHROOM2 that 
influenced both transcript abundance and CRC risk more than the original tagging 
SNP. Functional verification with gene reporter assays indicated that Indel24 
displays differential allelic control over transcriptional activity. Further in silico 
analysis and mutations to the reporter gene constructs provided evidence that Indel24 
modulates transcription by modifying the spacing between CCAAT motifs and the 
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consequent binding affinity of NF-Y transcription factor. siRNA depletion of  NF-Y 
was associated with a reduction in transcriptional activity of the Indel24 gene 
construct as well as endogenous SHROOM2, which is strongly supportive of the 
interaction between Indel24 and NF-Y in the transcriptional activation of 
SHROOM2. Preliminary evidence is suggestive of SHROOM2 being expressed at the 
top of the intestinal epithelial crypt and playing a role in cell cycle regulation. 
Hypothesis-driven approaches can also be of utility in demonstrating functionality of 
CRC risk variants, complementing the hypothesis-free approach of eQTL analysis. 
Guided by a recently discovered gene-environment interaction between the 16q22.1 
risk variant and circulating vitamin D levels, the influence of the rs9929218 SNP on 
CDH1 gene expression was examined, in relation to the expression of putative 
regulatory genes derived from in silico analysis and studies of other target genes. 
Although there was no direct association between rs9929218 and CDH1 expression, 
there were multiple two-way interactions that were together suggestive of rs9929218 
influencing the VDR/FOXO4 regulation of CDH1. This provides functional support 
for the mechanism underlying the epidemiological observation of the gene-
environment interaction between 16q22.1 and vitamin D, and demonstrates a 
candidate-based approach in deciphering the link between genetic locus and CRC 
susceptibility. 
In summary, the research presented in this thesis has validated the experimental 
rationale of utilising expression studies of normal colorectal mucosa to hone in on 
the molecular mechanisms and susceptibility genes underlying the association 









Large bowel cancer is the third most common cause of cancer worldwide and the 
fourth biggest cause of cancer deaths. Large-scale comparative studies of people with 
and without colorectal cancer have shown that there are inherited genetic factors that 
predispose one to the disease. These genetic factors are present at varying 
frequencies in the general population with varying effects on disease risk; rare 
genetic mutations have a big impact on the lifetime chances of developing the 
disease, whereas common normal DNA sequence differences have a smaller 
influence on disease susceptibility.  
Although the risk conferred by these common DNA differences are individually 
modest, collectively they have a significant influence on the risk of developing the 
disease. How these variants lead to the development of large bowel cancer is poorly 
understood, and this study seeks to shed light on the underlying mechanisms. 
Understanding how these heritable factors lead to disease is important as not only 
will it improve our understanding of how cancer develops, it will also inform the 
design of preventative and therapeutic strategies.  
By analysing the cells of the human large bowel and blood, this study demonstrates 
that some of these common genetic differences linked to large bowel cancer do not 
alter the function of genes, but instead influence the levels of gene products that are 
expressed. Further investigation of one of the genetic variants with the strongest 
influence on gene expression identifies the underlying molecular mechanism and the 
gene it influences (known as SHROOM2). The research presented in this thesis also 
presents a framework of investigation into the function of this gene in the large 
bowel, and how differences in its expression could lead to large bowel cancer. 
Finally, this thesis describes the investigation of the molecular mechanism 
underlying the synergistic effect of DNA variation and vitamin D levels on the risk 
of developing large bowel cancer. This is an important aspect to address as it is 
known that large bowel cancer arises from a combination of genetic and 
environmental factors, and a clearer understanding of this complex relationship will 
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     The understanding of the genetic predisposition to colorectal cancer (CRC) has 
progressed in the last decade with the advent of genom -wide association studies 
(GWAS). At least twenty-five common genetic variants have been established to be 
associated with CRC risk, invoking the common disease-common variant paradigm 
(Reich et al, 2001). However, the functional mechanisms by which they influence 
risk are not well-understood. Therefore, the investigation into these mechanisms has 
considerable relevance to understanding the aetiopath genesis of this complex 
disease, which may ultimately lead to the discovery of novel therapeutic and 
preventative targets. The research presented in this thesis has systematically 
investigated whether these risk loci are associated with the baseline expression of 
nearby genes in tissue types relevant to colorectal cancer.  Significant associations 
are prioritised and followed-up with functional assy  to elucidate the causal 
molecular mechanisms. 
     The importance of delineating the molecular mechanisms that underlie CRC is 
underscored by the fact that colorectal cancer is a major health problem globally. In 
this introductory chapter, the incidence and burden of CRC is firstly discussed. The 
molecular events giving rise to CRC and its cell of origin are considered as these are 
pertinent issues that will influence the study design and the interpretation of various 
aspects of the gene expression analysis. A review of the risk factors associated with 
CRC is presented, including dietary/lifestyle factors, inflammation, the microbiome 
and genetic predisposition. This ranges from rare fmilial cancer syndromes to low-
penetrance common susceptibility alleles, which form the impetus for this research. 
Though limited, the current understanding of the causal variants and mechanisms is 
described. As all of these risk loci reside within non-coding regions, it is thought that 
they confer risk by subtly influencing the regulation of gene expression and may also 
act as expression quantitative trait loci (eQTL). The use of eQTL analysis in complex 
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disease traits and the functional annotation of CRC risk loci is therefore discussed. 
Finally, the aims of the project are presented and the experimental approaches are 
described.  
1.2 Colorectal cancer: epidemiology and pathogenesi s 
1.2.1 Incidence and burden  
     Large bowel cancer, or colorectal cancer (CRC) is the third most common cause 
of cancer worldwide and the fourth biggest cause of cancer mortality, with nearly 1.4 
million new cases diagnosed in 2012 (World Cancer Rsearch Fund International; 
URL1.1). It is more common in the developed world, where the incidence is over 
two and a half times higher in developed countries compared to less developed ones. 
In the United Kingdom, there were on average 22,517 newly diagnosed cases of 
CRC per year in men, and 17,846 new cases in women duri g 2008-2010 (Office for 
National Statistics; URL1.2). It is estimated that 1 in 14 men and 1 in 19 women will 
develop CRC at some point in their lives (Cancer Research UK; URL1.3). In the 
United States, there has been a steady decline in th  i cidence of CRC in patients age 
50 years or older during 1975-2010, but the opposite has been observed for young 
adults aged 20 to 49 years (Bailey et al, 2015).  
Age-standardised rates suggest that bowel cancer is more common in 
industrialised countries with westernised societies. Global data from 2008 indicates 
that the WHO European region had the highest incidee of colorectal cancer 
followed by the WHO Americas region, whereas WHO African region had the 
lowest incidence. According to the World Bank income groups for countries, high 
income countries had considerably higher CRC incidence rates than any other 
income group, with nearly five times higher than the rate in low income countries 
(World Health Organisation; URL1.4). However, it should be noted that this 
manifestation of colorectal cancer burden may partly reflect longer life expectancy in 
developed populations, as well as better diagnostic and recording tools. 
     With earlier detection and improvements in treatment strategies, CRC mortality 
rates have decreased overall in the UK since the early 1970s. However, although it is 
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a treatable disease with bowel surgery and adjuvant chemo-radiotherapy, the 
prognosis of CRC is still relatively poor. In 2012, there were 16,187 deaths from 
bowel cancer in the UK, of which 54% were men and 46% were women. (Cancer 
Research UK; URL1.5). Several factors are associated with higher risk of death, such 
as age, socio-economic deprivation, and most importantly, the stage of the cancer at 
diagnosis. In men, the five-year survival rate of 95% in stage I CRC falls 
dramatically to 7% in stage IV CRC. In women, five-year survival ranges from 100% 
at stage I to 8% at stage IV. There is compelling evidence that early detection and 
prevention by removal of premalignant polyps can reduc  mortality, as indicated by 
randomised trials of population screening (Towler et al, 2007) and intensive 
surveillance of genetically defined high-risk groups (Jarvinen et al, 2000). An 
understanding of the disease aetiology and risk factors will not only allow risk 
modifications and preventative therapies, but also have an impact on targeted 
screening and treatment strategies. 
 
1.2.2 Molecular genetics of colorectal cancer 
     Historically, CRC classification has been based only on clinical and pathological 
features. There is growing evidence that over the past decade that CRC is a 
heterogenous complex of diseases, where the molecular and genetic features of the 
tumour can determine prognosis and the response to therapeutic agents, in particular 
targeted therapy.  
     The sequence from the pre-malignant adenoma to c rcinoma is well understood 
on a clinical level, and Vogelstein first described in his multistep genetic model that 
the accumulation of multiple mutations leads to the selective growth advantage that 
underlies tumourigenesis (Fearon and Vogelstein, 1990). In this model, the early loss 
or mutation of APC serve as the initiating event in adenoma formation, with at least 
seven distinct mutations required for carcinogenesis. Since then, genome-wide 
sequencing of CRC have calculated about 80 mutated genes per tumour, with less 
than 15 mutations considered to be true drivers (Wood et al, 2007). More recently, 
the alternative route of colon cancer carcinogenesis via serrated polyps have been 
described to account for 30% of CRC, where activating mutations of the mitogen-
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activated protein kinase pathway components BRAF or KRAS play a prominent role 
in this pathway (as reviewed in Bettington et al, 2013). Although the precise 
molecular events that lead to the development of CRC and its phenotypic changes are 
still not fully understood, there is now clear evidence for the presence of different 
subtypes of CRC.  
     There are at least three distinct molecular pathw ys that have been recognised to 
give rise to CRC. The chromosomal instability (CIN) pathway is defined by the 
accumulation of numerical (aneuploidy) or structural chromosomal abnormalities 
that result in karyotypic variability. It is the most common manifestation of genomic 
instability in CRC, occurring in approximately 70% of colorectal tumours (Lengauer 
et al, 1997), and is characterised by chromosomal rearrangements and loss-of-
heterozygosity (LOH) at tumour suppressor gene loci. CIN tumours can also be 
discerned by the accumulation of mutations in specific oncogenes such as APC, 
KRAS, PIK3CA, BRAF, etc and tumour suppressor genes, but whether CIN creates 
the appropriate environment for the accumulation of these mutations or vice versa 
remains unclear (Pino et al, 2010).  
     The microsatellite instability (MSI) pathway is the other important pathway 
leading to genomic instability in CRC. It is characterised by genetic hypermutability 
caused by the dysfunction of DNA mismatch repair (MMR) genes. Deficiency in 
DNA repair gives rise to the accumulation of abnormalities in microsatellites, which 
are nucleotide repeat sequences of 1-6 base pairs th t are prone to mutations due to 
the inability of DNA polymerases to bind these sequence motifs efficiently. As a 
result of insertions or deletions in coding regions, frameshift mutations occur with 
subsequent deleterious protein truncations. The DNA MMR system is inactivated 
either by germline mutations in MMR genes (as seen in the familial syndrome Lynch 
Syndrome), or epigenetically by gene promoter hypermethylation and silencing of 
MLH1 in sporadic CRC (Herman et al, 1998; Veigel et al, 1998). More recently, the 
Cancer Genome Atlas Project (TCGA) demonstrated by whole-genome sequencing 
that a quarter of hypermutated tumours had somatic mismatch-repair gene and 
polymerase ε (POLE) mutations (Muzny et al, 2012). 
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     Microsatellite instability in sporadic CRC tha is related to hypermethylation and 
MLH1 silencing is dependent on the third molecular pathw y which is characterised 
by epigenetic instability as evident by the presence of widespread CpG island 
methylation (Toyota et al, 1999). The CpG Island Methylation Phenotype (CIMP) is 
associated with distinct genetic profiles, where CIMP1 is characterised by higher 
rates of MSI and BRAF mutations (Weisenberger et al, 2006; Shen et al, 2007), 
CIMP2 is associated with KRAS mutations, and CIMP-negative cases are enriched 
with TP53 mutations (Shen et al, 2007; Hinoue et al, 2012).  
     CRC subtyping has also been addressed using gene-expression profiling in large 
patient cohorts, where molecular expression subtypes have not only been associated 
with different molecular pathways and cellular phenotypes, but also with prognosis 
and treatment responses (Salazar et al, 2011; De Sousa et al, 2013; Sadanandam et
al, 2013).  
 
1.2.3 Cell of origin of colorectal cancer 
     The epithelial layer of the human large intestine consists of a single sheet of 
columnar epithelial cells, which form crypt-like invaginations into the lamina propria 
connective tissue to form the functional units of the colon. The four major terminally 
differentiated epithelial cell types in the colonic crypt are known as the enterocytes 
(absorptive cells), the goblet cells (mucus-secreting), the enteroendocrine cells 
(peptide hormone-secreting), and the recently charaterised tuft cells (opioid and 
prostaglandin-secreting) (Gerbe t al, 2013) (Figure 1.1). The organisation, 
architecture, differentiation and homeostasis of the crypt component cells are pivotal 
to the normal functioning of the colonic epithelium, and are thought to be maintained 
by the gene expression gradients of key signalling molecules along the vertical crypt 
axis, mediated by autocrine and paracrine pathways that arise from epithelial-
mesenchymal interactions (Figure 1.2). The key signalling pathways implicated are 
those of Wnt (Korinek et al, 1998; Pinto et al, 2003; Sansom et al, 2004), 
EphB/Ephrin B (Batlle et al, 2002), Notch (Jensen et al, 2000; van Es et al, 2005),  







Figure 1.1 In the colon (scanning electron micrograph in top panel), LGR5+ stem cells at the 
crypt base generate rapidly proliferating TA (transit-amplifying) cells in the lower half of the 
crypt (bottom left panel). TA cells subsequently differentiate into the mature lineages of the 
surface epithelium (enterocytes, goblet cells, enteroendocrine cells and tuft cells), as shown 
in the lineage tree (bottom right panel). Epithelial turnover occurs every 5–7 days. Adapted 





Figure 1.2 Signalling pathways that are involved in the regulation of homeostasis and 
determination of cell fate that are coupled to position along the vertical crypt axis of the 
epithelium. ISEMF, intestinal subepithelial myofibroblast; SMC, smooth muscle cell. 











     There is a high rate of cell death and rapid turnover due to persistent abrasion 
from the luminal contents, which imposes a requirement for daily self-renewal driven 
by small populations of adult stem cells. The evidence points towards a stem-cell 
population that resides at the base of the crypt within the stem-cell niche, formed by 
the stem cells themselves and surrounding mesenchymal cells, the intestinal 
subepithelial myofibroblasts. Crucially, lineage-tracing experiments in mice using 
inducible stem-cell markers have confirmed monoclonal conversion and 
multipotentiality in the intestinal crypts, where the stem cell marker LGR5+ crypt 
base columnar cells was shown to generate all epithelial lineages over a 60-day 
period (Barker et al, 2007). CD24+ and KIT+ goblet cells that are in close proximity 
to LGR5+ stem cells at the crypt base have been identified as probable niche 
components (Rothernberg et al, 2012), but the major source of Wnt in the colon has
yet to be identified.  
     Although genetic/epigenetic lesions are widely accepted to have a major role in 
determining tumour phenotype, it is also thought that cancers of distinct subtypes 
may derive from different ‘cells of origin’ leading to inter- and intra-tumoural 
heterogeneity (Visvader, 2011). In studies of colorectal cancer, there is accumulating 
evidence that supports a bottom-up theory of cancer origin, as the ability of stem 
cells to indefinitely self-renew while generating new functional epithelia makes them 
prime candidates for accumulating sequential genetic or epigenetic mutations that 
promote oncogenesis. Two distinct crypt stem cells have been identified as the cells 
of origin of intestinal cancers using an in-vivo targeting approach in mouse models 
that involves lineage tracing of cells as they undergo transformation. APC deletion in 
long-lived LGR5+ stem cells but not in short-lived transit-amplifying cells revealed 
that intestinal cancer in mice originates from crypt stem cells (Barker et al, 2009). 
This target cell is also marked by PROM1 (Zhu et al, 2009). A BMI1+ stem cell 
located in the +4 or +5 position from the base of the crypt and therefore distinct from 
the LGR5+ stem cell was also shown to be susceptible to tumourigenesis by 
deregulated Wnt signalling.  
     In contrast, the top-down hypothesis of intestinal cancer postulates that any cell in 
the normal cellular hierarchy with proliferative capacity could also serve as a cell of 
origin of cancer, if it acquires mutations that re-instigate self-renewal capacity and 
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prevent differentiation to a post-mitotic state. Supporting this paradigm are several 
recent transgenic mouse model studies that implicate distinct mechanisms involving 
non-stem cells. Schwitalla et al demonstrated that the combination of β-catenin 
activation and NF-κB signaling can convert LGR5– cells into LGR5+ stem cells that 
give rise to intestinal neoplasms, exemplifying the concept of cell-type plasticity and 
bidirectional conversion that results in the dedifferentiation of non-stem cells, 
allowing them to act as tumour progenitors (Schwitalla et al, 2013). Consistent with 
this study, a lineage-tracing study of tuft cells demonstrated relative quiescence and 
longevity of a small number of DCLK1+ cells, which converted into potent cancer-
initiating cells when subjected to a combination of APC loss and an inflammatory 
stimulus (Westphalen et al; 2014). Non-inflammatory processes have also been 
implicated; a recent mouse model of hereditary mixed polyposis syndrome (HMPS) 
showed that the aberrant epithelial expression of GREM1 can promote the 
persistence and/or reacquisition of stem cell and tumour-initiating properties in 
LGR5– progenitor cells that have exited the stem cell niche by disrupting homeostatic 
intestinal morphogen gradients (Davis et al, 2015). In all likelihood, the cellular and 
molecular mechanisms underlying both hypotheses are not mutually exclusive and 
most probably act together as well as interact withextrinsic mechanisms such as the 
stromal micro-environment to determine tumour histopa hology and behaviour. 
1.3 Colorectal cancer: risk factors 
     Colorectal cancer typically develops over many years, with a multifactorial 
aetiology that involves environmental factors, genetic susceptibility and their 
interactions. It occurs more frequently in the distal large bowel (descending colon 
and rectum) compared to the more proximal regions of the large intestine (Rabaneck 
et al, 2003), which might reflect differences in the luminal environment and inherent 
cellular variation between these gut compartments. The risk factors that increases 
ones susceptibility to the disease have been extensively reviewed elsewhere (Raskov 
et al, 2014; Tenesa et al, 2009; Terzić et al, 2010; Louis et al, 2014) but the main 




1.3.1 Dietary and lifestyle risk factors  
     The higher incidence of CRC in developed countries is suggestive of a 
contribution from environmental factors, broadly defin d to include a wide range of 
cultural, lifestyle and dietary practices. This is evident from early studies of migrants 
from low to high incidence countries, who attain cancer incidence rates similar to 
those of their adopted country within a single generation (as reviewed by Boyle et al, 
2000). Supporting this further are the rapidly increasing incidence rates in developed 
and westernised Asian countries with previously low rates, possibly reflecting 
lifestyle changes as well as gene-environment interac ions (as reviewed in Sung et al, 
2005). 
     Although there is little doubt that diet contributes to the development of CRC, 
studies that accurately examine the relationship between a specific food item and 
cancer are difficult to design, not least because the dietary assessment methods are 
inherently subjected to recall bias. Nevertheless, there are several dietary elements 
that have been shown to be linked to CRC.  
     A high intake of dietary fibre, in particular cereal fibre and whole grains, has been 
associated with a reduced risk of colorectal cancer (Aune et al, 2011). The partial or 
total fermentation of fibre in the colon leads to the production of short chain fatty 
acids such as butyrate, and it is thought that these play a pivotal role in maintaining 
normal colonic function and preventing disease by reducing the intraluminal pH, 
decreasing the conversion of bile acids to secondary bile acids (Birkett et al, 1996), 
and more importantly, exerting anti-proliferative pro erties and tumour-suppressive 
effects (Leonel et al, 2012; Fung et al, 2013). Dietary fibres also have the effect of 
diluting stool contents, bulking and increasing thefrequency of bowel movements, 
reducing the concentration and contact time of carcinogens (Anderson et al, 2009).   
     Numerous prospective studies have linked meat consumption, in particular red 
meat and processed meat, to a higher risk of CRC (Larsson et al, 2006; Chan et al, 
2011). A dose-response meta-analysis of epidemiological studies suggest that there 
was a 24% increase in CRC risk for an increase of 120g/day of red meat and a 36% 
increase in risk for 30g/day of processed meat (Norat et al, 2002). It is postulated that 
the haem iron in red meat has a catalytic effect on he endogenous formation of 
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carcinogenic N-nitroso compounds and the formation of cytotoxic and genotoxic 
aldehydes (Bastide t al, 2011). The nitrites found in processed meat are also
converted to N-nitroso compounds in the bowel.  
     Early epidemiological observations showed thate incidence and death rates of 
CRC were lower among individuals living in southern latitudes with relatively higher 
sunlight exposure, than among those living at northern latitudes (Garland et al, 
1980). Because exposure to ultraviolet-B sunlight leads to the production of vitamin 
D, it was hypothesised that the variation in vitamin D levels might account for this 
association. This hypothesis have since been tested in various ways, including 
association studies with annual solar radiation levels (Mizoue et al, 2004), 
seasonality (Robsahm et al, 2004), dietary vitamin D intake (Grant e al, 2004; 
Giovannucci et al, 2005; Touvier et al, 2011), pre-diagnostic circulating vitamin D 
levels (Garland et al, 1989; Tangrea et al, 1997; Feskanich et al, 2004), genetic 
polymorphisms in the vitamin D receptor (Wong et al, 2003; Park et al, 2005, 
Touvier et al, 2011), and a composite score of multiple vitamin D predictors 
including skin pigmentation, region of residence, dietary intake, body mass index 
and physical activity (Giovannucci et al, 2005). Although establishing a causal 
relationship between CRC incidence and vitamin D is challenging because 
environmental risk factors associated with CRC may also be associated with vitamin 
D deficiency (e.g. co-causality with physical activity), all the epidemiological 
findings point towards hypovitaminosis D as a risk factor for developing CRC, with 
biological data to suggest that the vitamin D pathwy activation induces cellular 
differentiation and inhibits proliferation, invasiveness, angiogenesis and metastatic 
potential (as reviewed by Peterlik et al, 2004).  
     There is also some evidence of an association between total energy intake and the 
risk of developing CRC. However, this is relationship is likely to be indirect and may 
be dependent on other factors, such as physical activity (as reviewed by Wiseman, 
2008). Exercise appears to have a dose-response reduction in the rate of CRC, and it 
is postulated that the increase in insulin-like growth factor-binding protein and the 
reduction of prostaglandins may be the mechanism by which exercise provides this 
protective effect. Other non-dietary factors have also been associated with increasing 
the risk of CRC. Tobacco smoking doubles the risk of colorectal adenomas (Botteri 
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et al, 2008), and other cohort studies have found that alcohol intake increases the risk 
of CRC (Moskal et al, 2007).  
1.3.2 Inflammation 
     Inflammatory bowel disease is a major risk factor for developing colorectal 
cancer. Over 20% of patients with inflammatory bowel disease develop colitis-
associated cancer (CAC) within 30 years of disease on t, a subtype of CRC that is 
associated with a high mortality of >50% (Lakatos et al, 2008). Although CAC is 
thought of as a distinct subtype of colorectal cancer, there are similarities between 
CAC and other types of CRC that develop without anysigns of overt inflammatory 
disease. The essential stages of cancer development such as aberrant crypt foci, 
polyps, adenomas and carcinomas, as well as common genetic and signalling 
pathways such as those involving Wnt, β-catenin, KRAS, p53, TGF-β, and DNA 
mismatch repair, are similar between CAC and sporadic CRC (as reviewed by Terzić 
et al, 2010). Furthermore, sporadic CRC display inflammatory infiltration and 
increased pro-inflammatory cytokine expression (Clevers, 2004; Atreya et al, 2008). 
There is evidence from numerous observational studies that non-steroidal anti-
inflammatory drugs such as sulindac, celecoxib and aspirin may have 
chemopreventative effects, and it is thought that tese compounds mediate risk 
reduction by modulating cyclooxygenase (COX) enzymatic ctivity and the nuclear 
factor-κB (NK-κB) pathway (Yamamoto et al, 1999; Larsson et al, 2006, Flossmann 
et al, 2007; Chan et al, 2007; Arber et al, 2006, Meyskens et al, 2008; Half et al, 
2009). Of these agents, the evidence for aspirin is mo t convincing, with a large 
randomised controlled trial showing a risk reduction n high-risk individuals taking 
low-dose aspirin (Burn et al, 2011). 
1.3.3 The microbiome 
     There is emerging interest in the role of the microbiota in the initiation and 
progression of CRC. Microbiome changes that have been r ported to be observed in 
CRC patients include S. bovis (as reviewed in Burnett-Hartman et al, 2008), 
Streptococcus spp. (Wang et al, 2012), Escherichia coli (Bonnet et al, 2014), 
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Fusobacterium nucleatum (Castellarin et al, 2012; Kostic et al, 2012), Clostridium 
(Scanlan et al, 2008), Bacteroides (Wang et al, 2012) and various butyrate- 
producing bacteria (Balamurugan et al, 2008; Wang et al, 2012). Apart from these 
observed associations, experimental animal studies support a direct influence of the 
gut microbiota on tumour formation (Dove et al, 1997; Arthur et al, 2012) that is 
inter-dependent with the host inflammatory response (Arthur et al, 2014; Boleji et al, 
2010).  
     Bacterial metabolism in the colon is fermentative and also utilises anaerobic 
respiration. As alluded to in the previous section, undigested dietary components and 
endogenous products are fermented by the anaerobic microbial community to 
produce an extraordinarily wide range of metabolites. The major fermentation 
products are organic acids, in particular the short-chain fatty acids (SCFA) acetate, 
propionate and butyrates. Aside from providing an energy source to gut epithelial 
cells, SCFA have been shown to regulate colonic regulatory T-cells (Smith et al, 
2013), downregulate pro-inflammatory cytokines in colonic macrophages by 
inhibiting the activity of histone deacetylases (Chang et al, 2014), selectively induce 
apoptosis of CRC cells (Buda et al, 2003; Clarke et al, 2008), and maintain intestinal 
homeostasis. Prominent butyrate-producing species indicates healthy, diverse 
microbiota, and maintains favourable conditions fora stable and healthy gut 
community. By contrast, dysbiosis is characterized by a reduction in microbial 
diversity and an increase in pro-inflammatory, pathogenic species, which can be 
caused by a poor diet, antimicrobial therapy or genetic predisposition.  
     The microbial communities that inhabit our gastrointestinal tract are tractable 
environmental factors that we are exposed to continuously, and it has become 
increasingly clear that the collective activities of the resident gut microbiota and their 
metabolic products plays a role in the development of CRC (as reviewed by Schwabe 
et al, 2013; Louis et al, 2014). Hence, it is likely that there is a multifaceted 
relationship between diet and microbial metabolism that promotes CRC via pro-





1.3.4 Genetic heritability  
     It has long been known that inherited susceptibility plays an important role in the 
predisposition to CRC. The earliest evidence for this came from epidemiological 
studies in the fifties that showed a 2-3 fold increase in risk in first degree relatives of 
CRC patients (Johns et al, 2001). Analysis of phenotype concordance in twins 
estimates the heritability of colorectal cancer on the liability scale to be around 0.35 
(Lichtenstein et al, 2000). Until recently, our understanding of the hreditary 
component was based on rare, high-penetrance mutations in a few genes, such as 
APC, mismatch repair (MMR) genes, SMAD4, and MUTYH. Despite the large effects 
of these rare variants, their low allele frequency means their overall contribution to 
disease burden is small (Foulkes et al, 2008). Statistical modelling of the pattern of 
familial occurrence of colorectal cancer after exclusion of known high-risk genes 
suggest that the remaining genetic heritability is likely to be polygenic with the co-
inheritance of multiple genetic variants, each with a modest individual effect, causing 
a wide range of risk in the population (Figure 1.3). Rare, moderately-penetrant risk 
alleles (MAF<2%; relative risks>2.0) and common, low-penetrance alleles 
(MAF>10%; OR<1.5) are likely to occur as a continuum, and extensive efforts are 
underway to comprehensively identify these susceptibility variants. 
 
Figure 1.3. Polygenic model of disease susceptibility. Cases have a shift towards a higher 
number of high risk alleles. Adapted from Whiffin et al, 2014.  
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1.3.4.1 Very rare, high-penetrance familial colorec tal cancer 
syndromes 
     Hereditary CRC, where a clear genetic basis for the disease has been defined, 
accounts for 4-6% of colon cancer incidence (Rustgi, 2007). Family-based genetic 
linkage and positional cloning studies have led to the identification of numerous 
CRC susceptibility genes (Table 1.1). The two major Mendelian cancer syndromes 
that account for the vast majority of hereditary CRC cases include Familial 
Adenomatous Polyposis (FAP) and Lynch Syndrome.   
 
 





APC FAP 90% by age 45 Dominant 
Mismatch repair 
genes 






SMAD4/BMPR1A Juvenile Polyposis 
syndrome 
17%–68% by age 
60 
Dominant 
STK11 Peutz-Jeghers syndrome 39% by age 70 Dominant 
PTEN Cowden syndrome 15% lifetime risk Dominant 
POLD1/POLE Oligopolyposis  Dominant 
Table 1.1 Familial CRC syndromes and the associated high-penetrance gene mutations. 
Adapted from Whiffin et al, 2014.  
 
 
     Familial adenomatous polyposis (FAP) is characterized by the development of 
hundreds to thousands of benign adenomatous polyps that carpet the colon and 
rectum of affected individuals. These polyps usually ppear during the second or 
third decade of life. If the colon is not removed, cancer will inevitably develop in all 
FAP patients, with an average age of colon cancer development of 39 years (Wills et
al, 2002). It is inherited as an autosomal dominant disease, with a population 
16 
 
incidence of approximately 1 in 8000 (Bisgaard et al, 1994). Germline mutations of 
the APC gene on chromosome 5q21 is responsible for over 95% of affected families. 
APC mutations achieve near 100% penetrance, although there is marked variation in 
phenotypic expression of the disease. Extracolonic tumours also occur and include 
small bowel, gastric and periampullary tumours, adrenal adenomas and carcinomas, 
and thyroid carcinomas. Other associated lesions include desmoid tumours and 
congenital hypertrophy of the retinal pigment epithel um (CHRPE) (Lynch et al, 
1998). 
     The gene product of the intact APC gene functions as a tumour suppressor. It is a 
negative regulator in the Wnt signalling pathway (Goss et al, 2000), where it binds to 
and phosphorylates soluble beta-catenin leading to its cytosolic degradation. In FAP, 
the loss of functioning APC protein leads to the unregulated translocation and 
accumulation of beta-catenin in the cell nucleus, where it interacts with TCF/LEF 
transcription factors to constitutively activate th transcription of many gene targets 
including MYC, CCND1, CD44 and BMP4 (Tetsu et al, 1999; He et al, 1998; van de 
Wetering et al, 2002). The loss of wild-type APC may also affect tumourigenesis via 
other mechanisms such as the regulation of cell migration (Kawasaki et al, 2003; 
Sansom et al, 2004) and the organisation of the actin cytoskeletal network (Watanabe 
et al, 2004).  
     Lynch Syndrome is an autosomal dominant disorder and is the most common 
familial CRC syndrome, accounting for 2% - 3% of all CRC cases (Lynch et al, 
2000). Without a distinct polyposis phenotype, a detailed family history becomes 
critical in the detection of Lynch Syndrome families. Lynch Syndrome tumours tend 
to display an earlier onset than sporadic colon cancers and are more likely to occur in 
the proximal colon (Lynch et al, 2009). Apart from CRC, Lynch Syndrome families 
also see a predisposition for extra-colonic cancers, most notably endometrial cancers, 
as well as cancers of the ovary, small intestine, stomach, hepatobiliary tract, urinary 
tract and brain. Germline mutations in one of the MMR genes are responsible for this 
susceptibility disorder, and confers a lifetime risk of CRC and endometrial cancer of 
60-80% and 40-60% respectively (Meyer t al, 2009). The penetrance has been 
observed to be significantly greater in males than females (74% vs 30%) but the risk 
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of endometrial cancer exceeded that for CRC in femal s (42%) (Dunlop et al, 1997), 
suggesting that there are gender-specific modifiers of isk. 
     There has been a total of seven genes identified as members of the MMR family, 
with the majority of Lynch Syndrome families having mutations in either MSH2 or 
MLH1 (Liu et al, 1996; Mitchell et al, 2002). Mutations of MSH6 have been 
identified in a small minority of cases (Kolodner et al, 1999), while rare mutations in 
PMS1 and PMS2 have been reported (Nicolaides t al, 1994; Worthley et al, 2005). 
Lynch Syndrome is usually caused by the inheritance of one mutant MMR allele and 
loss of heterozygosity at the remaining wild-type allele. This leads to a mutator 
phenotype where cells accumulate further mutations at an amplified rate, increasing 
the probability of mutations in other proto-oncogenes and tumour suppressors. The 
mutator phenotype manifests as a specific genomic instability event at small repeated 
sequences in DNA called microsatellite instability (Liu et al, 1996), as the MMR 
system is less effective in correcting the slippage error of DNA polymerase at highly 
repetitive regions of DNA. There are also other non-repair functions of the MMR 
pathway that may contribute to tumourigenesis, such as the activation of cell cycle 
checkpoints and apoptosis in response to DNA-damaging agents and the 
maintenance of homologous recombination fidelity (as reviewed by Heinen, 2011). 
Evidence from studies of mouse models suggest that although the development of a 
mutator phenotype is sufficient to drive tumourigenesis, the ability of MMR-
defective cells to survive under conditions of increased damage may accelerate the 
process (Lin et al, 2004; Yang et al; 2004).  
     In the last decade, families with an attenuated FAP-like phenotype that do not 
appear to carry any germline mutation in APC have been described. Over 25% of 
these patients carried germline biallelic mutations in the base-excision repair gene 
MUTYH (Al-Tassan et al, 2002; Jones et al, 2002; Sieber et al, 2003; Farrington et 
al; 2005), and this form of recessive hereditary cancer has been termed MUTYH-
associated polyposis (MAP). More recently, specific germline exonuclease domain 
mutations in polymerase proofreading genes POLD1 and POLE have also been 
identified to be causative for the development of multiple colorectal adenomas and 
CRC (Palles et al, 2013). Collectively, the MMR defects of Lynch Syndrome, base 
excision repair defects that cause MAP, and the mutations in proofreading genes 
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emphasise the critical role of replication errors and coupled repair of base pair-level 
mutations in the predisposition to CRC.  
     Rarer mutations in other genes associated with hereditary CRC include those in 
STK11 (Peutz-Jeghers syndrome), PTEN (Cowden’s disease) and BMPR1A/SMAD4 
(Juvenile Polyposis) (Ngeow et al, 2013), where CRC risk is mediated through the 
development of hamartomas or mixed polyps. In comparison to the gatekeeper 
function of the APC gene and the caretaker roles of the mismatch repair and MUTYH 
genes, these genes are believed to create an epithelial milieu at risk for neoplastic 
development and have been dubbed ‘landscaper’ genes (Kinzler et al, 1998), 
highlighting the various signalling pathways that contributes to the formation of 
cancer.  
1.3.4.2 Rare, moderately-penetrant risk variants 
     Candidate gene resequencing studies in affected families have been the mainstay 
of the methodologies used to identify this subgroup of risk variants. As these 
approaches relied on a priori knowledge, their success has been hampered by our 
limited knowledge of tumour biology. Rare successes of this approach include the 
discovery of the missense variant (APC I1307K) thatis present in ~6% of Ashkenazi 
Jews (Laken et al, 1997). The APC I1307K T>A variant creates a small 
hypermutable region that appears to increase replication errors in APC, increasing 
the risk of CRC by approximately two-fold.  
     With the advent of large-scale exome sequencing studies in recent years, exome 
arrays have been specifically designed to allow exome-wide systematic interrogation 
of coding variants with putative detrimental functional consequences. In a large 
unrelated case-control study, four novel coding variants were identified to be 
associated with CRC risk (Timofeeva et al, submitted). However, the minor alleles of 
these variants are common (MAF 0.09-0.50) with modest effect sizes (OR 1.08-
1.15). No rare alleles (MAF<0.05) of moderate effect were identified, despite 
adequate power to detect such effect sizes. This is contrary to the expectation that 
coding sequence variants with putative deleterious effects might have a more 
profound impact on risk. This suggests that rare genetic variation of moderate 
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penetrance are likely to segregate in families, and that exome and genome 
sequencing of trios and families may be a better strategy to identify these variants. 
1.3.4.3 Common genetic risk variants 
     A substantial proportion of the remaining heritable risk is likely to be accounted 
for by numerous low-penetrance genetic variants, each with a relatively high 
frequency in the population, as described in the “common disease-common variant” 
hypothesis. This model posits that if a heritable dis ase is common in the population, 
then the genetic contributors will also be common in the population. However, even 
though the contribution of an individual variant to the overall inherited susceptibility 
of a disease may be relatively large, the penetrance of these variants will be very 
small, which would explain why these variants rarely cause multiple cases in families 
and hence are not detectable through genetic linkage studies. 
Until mid-2007, no common variants contributing to the heritability of colorectal 
cancer risk had been successfully identified and consistently replicated. In the last 
decade, genome-wide association studies (GWAS) haveprovided a new conceptual 
framework in the search for the genetic basis of CRC. By exploiting the non-random 
coinheritance of genetic variants (linkage disequilibrium [LD]), these studies utilise 
single nucleotide polymorphism (SNP) “tags” for haplotypes to representatively 
assay the entire genome. As the genome is screened without any prior hypothesis for 
specific regions, genes, or variants thereof, GWAS are regarded as “agnostic” or 
hypothesis-generating, rather than hypothesis-driven. The last decade has seen the 
assembly of large well-characterised case-control serie  with sufficient power to 
account for the large number of statistical tests performed and detect small effect 
sizes. Facilitated by technological advances and cost-reduction in high-density 
reproducible genotyping platforms, over twenty common low-penetrance variants 
have since been identified to be associated with CRC, all of which have been 







tagSNP Locus SNP position MAF 
Effect size: 
OR (95% CI) 
Reference 
rs10911251 1q25.3 chr1:183081194 0.39 1.09 (1.06-1.13) Peters et al, 2013 
rs6687758 1q41 chr1:222164948 0.22 1.09 (1.06–1.12) Houlston et al, 2010 
rs6691170 1q41 chr1:222045446 0.26 1.06 (1.03-1.09) Houlston et al, 2010 
rs10936599 3q26.2 chr3:169492101 0.30 0.93 (0.91–0.96) Houlston et al, 2010 
rs1321311 6p21.2 chr6:36622900 0.25 1.10 (1.07-1.13) Dunlop et al, 2012 
rs16892766 8q23.3 chr8:117630683 0.07 1.27 (1.20-1.34)* Tomlinson et al, 2008 
rs6983267 8q24.21 chr8:128413305 0.49 1.17 (1.12-1.23)* 
Zanke et al, 2007; 
Tomlinson et al, 2007 
rs1035209 10q24.2 chr10:101345366 0.14 1.12 (1.08-1.16) Whiffin et al, 2014 
rs10795668 10p14 chr10:8701219 0.33 0.87 (0.83-0.91)* Tomlinson et al, 2008 
rs3802842 11q23.1 chr11:111171709 0.29 1.11 (1.08-1.15) Tenesa et al, 2008 
rs3824999 11q13.4 chr11:74345550 0.38 1.08 (1.05-1.10) Dunlop et al, 2012 
rs3217810 12p13.32 chr12:4388271 0.06 1.20 (1.12-1.28) Peters et al, 2013 
rs11169552 12q13.13 chr12:51155663 0.24 0.92 (0.90–0.95) Houlston et al, 2010 
rs7136702 12q13.13 chr12:50880216 0.46 1.06 (1.04–1.08) Houlston et al, 2010 
rs1957636 14q22.2 chr14:54560018 0.43 1.08 (1.06-1.11) Tomlinson et al, 2011 
rs4444235 14q22.2 chr14:54410919 0.46 1.11 (1.08-1.15) Houlston et al, 2008 
rs11632715 15q13.3 chr15:33004247 0.47 1.12 (1.08-1.16) Tomlinson et al, 2011 
rs16969681 15q13.3 chr15:32993111 0.18 1.18 (1.11-1.25) Tomlinson et al, 2011 
rs9929218 16q22.1 chr16:68820946 0.29 0.90 (0.87-0.94) Houlston et al, 2008 
rs4939827 18q21.1 chr18:46453463 0.48 0.86 (0.79–0.92) Broderick et al, 2007 
rs10411210 19q13.11 chr19:33532300 0.10 0.83 (0.78-0.88) Houlston et al, 2008 
rs4813802 20p12.3 chr20:6699595 0.25 1.09 (1.06-1.12) Tomlinson et al, 2011 
rs4925386 20q13.33 chr20:60921044 0.41 0.93 (0.91–0.95) Houlston et al, 2010 
rs961253 20p12.3 chr20:6404281 0.35 1.12 (1.08-1.16) Houlston et al, 2008 
rs5934683 Xp22.2 chrX:9751474 0.37 1.07 (1.04-1.10) Dunlop et al, 2012 
Table 1.2 Twenty-five single-nucleotide polymorphisms that are associated with CRC as 
identified from GWAS. * denotes OR for heterozygotes are presented when the OR per allele 







     The first GWAS for CRC were carried out in Scotland (Zanke et al, 2007; Tenesa 
et al, 2008), England (Tomlinson et al, 2007; Broderick et al, 2008), and Canada 
(Zanke et al, 2007). These studies utilised a primary phase that involved modest 
sample sizes (~1000 cases and 1000 controls genotyped for ~0.5 million tagging 
SNPs), followed by larger validation phases of those SNPs with the strongest signals 
of association. Although the six initial genetic variant associations with CRC were 
highly significant and passed the stringent threshold of multiple-testing, the effect 
size of these variants were modest at best (odds ratio ≈ 1.2). Consequently, the power 
to detect the effects of such loci was modest, withthe likelihood of discovery being 
highly sensitive to small chance differences in genotype frequencies. Hence, it is 
thought that many more CRC loci of similar or smaller effect size may exist, 
prompting further large-scale collaborative efforts to discover new risk variants that 
may not be easily discoverable owing to small effect sizes and/or low risk allele 
frequencies. Meta-analyses of all initial UK GWAS data (Houlston et al, 2008) and 
further case-control sets (Houlston et al, 2010, Dunlop et al, 2012; Whiffin et al, 
2014) revealed fourteen further risk loci with even smaller effect sizes (odds ratio ≤ 
1.1) than those that had been detected previously. Of note, an X-linked locus at 
Xp22.2 was associated with CRC, and represents the first vidence for the role of X-
chromosome variation in the predisposition to a non-sex specific cancer (Dunlop et
al, 2012).  
     Other new variants have also been discovered by modifying the traditional 
GWAS approaches. A candidate-gene based fine-mapping study was able to identify 
new predisposition tagging SNPs, as well as deconvolute the tagSNP association at 
the GREM1 locus, demonstrating that the original rs4779584 SNP was a synthetic 
association tagging two independent functional SNPs (Tomlinson et al, 2011).  To 
increase sample size and statistical power, a meta-analysis included colorectal 
adenoma cases based on the knowledge that adenomas are well-defined CRC 
precursors and hence share a similar aetiology with the malignant phenotype (Peters 
et al, 2013). However, two out of their four putative associations failed to be 
replicated in another meta-analysis that shared an overlapping sample set (Whiffin et 
al, 2014). As these studies relied on different imputation references (HapMap 30 
trios in Peters et al, 2013 versus 1000 Genomes Project in Whiffin et al, 2014) to 
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recover the genotypes of this two SNPs, the failure of replication is likely to reflect 
discrepancies in imputation, a key issue pertinent to the later GWAS studies. 
Although imputation with publicly available, well-catalogued deep-sequencing data 
is a highly useful and cost-effective measure to complement genotyping arrays, 
technical validation of imputation fidelity by sequencing is paramount to avoid 
spurious results. 
     GWAS have proved to be a powerful approach in identifying common, low 
penetrance susceptibility loci for CRC without prior knowledge of disease pathways. 
Although each individual risk allele confers only a small relative risk, the SNPs are 
common and hence contribute significantly to the overall incidence of CRC. 
Furthermore, the accrual of risk variants in an individual also impacts significantly 
on an individual’s risk of developing CRC (Figure 1.4), and may allow the 
identification of higher-risk individuals in the gen ral population who might benefit 
from earlier screening (Dunlop et al, 2012; Lubbe et al, 2012). Although the 
collective risk conferred by currently identified common variation explains only ~2% 
of colorectal cancer, this estimate is likely to be conservative for several reasons. 
Firstly, the effect of the causal variant(s) at each locus is expected to be larger than 
the association detected by the tagging variant. As evidenced by the 14q22 
association, multiple risk variants may exist at each locus, including low-frequency 
variants with significantly larger effects (Tomlinson et al, 2011). Secondly, the 
interactions of these variants with epigenetic regulation or environmental factors may 
lead to a greater increase in disease risk. Epistatic interactions between these low-
penetrance variants could in theory result in a larger impact on CRC risk (Zuk et al, 
2012), however, the evidence to date suggests that the effects of most risk loci appear 
to be independent. Aside from effect underestimation of established risk loci, the 
remaining heritable susceptibility may also be embodied in a multitude of common 
risk alleles with even smaller effect sizes that are yet to be identified. This is 
evidenced by larger and more highly-powered GWAS in breast (Michailidou et al, 
2013) and prostate (Eeles t al, 2013) cancer, identifying 41 and 23 novel risk loci 
respectively. Furthermore, structural variation such as indels and copy number 
variation that are likely to play a role in disease pr disposition are not optimally 
captured by commerical GWAS arrays, and may account for some of the missing 
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heritability that have eluded GWAS efforts thus far. A new generation of studies 
involving exome and whole-genome sequencing, as well as gene-environment 
interactions are hence underway to improve our understanding in the inherited 




Figure 1.4 Plots showing the increasing odds ratios for colorectal cancer with the increasing 
number of risk alleles, London, United Kingdom, 1999–2007. The vertical bars represent 
95% confidence intervals. The horizontal line denotes the null value (odds ratio = 1.0. 





1.4 Functional effects of low-penetrance CRC risk v ariants  
     As alluded to in the previous section, GWAS in general have detected risk 
variants with only modest effect sizes that are deemed too small to be meaningful. 
However, individually small effect sizes represent the reality of common genetic 
variation and do not necessarily preclude clinical utility. For instance, a GWAS hit 
for circulating lipid levels maps to the HMG-CoA reductase (HMGCR) gene 
(Kathiresan et al, 2008), the rate-limiting enzyme in cholesterol biosynthesis and the 
target of the extremely successful cholesterol-lowering statin drug. This discrepancy 
occurs because a drug’s efficacy bears little relation to the degree of genetic variation 
in its target gene. Similarly, the size of the biological effect cannot be predicted by 
the epidemiological risk, or vice versa, not least due to pathway redundancies. 
Unravelling the mechanisms underlying GWAS associations will ultimately bring us 
closer to elucidating the genetic basis of complex disease, which in turn could 
identify novel causative biological pathways that may be suitable targets for 
chemopreventative drug development or repositioning of known therapeutics, as well 
as offer opportunities for personalised medicine. 
     The GWAS association signals in CRC have yet to be translated into a full 
understanding of the genetic elements that are mediating the effects of these 
susceptibility loci. Modern GWAS genotyping chips typically target SNPs chosen to 
capture variation across large genomic regions. These SNPs are not selected for 
having likely functional consequences, hence, hits from a successful GWAS merely 
mark a locus that encompasses one or more genetic variants that have biological 
functions driving the observed association with the trait phenotype. Contrary to early 
expectations, none of the GWAS-identified CRC risk variants are in protein-coding 
regions (Table 1.3). Assuming that the same is true for the candidate causal SNPs 
within the tagged haplotype block, the common heritability of CRC risk is thought to 
be mediated through genetic variation that influence gene regulation rather than 
protein sequence. The major challenge post-GWAS is to find the strongest candidate 





SNP Locus Closest gene Relative position Reference 
rs10911251 1q25.3 LAMC1 Intronic Peters et al, 2013 
rs6687758 1q41 DUSP10 125Kb upstream Houlston et al, 2010 
rs6691170 1q41 DUSP10 250Kb upstream Houlston et al, 2010 
rs10936599 3q26.2 MYNN Intronic Houlston et al, 2010 
rs1321311 6p21.2 CDKN1A 21Kb upstream Dunlop et al, 2012 
rs16892766 8q23.3 EIF3H 24Kb downstream Tomlinson et al, 2008 
rs6983267 8q24.21 POU5F1B 13Kb upstream Zanke et al, 2007; 
Tomlinson et al, 2007 
rs1035209 10q24.2 SLC25A28 25Kb downstream Whiffin et al, 2014 
rs10795668 10p14 BC031880* 400Mb downstream Tomlinson et al, 2008 
rs3802842 11q23.1 COLCA2 Intronic Tenesa et al, 2008 
rs3824999 11q13.4 POLD3 Intronic Dunlop et al, 2012 
rs3217810 12p13.32 CCND2 Intronic Peters et al, 2013 
rs11169552 12q13.13 DIP2B 2.5Kb upstream Houlston et al, 2010 
rs7136702 12q13.13 LARP4 6.5Kb downstream Houlston et al, 2010 
rs1957636 14q22.2 BMP4 135Kb upstream Tomlinson et al, 2011 
rs4444235 14q22.2 BMP4 5.5Kb downstream Houlston et al, 2008 
rs11632715 15q13.3 GREM1 6Kb upstream Tomlinson et al, 2011 
rs16969681 15q13.3 SCG5 59Kb downstream Tomlinson et al, 2011 
rs9929218 16q22.1 CDH1 Intronic Houlston et al, 2008 
rs4939827 18q21.1 SMAD7 Intronic Broderick et al, 2007 
rs10411210 19q13.11 RHPN2 Intronic Houlston et al, 2008 
rs4813802 20p12.3 BMP2 49Kb upstream Tomlinson et al, 2011 
rs961253 20p12.3 BMP2 344Kb upstream Houlston et al, 2008 
rs4925386 20q13.33 LAMA5 Intronic Houlston et al, 2010 
rs5934683 Xp22.2 GPR143 Intronic Dunlop et al, 2012 
Table 1.3 The location of the tagging SNPs associated with CRC risk in relation to the 










     Identification of the truly causal variant requires a complete catalogue of all 
variants within the locus and the generation of such a catalogue has been the rate-
limiting step. Fine-mapping of CRC risk loci is very much in its infancy, with most 
studies attempting to only narrow down the location of putative functional variants 
by imputation and targeted re-sequencing methods (Pittman et al, 2008; Carvajal-
Carmona et al, 2011; Whiffin et al, 2013). While these studies suggest candidate 
regions, very few functional studies have been carried out to test these postulations.  
The most well-studied CRC locus is the 8q24.21 locus, which despite its location in a 
gene desert, has pleiotropic effects on cancer susceptibility. Apart from its 
association with CRC, this locus also habours risk loci for solid tumours such as 
breast (Easton et al, 2007), prostate (Al Olama et al, 2009), ovarian (Ghoussaini et
al, 2008) and bladder cancer (Kiemeney et al, 2008), as well as chronic lymphocytic 
leukemia (Crowther-Swanepoel et al, 2010). The rs6983267 SNP which is associated 
with increased risk of both colorectal and prostate cancers lie within an 
evolutionarily conserved region, and has been shown via computational predictions, 
enhancer reporter assays, chromatin-immunoprecipitation (ChIP) and transgenic 
mouse embryos to possess in silico, in vitro and in vivo properties of an enhancer, 
with allele-specific differential binding to the Wnt-regulated transcription factors 
TCF4 (Tuupanen et al, 2009; Sotelo et al, 2010) and TCF7L2 (Pomerantz et al, 
2009). The target gene of this proposed enhancer element is not immediately 
obvious; although the well-known CRC proto-oncogene MYC lies ~335kb telomeric 
to rs6983267, there is a lack of association between th  rs6983267 and gene 
expression in normal colorectal tissue or paired tumo rs. However, chromosome 
conformation capture (3C) techniques demonstrated long-range physical interaction 
between the enhancer element and MYC in a tissue-specific manner (Pomerantz et al, 
2009; Sotelo et al, 2010). Altogether, the evidence from these functio al studies 
suggests that the 8q24 risk locus acts as part of a cis-regulatory enhancer element for 
the MYC proto-oncogene, mediating CRC risk through its differential binding with 
TCF transcription factors.  
     Evidence for functionality at the 8q23.3 and 18q21 CRC risk loci have also been 
demonstrated by targeted re-sequencing and functional assays. At the 8q23.3 locus, 
the putative causal variant rs16888589 was validated using reporter gene assays and 
27 
 
electrophoretic mobility shift assays (EMSA), with 3C analysis demonstrating a 
physical interaction between the encompassing control element and the promoter 
region of EIF3H located 144kb telomeric to the SNP (Pittman et al, 2010). At the 
18q21 locus, a transgenic Xenopus model system was utilised to demonstrate that the 
putative causal variant intronic to SMAD7 (Novel 1) is associated with a reduced 
expression of SMAD7 in the colorectum (Pittman et al, 2009). There is also evidence 
that the tagging SNP rs4929827 is associated with SMAD7 expression in human 
lymphoblastoid cell lines (Broderick et al, 2007). 
     Apart from these three loci described above, direct evidence implicating 
functionality of the remaining GWAS risk loci was scarce prior to the conception of 
this PhD project. Two cis-expression quantitative trait loci studies have since 
replicated part of my findings (Loo et al, 2012; Closa et al, 2014) and will be 
discussed whenever relevant in result Chapter 6. 
1.5 eQTL 
     Landmark studies have clearly demonstrated that ere is extensive natural 
variation in human gene expression within the same cell type and development stage, 
and that the gene expression phenotype is highly inf ue ced by inherited DNA 
sequence variation (Cheung et al 2003; Morley et al, 2004; Stranger et al, 2005; 
Goring et al, 2007; Dixon et al, 2007). These non-coding germline variants are 
termed expression quantitative trait loci (eQTLs); they are referred to as local or cis-
eQTLs when they map to the approximate location of the target gene, whereas those 
that map to considerable distances from the gene they regulate, often on different 
non-homologous chromosomes, are referred to as distant or trans-eQTLs. As the 
terminology cis- and trans- connote mechanism, it has been cautioned that this 
designation is best-reserved for use only when the functional variant has been 
identified (Rockman et al, 2006). The distinction between local and distant is 
arbitrary, and is usually pre-defined by study authors to be within 1-2 Mb of the 




1.5.1 Utility of eQTL in complex disease traits 
     eQTLs have been implicated in the predisposition o complex diseases in twin 
studies (Grundberg et al, 2012) as well as empirical studies of lymphoblastoid cell 
lines (Nicolae et al, 2010). By mapping the genetic architecture of gene xpression in 
human tissues, eQTL studies can be useful in discovering candidate susceptibility 
genes for multifactorial diseases. The value of this has been illustrated by several 
proof-of-principle studies. Genome-wide transcriptional profiles of lymphocytes 
from the San Antonio Family Heart Study demonstrated that cis-eQTLs can be used 
as a discovery tool to identify novel candidate genes (and variants therein) that 
influence complex traits, e.g. VNN1 gene and high-density lipoprotein cholesterol 
concentration (Goring et al, 2007). Another study examining genetic markers of 
childhood asthma incorporated eQTL analysis of EBV-transformed lymphoblastoid 
cell lines (LCL) as a component of the GWAS design, a d utilised it to identify a 
novel candidate susceptibility gene ORMDL3 for childhood asthma (Moffat et al, 
2007). This has since spurred functional studies and transgenic mouse models 
demonstrating a role for this gene in asthma pathogenesis, providing valuable 
insights into the molecular mechanisms of proinflammatory diseases (Cantero-
Recasens et al, 2009; Ha et al, 2013; Miller et al, 2014). Such findings have 
encouraged the use of eQTL data as a tool for interpreting results from GWASs, 
bridging the gap between common genetic markers for disease and the underlying 
mechanisms for clinical phenotypes. Importantly, eQTL annotation is carried out in 
an unbiased fashion, where the mapping of associatins between alleles and target 
genes require no prior knowledge of functional mechanisms. Analyses of Crohn’s 
disease are an example of this approach, where the biological effects of genetic 
markers were not readily deducible. Examination of LCL eQTL databases showed 
that one or more of these polymorphisms act as cis-acting factors influencing 
expression of genes (Libioulle et al, 2007). Similarly, the causal variant and causal 
gene for an LDL-cholesterol locus was identified by examining cis-gene expression 
levels in the liver and adipose tissue, providing the impetus for functional 
investigations of the implicated gene SORT1 and its role in a novel lipoprotein 
regulatory pathway (Musunuru et al, 2010). More complex analysis of genetic 
variants that perturb networks through eQTL effects ha  provided important novel 
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insights into the unravelling of complex trait genetics (Emilsson et al, 2008), as the 
genome exerts it functions through complex networks and multiple pathways that 
produce a wide range of responses. Hence, eQTL studie  can be a powerful 
interpretive biological tool, and are integral in the systematic identification of 
transcriptional modules and construction of regulatory networks.  
1.5.2 eQTL in the functional annotation of CRC risk  loci 
     For several of the colorectal cancer risk loci, there is indirect evidence of an 
association with gene expression, but the evidence is ircumstantial at best as they 
are largely based on SNPs in linkage disequilibrium with that tagging SNP. For 
example, the CDH1 intron variant rs9929218 is in strong linkage disequilibrium with 
a CDH1 promoter variant (Houlston et al, 2008), which has been reported to 
influence CDH1 transcription in prostate cancer cell lines (Li et al, 2000). The 
12q13.13 variant is in linkage disequilibrium with SNPs associated with DIP2B 
expression in lymphoblastoid cell lines, and the LAMA5 intronic variant rs4925386 is 
in linkage disequilibrium with an eQTL for LAMA5 expression in the liver (Houlston 
et al, 2010). However, the lack of an apparent effect on expression may merely 
reflect tissue-specificity of regulatory mechanisms. Most expression quantitative trait 
loci (eQTL) data sets are derived from only a limited number of source cell types, 
including monocytes, lymphoblastoid cells, liver and brain cells, and have not been 
comprehensively catalogued in colorectal tissue. This is a particularly important 
consideration as an estimated 50%-90% of eQTL are tissue dependent (Dimas et al, 
2009; Nica et al, 2011), and trait-associated variants tend to exert more cell-type 
specificity (Fu et al, 2012; Brown et al, 2013). The other crucial aspect of the 
selection of tissue type in the measurement of eQTLs is the normality of the target 
tissue. Given that somatic alterations present in ca cer cells can greatly affect 
expression (Figure 1.5), subtle genomic influences on expression can be masked 
(Curtis et al, 2012) and consequently be undetectable. Hence, it has been suggested 
that eQTL studies should be performed on non-aberrant cells representative of the 
cell of origin for the disease under study (Edwards et al, 2013).  
     Finally, it should be noted that the identificat on of an eQTL provides only an 
associative link between genotype and gene transcription; although it may imply 
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causality, functional molecular approaches will be n cessary to elucidate the 
underlying mechanism. Critically, even if a transcript is associated with a risk allele, 
this is not definitive of causation and functional fol ow up with assays relevant to the 
disease trait will be needed to demonstrate that a gene is directly involved in disease 
















Figure 1.5 Somatic variants influence breast tumour expression architecture to a much 
greater extent than germline variants. Venn diagrams depict the relative contribution of 
SNPs, copy number variations (CNVs) and somatic copy number aberrations (CNAs) to 
genome-wide, cis- and trans- tumour expression variation for significant expression 







1.6 Research Aims 
     The large knowledge gap between the epidemiology and functional biology of 
common genetic variation in colorectal cancer, calls for studies that will translate 
CRC genetic associations into function. The overarching aim of this project is to 
functionally characterise these germline risk variants, with a view to improve the 
understanding of the biological mechanism(s) underlying these risk loci.  
     As all of the established risk loci reside within non-coding regions, it was 
hypothesised that they influence tissue-specific regulatory mechanisms and 
consequently, exert subtle effects on gene expression levels. The starting point for 
this project was to systematically investigate the functionality of common, low-
penetrance risk variants using an unbiased eQTL appro ch that mirrors the agnostic 
style of GWAS. In view of the overall lack of direct association between these 
germline risk variants and expression in extra-colonic tissue types, it was 
hypothesised that any functional effects will be most prominent in the normal 
colorectal tissue, in particular the mucosal epithelial layer that harbours the cell of 
origin of colorectal cancer. Matched peripheral blood mononuclear cells (PBMC) 
will also be examined, as not only does this offer insight into the tissue-specificity of 
the underlying functional biology, any overlap betwen the two tissue-types could be 
advantageous in the context of identifying clinical biomarkers that are more easily 
accessible from patients. By integrating data from high-density DNA arrays and 
case-control series, the project also aims to identify the causal variant(s) that is most 
associated with specific gene expression as well as clinical risk.  
     Findings from the initial screening phases of the project will be rationalised and 
prioritised for further functional follow-up studies using molecular approaches. This 
is important, as few genes implicated in GWAS were p viously evaluated in 
candidate gene studies. Surprisingly also, none of the currently identified loci are 
known to be involved in DNA repair, the principal pathway underscoring high-
penetrance CRC susceptibility and a large proportion of sporadic CRC. Hence, 
evidence of the functional mechanism underlying these associations will not only 
provide support for the GWAS approach in the discovery of common risk variants, it 
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will also allow the identification of target genes, offering new insights into the 
aetiology and pathogenesis of sporadic colorectal cancer.  
1.7 Experimental approach 
     Several methodological approaches will be utilised in this project to bridge the 
gap between genetic risk and biological function, demonstrating a collaborative 
framework between clinicians, genetic epidemiologists and molecular biologists.  
The principal theme of this project is to examine th  association between genetic risk 
variants and gene expression in relevant non-aberrant tissue-types. To achieve this, 
normal mucosa specimens and matching blood from patients undergoing large bowel 
surgery were systematically collected and analysed. To simultaneously examine the 
expression of multiple genes, transcriptome-wide gene xpression profiling with 
microarrays was utilised to maximise cost-effectiveness. As degradation of RNA 
compromises the ability to detect differential expression of genes especially those 
expressed at low levels, it is paramount that good quality, intact RNA was used to 
avoid poor data that may lead to erroneous conclusions. The isolation of intact RNA 
from the large bowel mucosa has inherent technical ch l enges and Chapter 3 focuses 
on the optimisation of this process to minimise RNA degradation that will have 
cascading detrimental effects on downstream experiments and analyses.  
     qRT-PCR technique is also a mainstay in this project due to the recurring themes 
of gene expression changes association with inherited variation. This highly-sensitive 
technique is of immense value in the same-sample validation of subtle differential 
gene expression results derived from microarray data, but its sensitivity is a double-
edged sword and may lead to misleading results if not rigorously performed. The 
appropriate use of reference genes can vastly influe ce the accuracy of qRT-PCR 
results, and Chapter 4 concentrates on the selection and validation of stably 
expressed reference genes used to normalise the expr ssion of genes of interest. 
Throughout Chapter 5, 6, 7 and 8, qRT-PCR quantifica on of gene expression will 
feature prominently in the assessment of differential expression and genotype-
dependent functional differences, and the work presented in Chapter 4 allows 
confidence in the robustness of the data.  
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     Prior to the analysis of gene expression in relation to genetic risk variants, 
expression was first evaluated in relation to clinio-pathological features in Chapter 
5. This serves as a form of internal validation, and lso highlights the need to adjust 
for such factors in the statistical analyses of the association between risk variants and 
gene expression.  
     Chapter 6 addresses the cis-eQTL analysis of the 25 CRC risk loci in normal large 
bowel mucosa and matching PBMC. This empirical approach is complemented by 
genotyping data from high-density arrays and imputation methods that aim to 
discover the functional variants underlying eQTL associations of risk loci.  
     The best eQTL associations are prioritised for technical validation, and Chapter 7 
addresses the molecular mechanism underlying the Xp22.2 locus. This was 
performed by first using targeted re-sequencing and fine-mapping to identify putative 
causal variants of the cis-eQTL association. Thereafter, candidate causal variants and 
the tagging SNP were compared with interrogation of publically available functional 
data, reporter gene assays, transient siRNA knockdown approaches, and CRC case-
control series.  These observational and experimental approaches culminates in the 
identification of the causal variant at the Xp22.2 locus that best explains the 
association with the target gene SHROOM2 as well as colorectal cancer genetic risk.  
     By inference, the target genes of the eQTL associations are likely to be associated 
with the risk of developing colorectal cancer. Chapter 8 describes functional follow-
up assays to dissect the role and expression pattern of SHROOM2, a gene that has not 
previously been implicated in CRC. Functional phenotypes such as cell population 
doubling, wound closure and transcriptomic profiles were assessed after transient 
siRNA knockdown in cell lines, and less conventional localisation approaches were 
sought as the lack of a specific antibody precluded the utility of immuno-staining 
techniques. 
     As revealed in Chapter 6, genetic variation exerts their effect on CRC risk in part 
by influencing the expression of cis-genes. However, it is also evident that there are 
still a large proportion of risk variants whose functions and target genes cannot be 
accounted for by cis-eQTL effects on baseline expression. Chapter 9 demonstrates an 
alternative approach that mirrors that of epidemiological gene-environment studies to 
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specifically investigate the 16q22.1 risk locus tagged by rs9929218, using the 
expression of the encompassing gene CDH1 as the measure of outcome. Vitamin D 
levels and its pathway activity are postulated to modify the influence of rs9929218 
on CDH1 expression, and this hypothesis is tested in the normal large bowel mucosa, 
cell lines and human colonic epithelial crypt organoids.  
     Although detailed discussion of the results is provided in each result chapter, 
Chapter 10 summaries the main themes and conclusions that have emerged during 
the entire course of this research.  
     Overall, the work presented in this thesis demonstrates a multi-disciplinary 
approach in understanding the mechanisms underlying CRC GWAS-identified risk 
variants. It demonstrates that unbiased empirical approaches can be used to prioritise 
candidate variants/genes for follow-up functional studies, as well as the value of 
candidate gene/pathway approaches towards the ultimate goal of understanding the 




















Materials and methods 
     This chapter describes the methods used in this thesis. More detailed methods are 
included in the results chapters where relevant. Where manufacturer’s protocols have 
been used, these have been referred to, and any adjustments made to the cited 
method have been detailed in the text. Standard safety procedures and COSHH 
regulations were adhered to. All cell line culture w re performed in a class 1 
biological safety cabinet, whereas all biological material from primary tissue was 
handled in a class 2 safety cabinet. Reagents marked with an asterisk (*) were 
prepared by the technical services department at the MRC Human Genetics Unit, 
IGMM. Where the pH of solutions was adjusted this was done by adding 
concentrated HCl or NaOH as appropriate and monitori g of pH using a 
microprocessor pH meter (Hanna Interments).  
2.1 Biological material 
     This study was set up and performed in collabor ti n with NHS Lothian/South 
East Scotland SAHSC Bioresource. All patients gave written informed consent. All 
information pertaining to subjects were in compliance with UK legislation and 
conform to the Tissue Act Scotland, 2006.  
     115 patients undergoing bowel resection operations for cancer, adenomas or non-
malignant disease at the Western General Hospital, Edinburgh, were recruited for 
colonic tissue and peripheral blood sampling (detailed in Chapter 5). A further 40 
patients undergoing bowel resection for colorectal ancer only were recruited for 
serial peripheral blood sampling (detailed in Chapter 9). Patients with known familial 
cancer syndromes, inflammatory bowel disease or those who have received pre-
operative adjuvant chemo-radiotherapy were excluded. R cruitment and tissue/blood 
sampling was carried out over the course of this PhD with assistance from the group 




2.1.1 Sampling of fresh large intestinal mucosa and  tumour 
     The resected bowel specimens were transported fresh to the pathology laboratory 
at room temperature immediately after each surgical resection. Macroscopic 
examination and assessment of the margins were performed by a pathologist for all 
specimens. Only tissue that is surplus to diagnostic requirement was taken. 
Undiseased colonic mucosa layers were dissected and separated from the muscularis 
at the resection margin furthest away from the tumor. Corresponding tumour were 
sampled by a pathologist whenever available and deemed to not interfere with the 
diagnosis. The fresh tissue samples were then flash-frozen in a cooling bath of 100% 
ethanol and dry ice, or stabilised in RNAlater® (Applied Biosystems) according to 
the manufacturer’s protocol. Samples were then stored at -80°C before further 
processing.  
2.1.2 Sampling of peripheral blood 
     Peripheral venous blood was drawn from patients using standard phlebotomy 
procedures. Blood for genomic DNA was collected in EDTA tubes, whereas blood 
for RNA and plasma extraction was collected in Lithium-Heparin tubes. When serial 
blood samples were required, surplus blood from clinical biochemistry requests were 
collected whenever possible to minimise the number of phlebotomy procedures for 
the patients.  
     Peripheral blood mononuclear cells (PBMCs) andplasma were isolated from 
approximately 9mls of fresh blood with Ficoll-Paque Plus (GE healthcare) according 
to the manufacturer’s protocol. PBMCs were processed immediately for RNA 







2.2 Cell culture 
Media, solutions and additives: 
Freezing medium 
10% Dimethylsulfoxide (DMSO) (Sigma) in foetal calf serum* 
Tissue culture medium 
Cell-line specific basal medium (Table 2.1) (Life Tchnologies) 
10% v/v foetal calf serum (FCS)* 
1% v/v Penicillin and streptomycin* 
Cell-line specific additional supplements (Table 2.1) 




Trypsin Versene (T/V) 
50% v/v Trypsin* 







     Cell lines stored in the liquid nitrogen facility at the MRC Human Genetics Unit 
were retrieved by rapid thawing in warm water and resuspending in 5mls of the 
appropriate tissue culture medium (Table 2.1) and then fed as required. After 3-4 
days in culture, culture supernatant was sent to technical services for mycoplasma 
testing with the MycoAlert™ Mycoplasma Detection Kit (Lonza) to ensure all cells 
used were mycoplasma-free. To retain the cell lines as renewable sources, at least 
3x106 cells were split from the main culture, centrifuged at 1200rpm and the cell 
pellet resuspended in 1ml freezing medium. The cells were cooled immediately and 
then sequentially frozen at -80°C and -140°C. 
 






CACO2 Colorectal cancer Adherent DMEM  
COLO320 Colorectal cancer Adherent DMEM  
DLD1 Colorectal cancer Adherent DMEM  
HCT116 Colorectal cancer Adherent DMEM  
HELA Cervical cancer Adherent DMEM  
HEK293 Embryonic kidney Adherent DMEM  
HT29 Colorectal cancer Adherent DMEM  
K562 Erythroleukemia Suspension RPMI  
LOVO Colorectal cancer Adherent DMEM  
MCF7 Breast adenocarcinoma Adherent DMEM  
PNT Prostate epithelium Adherent DMEM  
RKO Colorectal cancer Adherent DMEM  
RPE1 Retinal pigment epithelium Adherent DMEM/F12 1% v/v Glutamine* 
SW48 Colorectal cancer Adherent DMEM  
SW480 Colorectal cancer Adherent DMEM  
VACO425 Colorectal cancer Adherent DMEM  






2.2.1   Maintenance of adherent cell lines 
     For adherent cell lines, media was changed every 3-4 days to maintain cells in the 
logarithm phase of growth. Cell lines were passaged at 80-90% confluence using T/V 
solution after washing the cells with warm PBS. 
2.2.2 Maintenance of suspension cell lines 
     Suspension cell lines were grown in upright T-flasks and periodically shaken to 
break up the cell clumps. Cultures were fed every 2-4 days depending on the 
population doubling time, by removing half of the media from the flask and 
replacing it with a slightly increased volume of fresh media. Cultures were split 
when the cell count is approximately 2 x 106 cells/ml, with a minimum cell 
concentration of 200 x 103 cells/ml for each subculture to ensure optimal growth. 














2.3 RNA work 
2.3.1 RNA extraction 
Cell lines 
     Adherent cells of 80-90% confluence were detached from T25 flasks with a cell 
scraper into 2mL of cold PBS. The cells were pelletd by centrifugation at 1600rpm, 
resuspended in 1ml of TRIzol (Life Technologies), and total RNA extracted 
according to the manufacturer’s protocol. Alternatively, RNA from cell lines was 
extracted directly from the culture plates with the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions. Both techniques produced comparable 
RNA yield and quality.  
Fresh frozen human large intestinal mucosa and tumours 
     The method for extracting total RNA from fresh frozen human large intestinal 
mucosa required optimisation. The method presented here is the final optimised 
method; the optimisation process will be discussed in Chapter 3. Fresh frozen human 
large intestinal samples (no larger than 0.5cm in the smallest dimension) were 
transitioned to RNAlater-ICE® (Applied Biosystems) on dry ice and kept at -20°C 
for 16 hours before storage at -80°C according the manufacturer’s protocol. This was 
not necessary for samples already stabilised in RNAlater (Applied Biosystems) upon 
collection. The TissueLyser LT (Qiagen) and a single 0.2mm stainless steel bead 
were used for the mechanical disruption and homogenisation of samples. Total RNA 
was then isolated using the RiboPure Kit (Applied Biosystems) according to the 
manufacturer’s instructions. 
Fresh PBMC 
     RNA extraction for PBMCs were performed immediately after isolation from 
whole venous blood, using the Ambion® RiboPure™ Kit(Applied Biosystems) 
according to the manufacturer’s instructions.  
     All RNA was stored at -80°C until further analysis. 
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2.3.2 Evaluation of RNA quality and yield 
Gene expression profiling microarrays 
     RNA purity was measured using the Nanodrop® 800 spectrophotometer (Thermo 
Scientific), and all samples used for gene-expression profiling had the ratio of 
absorbance at 260nm and 280nm (A260/A280) of >1.8. RNA yield and integrity was 
measured using the 2100 Bioanalyzer® (Agilent Technologies). The RNA integrity 
numbers were ≥7 for normal mucosa RNA samples, ≥8 for PBMC RNA samples, 
and ≥9 for cell line RNA samples.  
PCR  
     For downstream experiments with RT-PCR and qRT-PCR, RNA yield and purity 
was measured with the Nanodrop® 800 spectrophotometer (Thermo Scientific), with 
all samples giving A260/A280 ratios of >1.8. 
2.3.3 DNase treatment of RNA 
     RNA samples were first treated with DNase in 10µl reactions. Final reaction 
concentrations were 100ng/µl total RNA, 1x RQ1 RNase-free DNase reaction buffer 
(Promega), 0.1 unit/µl RQ1 RNase-free DNase (Promega). The reaction was 
incubated at 37°C for 30 minutes. 1µl of RQ1 DNase Stop Solution (Promega) was 
then added and the reaction incubated at 65°C for 10 minutes to inactivate the 
DNase.  
2.3.4 cDNA synthesis from RNA 
     The DNase treated RNA samples were reversed transc ibed to cDNA using 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) (Promega) in 
a 20µl final reaction volume.  The final reaction con entrations were: 
50ng/µl input RNA 
10units/µl M-MLV RT (Promega) 
42 
 
1x M-MLV RT reaction buffer (Promega) 
0.4units/µl random primers (Roche) 
1mM dNTP (Promega) 
1 unit/µl RNasin® Ribonuclease Inhibitor (Promega) 
2.3.5 Quantitative real time PCR (qRT-PCR) 
     cDNA from cell lines were diluted to 1:20 working stock whereas cDNA from 
patient samples were diluted to 1:10 working stock. qRT-PCR was carried out in 
10µl final reaction volumes: 
2µl cDNA working stock 
5µl Taqman® Master Mix (Applied Biosystems) 
0.5µl Taqman® Gene Expression Assay (Applied Biosystem ) 
2.5µl nuclease-free H2O 
     The linearity and amplification efficiency of each individual gene expression 
assay were first tested using serial dilutions of cDNA from an expressing cell line to 
produce calibration curves. The threshold cycles (Ct) were plotted against the logged 
cDNA quantity, and the coefficient of correlation obtained for the fitted calibration 
curves (R2) were calculated. PCR amplification efficiencies were calculated from the 
slope of the log-linear portion of the calibration curves using the equation  
Efficiency = 10 (–1/slope)  - 1 
All assays used had highly linear calibration curves (R2 of >0.985) and efficiencies 
between 90% - 110%, indicating that the assays are well-optimised and the input 
template is of good quality. 
     All reactions were performed in triplicates. Amplification and detection of the 
amplified product was carried out with ABI PRISM HT 7900 Sequence Detection 
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System thermal cycler (Applied Biosystems) and read using SDS Version 2.3 
software (Applied Biosystems). The PCR reaction conditions were: 50°C – 2min, 
95°C – 10min, 95°C – 15secs, 60°C – 1min. The cycle was repeated 40x.  
     For detection of differential expression in the normal colorectal mucosa, the 
expression of genes of interest was normalised using three validated reference genes. 
The selection and validation of reference genes are described and discussed in more 
detail in Chapter 4. In the PBMCs, the housekeeping gene GAPDH was used as a 
reference gene for the normalisation of expression quantification. 
2.3.6 Whole transcriptome gene expression profiling  
     Expression profiling was accomplished using the HumanHT-12 v4.0 Expression 
BeadChip Arrays (Illumina, USA). Each array contains 50-mer probes representing 
more than 47,000 transcripts derived from the NCBI RefSeq Release 38 (November 
7, 2009),1 as well as legacy UniGene content. RNA was amplified and biotin-labelled 
using Ambion’s Illumina Total Prep RNA Amplification Kit (Ambion), as per 
manufacturer’s protocol. 500ng input total RNA was used, and in vitro transcription 
incubation was carried out for 14 hours. The quality nd yield of the amplified RNA 
(aRNA) was assessed with the 2100 Bioanalyzer® (Agilent Technologies) to ensure 
that the aRNA profile is as expected, producing a distribution of sizes from 250 to 
5500 nt with most of the aRNA at 1000 to 1500nt. This was then sent to Genetics 
Core, Wellcome Trust Clinical Research Facility, Edinburgh, for array hybridization 











2.4 DNA work 
2.4.1 DNA extraction from whole blood 
     Isolation of genomic DNA from whole blood was carried out using a Nucleon™ 
BACC Genomic DNA Extraction Kit (GE healthcare) according to the 
manufacturer’s instructions. DNA was suspended in TE and quantified using the 
Nanodrop 800 spectrophotometer (Thermo Scientific).  
2.4.2 PCR 
     PCR reactions were performed in a final volume of 25µl using platinum Taq® 
DNA polymerase (Invitrogen). Final reaction concentrations were 1x PCR buffer, 
0.2mM dNTPs, 1uM oligonucleotide primer (forward and reverse), 5ng DNA, 
2.5mM magnesium chloride, and 1 unit of platinum Taq® DNA polymerase. All 
reagents used were supplied by Invitrogen. Amplification was performed using a 
Peltier PCT225 thermal cycler (MJ Research) under the following standard 
conditions: 95°C for 5 minutes, (95°C for 30 seconds, 62°C for 30 seconds, 72°C for 
30 seconds) x 30 cycles, 72°C for 5 minutes.  
     Primers were supplied by Sigma as precipitates nd re-suspended in dH2O to a 
stock concentration of 20uM. These oligonucleotides will be referenced in the 
relevant chapters.   
2.4.3 Gel electrophoresis 
Solutions: 
10 x Tris-Acetate EDTA (TAE)* 
2M Tris 
5.7% w/v Glacial acetic acid 




100mM Na2EDTA (pH8.0) 
0.25% w/v Bromophenol blue 
30% w/v Sucrose 
     All PCR products were visualised on a gel before sequencing. 2% agarose gels 
were prepared using routine electrophoresis grade agarose (Biogene Ltd) and 1x 
TAE electrophoresis buffer. 5µl of ethidium bromide (BioRad) per 100ml of gel 
mixture was added to the gel for visualisation.  
     5µl of PCR products were loaded onto the gel with 3µl of loading buffer. Size 
markers used were generally a 1kb ladder (Invitrogen). The DNA was 
electrophoresed at 40-60V and visualised by UV trans-illumination using a Herolab 
trans-illuminator (Herolab, Weisloch). Images were visualised on the BioRad 
Chemidoc system using QuantityOne software (Biorad). 
2.4.4 Purification of PCR products 
     PCR products were first purified with the Exo-SAP clean-up protocol. 7.5µl 
reactions were prepared with: 
3µl of PCR product 
3.75µl of dH2O 
0.25µl of Exonuclease I (10units/µl) (USB) 
0.5µl of Shrimp Alkaline Phosphatase (1unit/µl) (USB) 
     Reactions were incubated under the following conditions using a Peltier PCT225 
thermal cycler (MJ Research) at 37°C for 15 minutes, 80°C for 15 minutes, and 4°C 




2.4.5 DNA sequencing 
     Sequencing of the purified PCR products were ca ried out in 10µl reactions using 
either individual Eppendorf tubes or in 96-well plates. The reactions consists of: 
3.5µl of purified PCR product 
5µl of dH2O 
1µl of Big Dye® Terminator V3.1 Kit * 
1µl of 20uM oligonucleotide primer (forward or revers ) 
     Amplification was performed on a Peltier PCT225 thermal cycler (MJ Research) 
at 96°C for 30 seconds, 50°C for 15 seconds, 60°C for 4 minutes, for 25 cycles. 
2.4.6 Precipitation of DNA from sequencing reaction s 
     After amplification, precipitation of sequenced DNA was carried out by adding 
50µl 95% ethanol and 2µl 3M NaOAC (pH 4) to each sequencing reaction mix. The 
mixture was incubated for 30 minutes at room temperature and then centrifuged at 
1200rpm for 30 minutes. The majority of the supernata t was removed from the 
wells by inverting the plates or tubes, and the residual removed by pulse spinning the 
upturned plates/tubes on paper towels at 800rpm. The DNA pellets were washed by 
adding 70% ethanol down the side of the wells and inverting the plate immediately to 
remove the supernatant. The pellets were dried by a further pulse spin and stored at -
20°C. The precipitated reaction products were re-suspended in HiDiTM  (Applied 
Biosystems), heated at 90°C for 2min, and resolved on the ABI PRISM® 3100 or 
3730 genetic analysers by Technical Services, MRC Human Genetics Unit, IGMM.  
2.4.7 Analysis of sequence data 
     Sequence data was analysed using Consed (Gordon et al, 1998) and Mutation 




2.5 Protein biology 
Solutions: 
Lysis Buffer 
100µl of 10X Whole Cell Lysis Buffer (Cell Signalling Technology) 
40µl of 25X Complete™ Protease inhibitor cocktail (Roche Diagnostics) 
10µl of 100mg/ml Pefabloc SC (Roche Diagnostics) 
1µl of 1mg/ml Pepstatin A (Sigma) 
1µl of 1M NaF (Sigma) 
1µl of 1M Na3VO4 (Sigma) 
5µl of 200mM phenylmethanesulfonylfluoride (PMSF) (Sigma) 
842µl of dH2O 
6x Sample Buffer 
20% w/v Glycerol 
2% w/v Sodium dodecyl sulfate (SDS) 
0.25% w/v Bromophenol blue 
1x Stacking buffer 
5% w/v β-mercaptoethanol 
4x Resolving Buffer 
1.5M Tris 




4x Stacking Buffer 
500mM Tris 
0.4% w/v SDS 
pH 6.8 
10x Running Buffer 
250mM Tris 
2M Glycine 
1% w/v SDS 
10x Wet Transfer Buffer 
250mM Tris 
2M Glycine 
1x Wet Transfer Buffer 
10% v/v 10x Wet Transfer Buffer 
10% v/v 100% methanol 
5% Resolving Gel 
1x Resolving buffer 
5% w/v Acrylamide 
0.15% w/v Ammonium persulphate (APS) 
0.01% w/v N,N,N’,N’,tetramethyl-1-2-diaminomethane (TEMED) 
8% Resolving Gel 
1x Resolving buffer 
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8% w/v Acrylamide 
0.15% w/v APS 
0.01% w/v TEMED 
4% Stacking Gel 
1x Stacking buffer 
4% w/v Acrylamide 
0.15% w/v APS 
0.01% w/v TEMED 
 
2.5.1 Preparation of total protein extracts 
Human normal colorectal mucosa  
     The TissueLyser LT (Qiagen) and a single 0.2mm stainless steel bead were used 
for the mechanical disruption and homogenisation of fresh frozen mucosa samples in 
lysis buffer. The lysis reaction was then incubated for 30 minutes on ice, with vortex 
mixing every 10 minutes. Debris was cleared by centrifugation at 13200rpm for 10 
minutes at 4°C. The supernatant containing total protein extract was collected and 
stored at -40°C. 
Cell lines 
     Adherent cells of 80-90% confluence were detached from T25 flasks with a cell 
scraper into 2mL of cold PBS. The cells were pelletd by centrifugation at 1600rpm 
and resuspended in 100µl of lysis buffer. Incubation, extraction and storage 




2.5.2 Cellular subfractionation of protein extracts  
     In order to quantify protein in the different subcellular compartments, DLD1 cells 
were grown to confluence in T75 flasks. The cells were then extracted using the 
ProteoExtract® Subcellular Proteome Extraction Kit (CalbioChem) as per the 
manufacturer’s instructions, allowing subfractionation of cellular protein in the 
cytoplasmic, membrane/organelle, nuclear and cytoskeleton compartments. Briefly, 
this kit utilises four specialised extraction buffers to sequentially extract the different 
subcellular compartments based on the differential solubility of proteins in each 
compartment. A schematic overview is shown in Figure 2.1.  
 
Figure 2.1 Illustration from the CalbioChem ProteoExtract® Kit protocol demonstrating the 
steps involved in the extraction of subcellular compartments. Four fractions are extracted 
enriched for: cytosolic fraction (F1), membrane/organelle protein fraction (F2), nucleic protein 
fraction (F3), cytoskeletal fraction (F4). A) Adherent SAOS cells were extracted using 
sequential buffers. Images show cells before and after the extraction with the respective 
extraction buffer. B) SDS-PAGE analysis of each subcellular fraction demonstrates distinct 
protein patterns of the respective fractions. C) The selectivity of subcellular extraction was 
demonstrated by immunoblotting against the indicated marker proteins.  
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     All protein extracts were stored at -40°C. The concentrations of the total protein 
extracts were determined by Bradford assays (Biorad) using bovine serum albumin 
(BSA) (Sigma) to generate a standard curve. All samples were measured in triplicate 
and concentrations calculated from the concentration gradient of the BSA standard 
curve. The extracts were then diluted in water to the same concentrations for Western 
blot analysis.  
2.5.3 Western Blot analysis 
     30-50µg of total protein extract was added to a 1:7.5 dilution of sample buffer and 
boiled for 3-5 minutes. Samples were resolved by denaturing SDS-PAGE on a 
5%/8% polyacrylamide gradient gel in 1x running buffer. Alternatively, a precast 4-
12% Bis-Tris Polyacrylamide Gel (NuPAGE® Novex®, Life Technologies) was used 
according to the manufacturer’s protocol. Pre-stained molecular weight markers 
(Biorad) were run in parallel. PVDF membranes (Biorad) were prepared by 
immersion in 100% methanol for 2 minutes. Protein was transferred from gels to 
membranes by wet transfer for 1 hour at 100V, at 4ºC, using 1x wet transfer buffer. 
This is followed by blocking of the blots in 5% w/v dried milk (Marvel) and 0.15% 
v/v Tween (Sigma) in PBS for 2 hours at room temperature. Blots were then probed 
with primary antibodies overnight at 4ºC in PBS/BSA/Azide*. Blots were washed 
afterwards in 0.15% Tween/PBS for 20 minutes x 3 with gentle shaking, then 
incubated in the appropriate species-specific horseradish peroxidase (HRP)-
conjugated secondary antibody in 5% milk/0.15% Tween/PBS for 1 hour at room 
temperature. Blots were again washed as previously before detection of specifically 
bound antibody by chemiluminescence using Luminol reagent (Santa Cruz 
Biotechnology). Luminol reagent was applied to the blots for 1 minute, followed by 
covering the blots with a plastic cover and exposure to Amersham Hyperfilm™ ECL 
(GE Healthcare).    
     Primary antibodies and dilutions are detailed n the relevant chapters. Goat anti-
rabbit IgG-HRP, goat anti-mouse IgG-HRP and donkey anti-goat IgG-HRP 
secondary antibodies (Santa Cruz) were used at 1:3000 dilutions. 
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2.6 Data analysis 
2.6.1 Statistical analysis 
Statistical analyses were performed using GraphPad, Excel and R. The tests used for 
each individual result are reported in the figure legends. Unless stated otherwise, p-
values of <0.05 was the significant threshold for reporting. The single asterisk * 
indicates p<0.05, the double asterisk ** indicates p<0.01, and the triple asterisk *** 
indicates p<0.001.  
2.6.2 Analysis of microarray gene expression data 2 
Microarray data, exported from Beadstudio, was processed and normalized using the 
R, Bioconductor beadarray and limma packages. Prior to normalization probes that 
were not detected (detection p-value > 0.01) on the microarrays were removed. 
Microarrays were quantile normalized to remove technical variation. The average 
signal of the biological replicates (n=3) were used for further analysis. ComBat batch 
correction was performed to control for batch effects. The limma package was used 
to find differential expressed genes, using the functio s lmFit, eBayes and topTable. 
Unless stated otherwise, age, gender, presenting pathology (cancer vs non-cancer) 
and the anatomical sampling site were used as co-variates in the analyses as 
appropriate. Multiple testing correction was calculated using FDR q-values 
(Benjamini & Hochberg, 1995) to minimise false negatives.  
2.6.3 Genomic annotations and functional prediction s 
The genome browsers Ensembl and UCSC browser (Kent et al, 2002; URL2.1) were 
used to interrogate publically available databases. All annotations were presented 
according to the human reference sequence build GRCh37.p12 (hg19). SIFT (Kumar 
et al, 2009) and PolyPhen (Adzhubei et al, 2010) were used for predicting the effects 
of coding non-synonymous variants on protein function. The JASPER matrix model 
(Mathelier et al, 2013) was utilised to predict the transcription factor binding 
                                                            
2
 Analysis performed by Graeme Grimes and Victoria Svinti, MRC Human Genetics Unit, IGMM. 
53 
 
affinities of oligonucleotide sequences. Functional enrichment analysis of 
differentially expressed genes was performed using the web-accessible tool DAVID 






























Isolation of high-quality intact RNA from human col orectal 
normal mucosa 
3.1 Introduction 
     The extraction of intact RNA from fresh frozen human colonic normal mucosa 
has been a technically challenging aspect of this sudy. Various factors can have an 
undesirable impact on the RNA integrity, such as ischaemic time (Huang et al, 2001; 
Spruessel et al, 2004), endogenous RNases, exposure to environmental RNases and 
freeze-thawing during the processing of tissue samples (Botling et al, 2009).      It is 
widely recognised that intact input mRNA is critical for gene expression array 
analysis, as using degraded mRNA may result in misleading variability and 
transcriptional differences. Conventionally, the 28S:18S rRNA ratio has been used as 
a measure of mRNA quality, with a 2:1 ratio considere  the benchmark for intact 
RNA.  However, this method is somewhat subjective because the appearance of the 
rRNA bands can be affected by the electrophoresis conditions, the amount of RNA 
loaded and the saturation of ethidium bromide fluorescence (Palmer et al, 2004). 
Moreover, relatively large amounts of RNA are required for the gel electrophoresis, 
which may not be possible when there is limited sample amount from small human 
biopsies. The Agilent 2100 Bioanalyzer is an increasingly used analytical tool for 
total RNA analysis, using a combination of microfluidics, capillary electrophoresis 
and fluorescence to evaluate concentration and integr ty. The RIN (RNA integrity 
number) generated by an automated algorithm has been shown to be an effective 
method to assess RNA quality (Strand et al, 2007; Copois et al, 2007, Schroeder et 
al, 2006). A RIN of ≥7.0 is generally accepted as adequate integrity for amplification 
and microarray analysis of human tissues. This chapter will discuss some of the 
challenges I have faced and present the results of several RNA extraction techniques 
in an effort to establish a replicable and robust extraction protocol for microarray 
quality RNA, from fresh frozen human colorectal normal mucosa. 
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3.2 Methodological overview 
3.2.1 Study subjects and biological material 
     To explore the functional effects of common geetic risk variants in the normal 
colonic mucosa, 115 fresh normal mucosa were harvested immediately after surgical 
resection of colorectal adenocarcinoma (n=99), tubulo-villous (n=8) and villous 
(n=2) adenomas or non-neoplastic conditions (n=6), as described in Chapter 2. The 
tissue samples collected were flash-frozen in ethanol/dry ice or allowed to equilibrate 
in the RNA-stabilising solution RNAlater® (Life Technologies) to preserve RNA 
integrity.  
3.2.2 RNA extraction 
     RNA extraction was performed using guanidinium thiocyanate-phenol-
chloroform extraction methods with TRIzol® reagent (Life Technologies) and the 
Ambion® RiboPure™ Kit (Life Technologies), according to the manufacturers’ 
protocols.  To optimise the quality and quantity of RNA extracted, several technical 
aspects to the protocols were modified and will be discussed in more detail in 3.3. 
Specifically, these include the use of RNAse inhibitors (Superase•In™, Life 
Technologies), RNAlater®-ICE Frozen Tissue Transition Solution (Life 
Technologies), and mechanical disruption of the mucosa samples with a bead mill 
homogeniser TissueLyser LT (Qiagen). 
3.2.3 Evaluation of RNA quality and yield 
     RNA purity was evaluated using the Nanodrop® 800 spectrophotometer (Thermo 
Scientific), whereas RNA integrity and yield was measured with the 2100 






3.3.1 RNA-stabilising solutions and RNase inhibitor s  
     The existing in-house protocol for RNA extraction from primary tissue utilises 
TRIzol® reagent (Life Technologies) using an adapted protocol. Flash-frozen tissue 
was cut out from cryovials and then manually disrupted with a scalpel before 
immersing in TRIzol®. This process of disruption was continued by grinding of the 
tissue with a mini-pestle. This was followed by phase separation, RNA precipitation, 
wash and redissolving as per the manufacturer’s protocol. Although this procedure 
was performed on ice quickly, the yield of the extrac ion ranged from 620-2720ng, 
with RINs ranging from 2.1-4.2 (Figure 3.1), which were suboptimal for gene 
expression assays.  
  
 
Figure 3.1. Quality parameters of the RNA extracted with the in-house RNA extraction 
protocol utilising Trizol® in four representative normal mucosa samples (lanes 1-4). Digital 
gel electrophoresis was performed using the 2100 Bioanalyzer® (Agilent). Normal mucosa 
RNA samples were run concurrently with the RNA 6000 Nano ladder (Agilent) containing six 
RNA fragments ranging in size from 0.2 to 6.0 kb.  
 
Sample A260/A280 Yield (ng) RIN 
11913 1.94 1380 2.1 
11981 1.94 2720 4.2 
11934 1.92 980 2.2 
11588 1.86 620 2.1 
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     To optimise the recovery of intact RNA, a trial of RNA-stabilising solutions and 
RNA inhibitors was carried out on samples collected from the same patient at the 
same time (Table 3.1). RNAlater® is an aqueous solution designed specifically to 
preserve RNA integrity during the storage of fresh tissue and cells, thus 
circumventing the freeze-thawing process that comprises RNA integrity. 
RNAlater®-ICE is designed by the manufacturer for use on samples that are already 
frozen, allowing tissue to be transitioned from a frozen to non-frozen state for 
processing. As I already had a collection of snap-frozen tissue, RNAlater®-ICE was 
trialed alongside RNAlater® to assess the comparability of the two solutions. 







None 7840 1.93 2.9 
B RNAlater®-ICE Snap-frozen tissue sample (-80°C) 
immersed in RNAlater-ICE (-80°C) and 
allowed to thaw at -20°C for 16 hours. 
8880 1.98 5.5 
C RNAlater® Tissue sample immersed in RNAlater 
immediately after sampling, equilibrated 
at 4°C for 16 hours before discarding the 
solution and storing tissue at -80°C. 
1520 1.93 2.8 
D RNase 
Inhibitor 
80U of Superase•In™ placed onto tissue 
during mechanical disruption and 40U 
added into the supernatant collected after 
phase separation. 





As per B and D 5560 1.87 5.1 
F RNAlater® + 
RNase 
Inhibitor 
As per C and D 4720 1.71 7.6 
Table 3.1. Modifications to the RNA extraction protocol was performed on samples obtained 
from the same patient at the same time.  
     These initial results suggest that a combinatio  of RNAlater® and an RNase 
inhibitor would provide the most protection against RNA degradation during the 
extraction process. However, the effect of the RNase inihibitor is unclear, as there 
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appears to be no additional protective effect on untreated samples and samples 
treated with RNAlater®-ICE.  
3.3.2 Bead mill homogenisation and glass-fibre filt er RNA purification  
     As there were a significant number of tissue samples already snap-frozen on 
collection, I focused on using RNAlater®-ICE and RNase inhibitors to stabilise 
these samples. Although there was an improvement in the RIN values of some of 
these samples, it was not consistently reproducible across all samples (Table 3.2). As 
RNA degradation can occur quickly within the first few minutes of the tissue 
thawing, it is likely that RNA degradation has alredy occurred within some of these 
tissue samples, when they were removed from -80ºC storage and handled for 
previous extractions. It is also possible that degradation occurred as a result of 
inefficient lysis and homogenisation.  
 
 In-house protocol RNAlater ®-ICE and Superase•In™ 
Sample A260/280 Yield (ng/µl) RIN A260/280 Yield (ng/µl) RIN 
11913 1.94 1380 2.1 1.87 2180 6.2 
11981 1.94 2720 4.2 1.87 4600 2.5 
11934 1.92 980 2.2 1.88 6840 5.6 
11588 1.86 620 2.1 1.81 1920 2.5 
Table 3.2. Quality parameters of RNA when samples were re-extracted with modifications 
using RNAlater-ICE and RNase inhibitors.  
 
     To seek further improvement in the quality of isolated RNA, replicate samples 
that have not previously been removed from -80ºC storage were used, and several 
additional modifications to the protocol were made. A bead mill tissue homogeniser 
(TissueLyser LT, Qiagen) was used for more thorough mechanical disruption and 
homogenisation of the tissue, using a single 0.2mm stainless steel bead for a tissue 
biopsy of approximately half the size of the bead. The process of mechanical 
disruption was performed on dry ice instead of ice to prevent any thawing of the 
tissue samples. Additionally, a commercial RNA extraction kit Ambion® 
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RiboPure™ Kit (Life Technologies) that combines lysis with TRI Reagent® lysis 
and glass-fibre filter RNA purification was also used. The glass-fibre filter removes 
residual proteins and lipids as well as smaller degraded RNA fragments. The 
procedure is compatible with tissues that have been tr ated with either RNAlater® or 
RNAlater®-ICE. There was a marked improvement in the isolated RNA (Table 3.3), 
which was consistently replicated in subsequent extractions of more samples. This 
optimised protocol also produced similarly intact RNA from RNAlater® stablised 
samples (RIN>7). The RNAse-inhibitor was eventually removed from the protocol as 
it was not observed to further improve the quality of the extracted RNA.  
 
 RNAlater ®-ICE and Superase•In™ TissueLyser LT and RiboPure TM kit 
Sample A260/280 Yield (ng/µl) RIN A260/280 Yield (ng/µl) RIN 
11913 1.87 2180 6.2 2.12 3620 9 
11981 1.87 4600 2.5 2.17 2420 7.5 
11934 1.88 6840 5.6 2.30 2050 8.8 
11588 1.81 1920 2.5 2.28 3900 8.4 
Table 3.3. Quality parameters of RNA when samples were re-extracted with modifications 














3.4 Discussion  
     The extraction of RNA can be greatly complicated by the presence of ubiquitous 
and hardy ribonucleases that degrade RNA; these can be cellular RNases that are 
released from the cells, or those present in the environment. The isolation of RNA 
from normal colonic mucosa is particularly challenging as not only it is rich in 
RNAses, it is also much tougher compared to friable tumour tissue.  The optimisation 
of the RNA extraction process has demonstrated to me the technical challenges of 
preserving the quality of RNA to ensure accuracy of d wnstream experiments and 
observations. This learning process highlights the importance of robust and 
replicable techniques, as well as principles of optimisation, experimental planning 
and the use of controls. Ultimately, it facilitated and enabled the reliable analysis of 
genome-wide expression for the 115 colorectal mucosa samples collected from 




















Selection of reference genes for qRT-PCR quantifica tion of 
gene expression 
4.1 Introduction 
     Quantitative real time PCR (qRT-PCR) is an accurate, fast and sensitive 
measurement of gene expression. It is the method of choice to validate the results of 
microarray analysis, as well as to perform independent analysis on a defined number 
of genes on validation sets and cell lines. The sensitivity of this technique also means 
it is prone to confounding variation resulting from factors such as the quantity and 
quality of the template input, as well as the yields and efficiency of the extraction 
and the enzymatic reactions. A robust normalisation technique is therefore required 
to remove experimentally-induced non-biological variations and minimise 
quantification error.  
     The use of reference genes as internal controls is currently the preferred 
normalisation method (Huggett e al, 2005),  but there is increasing evidence that the 
expression of commonly used reference genes are cont xt dependent and can vary 
significantly between tissue types (Barber et al, 2005) and experimental conditions 
(Dheda et al, 2005). If unrecognised, expression changes in reference genes can lead 
to erroneous conclusions about real biological effects. This is a particularly important 
point to address in my study, as the differential expr ssion of target genes associated 
with common genetic variation is likely to be subtle and may be easily masked by 
any changes in the reference genes. 
     It is now recommended that normalisation against three or more validated 
reference genes is the most appropriate and universally applicable method (as 
reviewed by Derveaux et al, 2010). To select reference genes for a sample set, a pilot 
study should be performed to measure 10 candidate gen s in 10 representative 
samples. Using the raw non-normalised expression values, the expression stability 
can then be analysed using various mathematical algorithms and software e.g. 
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geNorm, BestKeeper and NormFinder (as reviewed by Vandesompele t al, 2009). 
The underlying principle of these algorithms is that the expression ratio of two 
proper reference genes should be constant across samples. 
     This chapter describes the results of the optimisation and selection of reference 





























4.2 Methodology overview 
4.2.1 Selection of candidate reference genes from m icroarray data 
     A subset of normal mucosa samples (n=44) collected in the early part of this 
project was analysed on the Illumina HT12 gene expression microarray as described 
in 2.3. Quantile-normalised and log-transformed data from this sample set was 
examined with reference to the genes conventionally used as endogenous controls in 
human gene expression studies. The maximum fold change (MFC) and the 
coefficient of variation (CV) for each of these genes were then calculated as 
measures of expression stability.  
4.2.2 qRT-PCR validation on representative samples 
     Based on the microarray gene expression data, the ten most stable candidate 
reference genes were shortlisted for a pilot study on representative samples. For each 
candidate reference gene, gene expression TaqMan® probe and primers were 
purchased from Life Technologies (Table 4.1). qRT-PCR was performed as 
described in 2.3.5. Linearity and amplification efficiency of each of these assays 
were first tested using serial dilutions of HCT116 cell line cDNA. 
Gene symbol Assay ID Context sequence  
PUM1 Hs00472881_m1 TGGGGAACATCAGATCATTCAGTTT 
ACTB Hs99999903_m1 CCTTTGCCGATCCGCCGCCCGTCCA 
RPL37A Hs01102345_m1 GGTGCCTGGACGTACAATACCACTT 
PGK1 Hs00943178_g1 AGCCCACAGCTCCATGGTAGGAGTC 
UBC Hs00824723_m1 GTGATCGTCACTTGACAATGCAGAT 
ABL1 Hs01104728_m1 GCGAGCATGTTGGCAGTGGAATCCC 
EIF2B1 Hs00426752_m1 ATCAAAGATGGAGCGACAATATTGA 
RPS17 Hs00734303_g1 GCTGAAGCTTTTGGACTTCGGCAGT 
TBP Hs00427620_m1 GCAGCTGCAAAATATTGTATCCACA 
RPL30 Hs00265497_m1 TATCATTGATCCAGGTGACTCTGAC 
Table 4.1. TaqMan® assay IDs of candidate reference genes.  
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     Next, the transcript abundance of the 10 candidate genes were measured in 
representative samples that comprised of cDNA from n rmal mucosa (n=11), tumour 
(n=9), ex-vivo normal mucosa (n=8), and colorectal ancer cell lines (n=20). Normal 
mucosa and tumour tissue were paired whenever possible, and samples were 
balanced by gender and anatomical site. Ex-vivo normal mucosa samples consisted 
of untreated samples and samples treated with BMP4 or TGF-β in culture. CRC cell 
lines consisted of 7 commonly used cell lines (SW480, HCT116, DLD1, HT29, 
VACO425, COLO320, CACO2) that were untreated or treated with BMP4, TGF-β, 
aspirin, lithium chloride or retinoic acid. These tr atments were performed as I had 
initially proposed to study the collective effect of CRC risk variants on the TGF-β 
signalling pathway, however, the study evolved to focus on individual variants as the 
preliminary results did not demonstrate a collective effect on TGF-β target genes. 
4.2.3 Stability ranking of candidate reference gene s 
     The raw CT values from the qRT-PCR were analysed using RefFinder (URL4.1), 
an online software tool that integrates four major computational programs 
(BestKeeper [Pffafl et al, 2004], GeNorm [Vandesompele et al, 2002], Normfinder 
[Anderson et al, 2004], and the comparative delta-Ct method [Silver et al, 2006]) to 
compare and rank the stability of candidate reference genes. Based on the rankings 
from each program, an appropriate weight is assigned to ach individual gene and the 










4.3.1 Candidate reference genes for pilot qRT-PCR s tudy 
     There are 32 genes conventionally used as reference gen s for human gene 
expression studies, with commercially available assay  (ABI) for each of them 
(URL4.2 and URL4.3). Of these, 30 genes had matched annotated probes on the 
Illumina HT12 microarray platform (Table 4.2). A candidate reference gene was 
defined as a gene with an MFC of less than 2 and a small CV (de Jonge t al, 2007). 
10 genes had a maximum fold change of >2 (Figure 4.1), hence were considered 
unsuitable and excluded from further ranking. The remaining 20 genes were then 
ranked according to their CV, with the 10 most stable genes selected for the pilot 






















Gene Description Annotated 
probes on 
HT12 
18S 18S ribosomal RNA No 
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase  Yes 
ACTB actin, beta  Yes 
B2M beta-2-microglobulin  Yes 
CASC3 cancer susceptibility candidate 3  Yes 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)  Yes 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1)  Yes 
EIF2B1 eukaryotic translation initiation factor 2B, subunit 1 alpha, 
26kDa  
Yes 
ELF1 E74-like factor 1 (ets domain transcription factor)  Yes 
GADD45A growth arrest and DNA-damage-inducible, alpha  Yes 
GAPDH glyceraldehyde-3-phosphate dehydrogenase  Yes 
GUSB glucuronidase, beta  Yes 
HMBS hydroxymethylbilane synthase  Yes 
HPRT1 hypoxanthine phosphoribosyltransferase 1  Yes 
IPO8 importin 8  Yes 
MRPL19 mitochondrial ribosomal protein L19  Yes 
MT-ATP6 mitochondrially encoded ATP synthase 6  No 
PES1 pescadillo homolog 1, containing BRCT domain (zebrafish)  Yes 
PGK1 phosphoglycerate kinase 1  Yes 
POLR2A polymerase (RNA) II (DNA directed) Yes 
POP4 processing of precursor 4, ribonuclease P/MRP subunit (S. 
cerevisiae)  
Yes 
PPIA peptidylprolyl isomerase A (cyclophilin A)  Yes 
PSMC4 proteasome (prosome, macropain) 26S subunit, ATPase, 4  Yes 
PUM1 pumilio homolog 1 (Drosophila)  Yes 
RPL30 ribosomal protein L30  Yes 
RPL37A ribosomal protein L37a  Yes 
RPLP0 ribosomal protein, large, P0  Yes 
RPS17 ribosomal protein S17  Yes 
TBP TATA box binding protein  Yes 
TFRC transferrin receptor (p90, CD71)  Yes 
UBC ubiquitin C  Yes 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta polypeptide  
Yes 












Figure 4.1. Maximum fold change (MFC) and coefficient of variation (CV) of the expression 
of 30 conventional reference genes in normal mucosa samples. Genes with an MFC>2 (red 





















Rank Gene symbol MeanExp SD CV MFC 
1 PUM1 9.589 0.102 1.06% 1.36 
2 RPL37A 10.128 0.108 1.07% 1.38 
3 UBC 13.522 0.149 1.10% 1.55 
4 ABL1 7.320 0.084 1.15% 1.26 
5 EIF2B1 8.195 0.108 1.32% 1.32 
6 RPS17 12.334 0.174 1.41% 1.79 
Excluded B2M 13.413 0.209 1.56% 2.07 
7 TBP 7.865 0.126 1.60% 1.53 
8 RPL30 12.699 0.211 1.66% 1.97 
9 ACTB 12.884 0.226 1.75% 1.97 
10 PGK1 9.793 0.173 1.76% 1.88 
11 ELF1 9.506 0.175 1.84% 1.63 
12 GUSB 8.970 0.175 1.95% 1.96 
13 YWHAZ 9.519 0.189 1.98% 1.64 
Excluded GAPDH 11.404 0.226 1.98% 2.18 
14 RPLP0 10.852 0.217 2.00% 1.84 
15 PES1 7.194 0.145 2.01% 1.53 
16 POP4 7.758 0.159 2.04% 1.81 
17 PPIA 7.440 0.153 2.06% 1.68 
18 POLR2A 9.423 0.215 2.28% 1.79 
19 CASC3 7.990 0.195 2.44% 1.85 
20 CDKN1B 8.611 0.222 2.58% 1.88 
Excluded  HPRT1 8.843 0.261 2.95% 2.20 
Excluded  HMBS 7.787 0.230 2.95% 2.37 
Excluded  MRPL19 8.620 0.262 3.03% 2.43 
Excluded  CDKN1A 11.021 0.367 3.33% 3.05 
Excluded  PSMC4 7.564 0.266 3.52% 2.18 
Excluded  IPO8 7.856 0.312 3.98% 2.75 
Excluded  GADD45A 8.119 0.338 4.16% 2.76 
Excluded  TFRC 11.222 0.523 4.66% 5.64 
Table 4.3. Conventional reference genes ranked according to their CV of expression in 44 
normal mucosa samples. Genes with an MFC >2 were considered unsuitable and excluded 
from stability ranking. (MeanExp=mean of expression, SD=standard deviation, 







4.3.2 qRT-PCR pilot study of candidate reference ge nes 
     The mean raw Ct values of the 10 candidate referenc genes for each of the 
sample subgroup are quantified and calculated (Table 4.4). There is a large range of 
expression levels across these 10 genes, with RPS17 being most highly expressed 
and TBP being the least expressed.   
 ABL1 ACTB EIF2B1 RPL30 PGK1 PUM1 RPS17 TBP RPL37A UBC 
NM 27.15 23.73 29.44 26.17 25.42 28.25 22.51 30.70 24.18 24.56 
T 26.68 22.80 28.56 25.43 24.12 27.54 21.81 29.80 23.08 24.07 
ENM 26.95 24.26 30.10 25.47 24.77 28.33 23.34 31.32 24.42 23.12 
CL 26.87 23.34 28.26 25.93 23.83 27.46 21.57 29.57 22.61 23.75 
Table 4.4. Comparison of mean cycle threshold (Ct) value across different sample groups. 
NM = normal mucosa tissue (n=11); T = colon tumour (n=9); ENM = ex-vivo normal mucosa, 
untreated or treated with BMP4 or TGFβ in culture (n=8); CL = colorectal cancer cell lines, 
untreated or treated with BMP4, TGFβ, aspirin, lithium chloride or retinoic acid (n=20). 
 
     The stability of these candidate reference genes are then analysed and ranked for 














1 EIF2B1 TBP PUM1 EIF2B1 ABL1 
2 TBP RPL37A TBP RPL30 EIF2B1 
3 UBC EIF2B1 ABL1 ABL1 ACTB 
4 RPL30 UBC EIF2B1 ACTB RPL30 
5 PGK1 PUM1 RPL30 RPL37A RPL37A 
6 ABL1 ACTB RPS17 PUM1 PUM1 
7 PUM1 RPL30 RPL37A PGK1 PGK1 
8 RPS17 ABL1 PGK1 TBP TBP 
9 ACTB PGK1 UBC RPS17 RPS17 
10 RPL37A RPS17 ACTB UBC UBC 
Table 4.5. Stability ranking of the candidate endogenous genes in a representative sample 
set. NM=normal mucosa. 
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     Guided by these results, EIF2B1, TBP and RPL30 were selected as reference 
genes for future qRT-PCR experiments on normal mucosa samples. Although UBC 
was ranked 3rd in the normal mucosa samples, it was ranked 9th in the ex-vivo normal 
mucosa samples, and was the least stably expressed gen  in CRC cell lines. As many 
of the samples in these 2 groups have been treated with variable courses of 
BMP4/TGFβ, it is possible that perturbations of the SMAD signalling pathway have 
an effect on UBC transcript levels. Consequently, UBC was not selected as a control 
to avoid any bias during the normalisation of target genes in normal mucosa, many of 
which may be involved in, or targeted by, SMAD signalli g. 
     EIF2B1, TBP and RPL30 are also well-ranked in the other subgroups and when 
all samples were analysed altogether; at least two of the three genes were 
consistently in the top 5 most stable genes across all subgroups. This makes them 
good reference genes for experiments requiring intra- and inter- subgroup 














     Due to the speed, sensitivity and specificity it offers, qRT-PCR is widely used in 
molecular diagnostics, life sciences, agriculture and medicine to quantify gene 
expression (Bustin et al, 2000; Kubista et al, 2006). It is one of the key experimental 
methods used in my investigation of gene expression in the context of common 
genetic variation associated with colorectal cancer. As these common variants have 
small effect sizes on cancer risk, it is thought that the associated differential 
expression, if any, is likely to also be small. Henc , rigorous selection of stably 
expressed reference genes for normalisation is essential to remove experimentally-
induced errors and optimise the detection of subtle variation.  
     Examining expression microarray data from the tissue type of interest to identify 
putative reference genes has become a popular approach in our era of high-
throughput cell biology (Popovici et al, 2009; de Jonge t al, 2007). By using this 
approach, I selected the ten most stable candidates from thirty-two commonly used 
reference genes for further qRT-PCR validation. These t n putative reference genes 
represent different cellular processes; the ribosomal proteins RPL30, RPL37A and 
RPS17, and EIF2B1 are involved in protein synthesis, TBP is a general transcription 
factor, ACTB is a structural cytoskeletal protein, PGK1 is a glycolytic enzyme, 
PUM1 is an RNA-binding protein, UBC is involved in ubiquitination and ABL1 is a 
tyrosine kinase with a role in many key processes linked to cellular growth and 
survival. Using a set of genes representing a variety of cellular functions is ideal for a 
pilot experiment, as this means any perturbations resulting from experimental 
conditions are less likely to affect all the putative reference genes. It is interesting to 
point out that GAPDH, a commonly used reference gene, is relatively unstable within 
this data set with a MFC of 2.18. This is consistent with previously published reports 
where variations in GAPDH expression have been observed in qRT-PCR 
experiments (Barber et al, 2005; Harper et al, 2003). This reinforces the notion that 
the expression of control genes can vary depending on tissue-type and experimental 




     Once putative reference genes have been identified and qRT-PCR validation 
performed, the circular problem of evaluating the stability of these genes can be 
resolved using the aforementioned mathematical algorithms. As there is considerable 
variation in the correlation among the various algorithms (Jacob et al, 2013), I 
utilised a web-based tool that integrates the four most commonly used approaches to 
assess the stability of these genes. It quickly becom s apparent that the expression 
variability of these genes differs between the tissue ubgroups. Though unsurprising, 
as heterogeneity is more likely in the tumour and cell line subgroups as compared to 
normal mucosa, this again demonstrates that expression variation of reference genes 
is present and dependent, at least in part, on the tissue type. More importantly, the 
difference in the normal mucosa and ex-vivo normal ucosa subgroup suggests that 
perturbations of the SMAD signalling pathway could systematically affect 
expression of these ‘housekeeping’ genes. Given that the SMAD signalling pathway 
is frequently altered in cancer, it is all the more c ucial that reference genes are 
validated when the experimental setup involves comparison between normal and 
tumour tissue. A good post-hoc experiment would be to compare the expression of a 
gene of interest normalised with the most stable ref rence gene, and the same gene 
normalised with the least stable reference gene. Any demonstrable difference would 
consolidate the importance of rationalising reference genes prior to their use for 
normalisation.     
     It is strongly recommended that three or more reference genes are used to reduce 
the effect of any variation in a single reference gene. However, it is recognised that 
this may not always be cost-effective, especially in experiments where the expected 
fold change in the expression of the gene of interes  is substantially larger than any 
potential variation in the reference gene expression. In these instances, the need for 
normalisation accuracy may have to be weighed up against the practical constraints 
of time and resources. Such is the case with my siRNA knockdown studies in cell 
lines, where there is 75-90% knockdown of the target genes (Figure 8.13). The use of 
a single reference gene may not be ideal but on this occasion we have accepted it as a 
caveat, given that the differential expression of the genes of interest is appreciably 
larger than the fluctuation of the reference gene expression. Other biological factors 
may also influence the choice of the reference genes, and should be carefully 
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considered when the information is available. For example, one of my experiments 
involved quantifying the knockdown of NF-Y subunits, which is a ubiquitous 
transcription-factor that is known to bind to variety of genes (7.3.4).  In this instance, 
TBP would be a good reference gene as it is known t lack the CCAAT consensus 
sequence for NF-Y binding (Nardini et al, 2013), and will be more likely than other 
reference genes to be unaffected by the depletion of NF-Y. Hence, a combination of 
biological justification and validation with a pilot experiment provides the ideal 
platform for the informed selection of qRT-PCR refence genes.   
     In conclusion, the reference genes EIF2B1, TBP and RPL30 were chosen to 
validate any differential expression as identified by microarray analysis of the 





















Gender- and site-specific differential gene express ion in the 
human colorectal normal mucosa 
5.1 Introduction 
     To systematically characterise the functional effect of low-penetrance common 
genetic variation that are associated with susceptibility to colorectal cancer, whole-
genome gene expression microarray analysis was undertaken to look for evidence of 
association with gene expression. Before analysing the gene expression data in 
relation to genetic risk variants, several clinical v riables were first examined in 
relation to global gene expression, namely age, gender, cancer status and anatomical 
sampling-site. Although the relevance of this to the functional characterisation of risk 
variants may not be immediately apparent, it would provide insight into the 
regulation and heterogeneity of gene expression in the normal colorectal mucosa. 
Positive findings would inform the design of the risk variant analyses to minimise 
confounding effects of these variables, hence optimising the detection of subtle 
effects that are associated with inherited variation. Examining these variables that are 
known to affect gene expression levels will also prvide a form of internal validation 
of the microarray platform used in this study. 
     Age- and gender- related differences in gene expression in the colon is relevant 
for two reasons. Firstly, colorectal cancer incidence is higher in men than women and 
strongly increases with age (as reviewed by Brenner et al, 2014). Secondly, previous 
studies have indicated that there are age-related changes in gene expression levels 
occurring in various human tissue types (Somel et al, 2006; Glass et al, 2013), as 
well as sexual dimorphism in non-reproductive tissues (reviewed by Rinn et al, 
2006). Although this has not been specifically demonstrated in the human large 
intestine, there is evidence that expression of some genes are gender-biased in the 
oesophageal (Menon et al, 2011) and small intestinal mucosa (Sankaran-Walters et 
al, 2013).  
75 
 
     The concept of field cancerisation has been proposed to explain the development 
of multiple primary tumours in the same organ and locally recurrent cancer in 
patients who have multifocal cancer without apparent familial predisposition. 
Providing evidence for this is a study describing methylation of the MGMT gene 
promoter in normal-appearing colorectal mucosa adjacent to colorectal cancer with 
MGMT promoter methylation (Shen et al, 2005). The proximity to the tumour 
appeared to influence the likelihood of hypermethylation in the normal mucosa. In 
view of this, the normal mucosa samples in my study were collected from the 
resection margin furthest from the tumour to minimise any field effect that may be 
present, and the presenting pathology of the donor patients were categorised as 
cancer or non-cancer for gene expression analysis.  
     There are known epidemiological, clinical and molecular differences between 
proximal and distal colon tumours, suggesting that the risk factors and 
transformation pathways of sporadic colorectal cancer differ according to the 
anatomical location within the colon (as reviewed by Iacopetta et al, 2002).  This 
may reflect the different biological characteristic of the normal colorectal mucosa 
within the different segments, or a segmental heterogeneity in the gut environment 
i.e. the microbiome and metabolites, or most likely, the interaction between a distinct 
environment and distinct target cells. The known site- pecific differences in normal 
and cancerous conditions of the colon is summarised in Table 5.1. In view of this, the 
sampling site for each of the normal mucosa samples collected for this study were 






Figure 5.1 Schematic drawing of the 
human colon illustrating the splenic 
flexure cut-off point, which determines 
the proximal/distal classification used in 





NORMAL Proximal colon Distal colon 
Development Embryonic midgut Embryonic hindgut 




Average crypt length Shorter Longer 
Short-chain fatty acid production by 
fermentation 
8-fold higher  
Mutagenic metabolites  Higher exposure 
Metabolism of bile acids Higher  
Activity of ornithin decarboxylase  Higher 
Methylation of ER gene Higher  
 
B)  
CANCER Proximal colon Distal colon 
Mismatch repair defective   (MSI-H) 30% 2% 
Mucinous tumours Frequent Infrequent 
Familial cancer syndromes Lynch Syndrome FAP 
Karyotype Pseudo-diploid Aneuploid with LOH 
Gene mutations  (TP53 and K-RAS) 
and C-MYC expression 
Lower frequency Higher frequency 
5-FU chemotherapy response Good Marginal or none 
Gender Proportion of cancer in the distal colon is lower 
among women than among men 
Table 5.1 Summary of the differences between the proximal and distal colon, in both normal 







5.2 Methodological overview 
5.2.1 Study subjects and biological material 
     115 normal colorectal mucosa samples were collected from patients undergoing 
large bowel resections as described in 2.1. The chara teristics of the study subjects 
are summarised in Table 5.2 and detailed in Table 5.3. Study subjects were 
categorised by age (≤60 or >60), gender, presenting pathology (cancer vs without 








Cancer Without cancer 
Presenting pathology 
99 16 
Proximal colon Distal colon 
Anatomical sampling site 
39 76 
















Study ID Gender Age Site Condition Matched 
PBMC 
2335 M 61 Proximal Adenocarcinoma Yes 
11481 M 82 Distal Adenocarcinoma Yes 
11559 F 71 Distal Adenocarcinoma Yes 
11588 F 88 Distal Adenocarcinoma No 
11868 F 77 Proximal Adenocarcinmoa No 
11913 M 51 Distal Adenocarcinoma Yes 
11915 F 86 Proximal Adenocarcinoma No 
11981 F 77 Distal Diverticular disease No 
11986 F 73 Distal Tubulo-villous adenoma  No 
11990 M 63 Distal Diverticulitis  No 
12002 M 77 Proximal Adenocarcinoma No 
12003 F 65 Distal Adenocarcinoma Yes 
12032 F 75 Proximal Adenocarcinoma No 
12033 M 73 Proximal Adenocarcinoma Yes 
12037 M 80 Distal Adenocarcinoma Yes 
12039 F 57 Distal Adenocarcinoma No 
12040 M 56 Proximal Adenocarcinoma Yes 
12041 F 67 Proximal Adenocarcinoma Yes 
12042 F 75 Proximal Adenocarcinoma Yes 
12046 F 57 Distal Adenocarcinoma No 
12047 F 79 Proximal Adenocarcinoma No 
12048 F 64 Distal Adenocarcinoma Yes 
12049 M 69 Distal Adenocarcinoma Yes 
12050 F 74 Distal Adenocarcinoma No 
12051 M 71 Proximal Tubulo-villous adenoma No 
12052 M 61 Distal Tubulo-villous adenoma No 
12053 F 79 Proximal Adenocarcinoma No 
12054 M 66 Distal Villous adenoma No 
12056 F 71 Proximal Adenocarcinoma No 
12057 M 68 Distal Adenocarcinoma No 
12059 M 70 Distal Adenocarcinoma Yes 
12061 M 62 Distal Adenocarcinoma No 
12063 M 58 Distal Adenocarcinoma No 
12064 F 67 Distal Adenocarcinoma Yes 
12065 F 79 Distal Adenocarcinoma Yes 
12067 M 62 Distal Adenocarcinoma Yes 
12068 F 75 Proximal Tubulo-villous adenoma No 
12069 F 80 Proximal Adenocarcinoma No 
12070 F 71 Proximal Adenocarcinoma No 
12071 M 67 Distal Adenocarcinoma Yes 
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12100 M 58 Distal Adenocarcinoma  No 
12114 M 64 Proximal Adenocarcinoma No 
12147 F 47 Distal Adenocarcinoma Yes 
12202 M 42 Distal Adenocarcinoma Yes 
12208 F 87 Proximal Adenocarcinoma Yes 
12234 M 47 Distal Adenocarcinoma Yes 
12236 M 76 Distal Adenocarcinoma Yes 
12253 M 65 Proximal Adenocarcinoma Yes 
12254 M 67 Proximal Adenocarcinoma No 
12255 F 74 Proximal Adenocarcinoma Yes 
12256 F 57 Distal Adenocarcinoma Yes 
12259 M 75 Proximal Adenocarcinoma Yes 
12260 F 57 Distal Adenocarcinoma No 
12272 M 65 Distal Adenocarcinoma No 
12304 M 59 Proximal Adenocarcinoma Yes 
12305 M 63 Distal Adenocarcinoma Yes 
12307 F 67 Distal Adenocarcinoma No 
12312 F 42 Distal Intestinal dysmobility  No 
12316 M 77 Proximal Villous adenoma No 
12369 M 80 Distal Adenocarcinoma Yes 
12370 M 41 Distal Diverticular disease No 
12407 F 64 Distal Adenocarcinoma Yes 
12408 M 67 Distal Adenocarcinoma Yes 
12409 M 50 Distal Adenocarcinoma No 
12412 F 75 Proximal Adenocarcinoma Yes 
12415 M 80 Distal Adenocarcinoma No 
12419 M 65 Proximal Adenocarcinoma Yes 
12421 F 59 Distal Adenocarcinoma No 
12433 M 59 Distal Adenocarcinoma Yes 
12435 M 83 Distal Adenocarcinoma Yes 
12451 M 79 Distal Tubulo-villous adenoma No 
12454 F 64 Distal Diverticular disease No 
12464 F 72 Proximal Adenocarcinoma No 
12468 M 55 Distal Adenocarcinoma Yes 
12473 M 86 Distal Adenocarcinoma Yes 
12475 M 80 Distal Adenocarcinoma Yes 
12477 F 65 Distal Adenocarcinoma Yes 
12481 F 39 Distal Adenocarcinoma Yes 
12483 F 54 Distal Adenocarcinoma Yes 
12519 M 47 Distal Adenocarcinoma Yes 
12520 F 60 Proximal Adenocarcinoma Yes 
12529 M 62 Distal Adenocarcinoma Yes 
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12555 M 69 Distal Tubulo-villus adenoma No 
12562 F 52 Distal Diverticular disease No 
12568 M 69 Proximal Tubulo-villous adenoma No 
12584 M 48 Distal Adenocarcinoma No 
12586 M 62 Distal Adenocarcinoma Yes 
12587 M 63 Proximal Adenocarcinoma No 
12597 M 84 Proximal Adenocarcinoma Yes 
12602 M 73 Distal Adenocarcinoma Yes 
12609 M 71 Proximal Adenocarcinoma Yes 
12619 F 80 Distal Adenocarcinoma Yes 
12624 F 33 Distal Adenocarcinoma Yes 
12630 M 69 Proximal Adenocarcinoma Yes 
12631 M 69 Distal Adenocarcinoma Yes 
12633 M 75 Distal Adenocarcinoma No 
12634 F 66 Proximal Adenocarcinoma Yes 
12645 F 27 Distal Adenocarcinoma  No 
12646 F 69 Distal Adenocarcinoma Yes 
12647 M 82 Proximal Adenocarcinoma Yes 
12650 M 65 Proximal Adenocarcinoma Yes 
12659 M 71 Distal Adenocarcinoma Yes 
12660 M 68 Distal Adenocarcinoma Yes 
12668 M 79 Distal Adenocarcinoma No 
12669 F 75 Distal Adenocarcinoma Yes 
12726 F 60 Distal Adenocarcinoma No 
12741 F 71 Proximal Adenocarcinoma No 
12751 F 79 Distal Adenocarcinoma No 
12775 F 61 Distal Adenocarcinoma No 
12779 M 73 Distal Adenocarcinoma No 
12810 M 63 Distal Adenocarcinoma No 
12812 M 52 Distal Adenocarcinoma No 
12813 M 78 Distal Adenocarcinoma No 
12854 F 67 Proximal Adenocarcinoma No 
12856 F 74 Proximal Tubulo-villous adenoma No 
Table 5.3 Characteristics of the 115 study subjects – age, gender, sampling site (proximal or 








5.2.2 Gene expression profiling and analysis  
     RNA was extracted, amplified and hybridised on Illumina HT12 gene expression 
microarrays as described in 2.3. The expression profiles of the 115 normal mucosa 
samples were analysed using the R limma package as described in 2.6.2, using the 
co-variates age, gender, presenting pathology and anatomical sampling site as 
categorised in Table 5.2.3 
5.2.3 qRT-PCR validation 
     Technical validation was performed with qRT-PCR as described in 2.3. EIF2B1, 
RPL30 and TBP were selected as reference genes for normalisation s described in 
Chapter 4. The Taqman® Gene Expression assays for the genes of interest are listed 
in Table 5.4.  
Gene symbol Assay ID Context sequence  
PRAC Hs00741541_g1 AGAGTGCTTTTCTCTCTAATAAGAA 
PITX2 Hs04234069_mH GAGTCCGGGTTTGGTTCAAGAATCG 
CKB Hs01058288_g1 CCTCACCCAGATTGAAACTCTCTTC 
OLFM4 Hs00197437_m1 TCCCACTCCAGGGAGCTGTGGTCAT  
L1TD1 Hs00219458_m1 TTTTTCGCCAGGCACCAAGGCACAG 
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 Analysis performed by Graeme Grimes, MRC Human Genetics Unit, IGMM. 
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5.3    Results 
5.3.1 No detectable differential expression in the normal mucosa 
between age groups and presenting pathology 
Approximately 29,000 probes were detected in the normal mucosa (p-value<0.01), 
mapping to approximately 20,000 unique annotated genes. The expression profiles of 
the 115 normal mucosa samples were analysed using the R limma package and 
showed no detectable differential expression by age (≤60, n=28 ; >60, n=87) or 
presenting pathology (with cancer, n=99 ; without cancer, n=16). However, it should 
be noted that these variables are not well-balanced, reducing the power to detect 
associated differences. 
5.3.2 Gender-specific differential expression of th e human colorectal 
mucosa 
23 genes were more highly expressed in males (n=64) whereas 22 genes were more 
highly expressed in females (n=51). All the genes that were significantly 













Gene FC AvgExp FDR q-Val Chr Description 
RPS4Y1 17.55 9.09 8.68E-122 Y ribosomal protein S4, Y-linked 1  
EIF1AY 5.76 8.03 9.70E-100 Y eukaryotic translation initiation 
factor 1A, Y-linked  
CYORF15A 2.64 7.42 1.85E-77 Y taxilin gamma 2, pseudogene on 
chrY 
EIF1AY 1.92 7.09 1.34E-68 Y eukaryotic translation initiation 
factor 1A, Y-linked  
JARID1D 2.12 7.16 1.38E-64 Y lysine (K)-specific demethylase 
5D on chrY 
LOC643123 1.45 6.79 1.28E-47 Y arylsulfatase F pseudogene 1 
ZFY 1.33 6.65 1.50E-41 Y zinc finger protein, Y-linked  
TMSB4Y 1.51 6.81 7.04E-41 Y thymosin beta 4, Y-linked  
PRKY 1.40 6.83 1.18E-38 Y protein kinase, Y-linked, 
pseudogene  
RPS4Y2 2.91 7.46 2.39E-37 Y ribosomal protein S4, Y-linked 2  
UTY 1.28 6.74 8.53E-30 Y ubiquitously transcribed 
tetratricopeptide repeat 
containing, Y-linked  
USP9Y 1.14 6.54 7.16E-22 Y ubiquitin specific peptidase 9, Y-
linked  
TTTY2 1.12 6.58 8.39E-18 Y testis-specific transcript, Y-linked 
2 (non-protein coding)  
TTTY14 1.12 6.62 2.40E-13 Y testis-specific transcript, Y-linked 
14 (non-protein coding)  
CD99 1.30 8.82 3.53E-10 X CD99 molecule 
DDX3Y 1.09 6.58 3.13E-06 Y DEAD (Asp-Glu-Ala-Asp) box 
helicase 3, Y-linked  
NLGN4Y 1.05 6.51 1.23E-05 Y neuroligin 4, Y-linked  
OSCP1 1.06 6.68 0.006 1 organic solute carrier partner 1  
DPM3 1.11 8.43 0.037 1 dolichyl-phosphate 
mannosyltransferase polypeptide 
3  
MGC72104 1.19 8.30 0.039 Y FSHD region gene 1 family, 
member B 
CSTF3 1.12 7.93 0.043 11 cleavage stimulation factor, 3’ 
pre-RNA, subunit 3, 77kDa  
ZMYND12 1.06 6.81 0.046 1 zinc finger, MYND-type 
containing 12  
LOC729137 1.08 6.67 0.047 Y zinc finger protein 839-like 
Table 5.5 23 unique genes are more highly expressed in males than females, listed in the 
order of adjusted p-value. Where more than one probe is present for a single gene, the 
probe with the highest p-value is presented. FC=fold change as calculated by male/female 





Gene Fc AvgExp FDR q-Val Chr Description 
XIST 4.05 7.74 1.36E-71 X X inactive specific transcript (non-
protein coding)  
HDHD1A 1.40 7.99 7.44E-22 X Haloacid Dehalogenase-Like 
Hydrolase Domain Containing 1 
UTX 1.21 7.38 1.38E-17 X Ubiquitously transcribed 
tetratricopeptide repeat, X 
chromosome 
ARSD 1.54 9.03 8.04E-15 X arylsulfatase D  
ZFX 1.11 6.90 1.49E-09 X zinc finger protein, X-linked  
U2AF1L2 1.21 7.81 2.30E-09 X CCCH Type Zinc Finger, RNA-
Binding Motif And Serine/Arginine 
Rich Protein 
TRAPPC2 1.23 8.30 9.70E-09 X trafficking protein particle complex 
2  
PNPLA4 1.11 6.74 3.38E-08 X patatin-like phospholipase domain 
containing 4  
PRKX 1.09 6.94 4.36E-07 X protein kinase, X-linked  
RPS4X 1.30 11.22 7.15E-07 X ribosomal protein S4, X-linked  
ARSE 1.17 7.11 1.64E-06 X arylsulfatase E (chondrodysplasia 
84unctate 1)  
ZRSR2 1.07 6.71 1.67E-05 X zinc finger (CCCH type), RNA-
binding motif and serine/arginine 
rich 2  
HEPH 1.23 9.29 3.63E-05 X hephaestin  
DDX3X 1.21 9.80 0.001 X DEAD (Asp-Glu-Ala-Asp) box 
helicase 3, X-linked  
EIF1AX 1.33 8.32 0.003 X eukaryotic translation initiation 
factor 1A, X-linked  
OFD1 1.16 7.87 0.003 X oral-facial-digital syndrome 1  
GYG2 1.12 7.05 0.007 X glycogenin 2  
POF1B 1.11 6.96 0.008 X premature ovarian failure, 1B  
NLRP2 1.17 6.91 0.015 19 NLR family, pyrin domain 
containing 2  
NLGN4X 1.14 7.19 0.019 X neuroligin 4, X-linked  
UBE1 1.17 9.53 0.035 X ubiquitin-activating enzyme E1 
COPS8 1.08 7.26 0.047 2 COP9 signalosome subunit 8  
Table 5.6 22 unique genes are more highly expressed in females than males, listed in the 
order of adjusted p-value. Where more than one probe is present for a single gene, the 
probe with the highest p-value is presented. FC=fold change as calculated by female/male 





5.3.3 Gene expression differences between the human  proximal and 
distal colorectal mucosa 
There was differential expression in 1303 probes (1007 unique genes) between the 
proximal (n=39) and the distal colon (n=76) (p-value<0.05, FDR adjusted), with 55 
unique genes showing >1.5 fold difference. 29 of these genes were expressed at a 
higher level in the proximal colon and 26 in the distal colon, as listed in Table 5.7 
and Table 5.8.  
qRT-PCR validation of these expression differences wa performed for five out of 
twelve genes with a differential fold change of >2, confirming the site-related 
differential expression observed for PITX2 (p<2.2E-16), L1TD1 (p=5.3E-13), 
OLFM4 (p=2.7E-07), PRAC (p<2.2E-16) and CKB (p=3.6E-07).4 Highly significant 
correlations with Spearman Rho values of >0.75 were observed between the two 
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Gene FC AvgExp FDR q-Val Description 
PITX2 2.83 7.17 7.03E-39 paired-like homeodomain 2 
L1TD1 2.01 7.35 4.64E-19 LINE-1 type transposase domain 
containing 1 
ETNK1 2.35 8.46 8.67E-15 ethanolamine kinase 1 
SLC23A3 1.66 7.48 1.02E-14 solute carrier family 23, member 3 
IGFBP2 1.65 7.91 1.36E-12 insulin-like growth factor binding protein 
2, 36kDa 
MB 1.55 7.61 3.75E-11 myoglobin 
MEP1B 1.56 7.02 1.43E-09 meprin A, beta 
SLC20A1 1.82 10.07 3.23E-09 solute carrier family 20 (phosphate 
transporter), member 1 
NQO1 1.57 10.08 3.48E-08 NAD(P)H dehydrogenase, quinone 1 
ANPEP 2.17 9.31 6.71E-08 alanyl (membrane) aminopeptidase 
ADH1C 1.62 11.13 1.54E-07 alcohol dehydrogenase 1C (class I), 
gamma polypeptide 
OLFM4 3.18 11.15 3.82E-07 olfactomedin 4 
OASL 1.62 7.67 1.07E-06 2’-5’-oligoadenylate synthetase-like 
FAM3B 1.69 6.73 2.93E-06 family with sequence similarity 3, 
member B 
PROM1 1.62 9.77 1.39E-05 prominin 1 
NR1H4 1.56 7.85 3.73E-05 nuclear receptor subfamily 1, group H, 
member 4 
DEFB1 1.57 8.6 8.54E-05 defensin, beta 1 
C6ORF105 1.55 9.28 0.000233 androgen-dependent TFPI-regulating 
protein 
OSTALPHA 1.97 8.32 0.000235 Solute carrier family 51, alpha subunit 
CCL13 1.74 8.86 0.000345 chemokine (C-C motif) ligand 13 
CCL8 1.69 9.23 0.000442 chemokine (C-C motif) ligand 8 
UGT2B15 1.75 8.36 0.002264 UDP glucuronosyltransferase 2 family, 
polypeptide B15 
DEFA5 1.84 7.28 0.006333 defensin, alpha 5, Paneth cell-specific 
UGT2B11 1.85 10.08 0.007722 UDP glucuronosyltransferase 2 family, 
polypeptide B11 
NBPF20 1.52 8.55 0.008969 Neuroblastoma Breakpoint Family 
Member 20 
REG3A 1.56 6.91 0.009994 regenerating islet-derived 3 alpha 
UGT2B17 1.84 9.55 0.012681 UDP glucuronosyltransferase 2 family, 
polypeptide B17 




9.58 0.021505 vasoactive intestinal peptide 
Table 5.7 Genes that are more highly expressed in the proximal colon compared to the distal 
colon, listed in order of adjusted p-value. Where more than one probe is present for a single 
gene, the probe with the highest p-value is presented. FC=fold change as calculated by 





Gene FC AvgExp FDR q-Val Description 
PRAC 17.39 9.26 7.76E-46 prostate cancer susceptibility gene 1 




CLDN8 3.29 9.54 1.68E-15 claudin 8 
ST3GAL4 1.66 7.36 2.99E-15 ST3 beta-galactoside alpha-2,3-
sialyltransferase 4 
HOXB13 1.85 7.13 5.78E-15 homeobox B13 
SPON1 1.61 9.38 7.52E-13 spondin 1, extracellular matrix protein 
LGALS2 1.85 8.56 1.77E-11 lectin, galactoside-binding, soluble, 2 
CAPN13 1.71 8.69 7.30E-11 calpain 13 
LOC387882 1.54 8.64 3.92E-09 uncharacterised 
CKB 2.06 10.79 5.19E-09 creatine kinase, brain 
MUC17 2.10 8.36 1.13E-08 mucin 17, cell surface associated 
TFF1 2.51 8.51 4.44E-08 trefoil factor 1 
LOC401321 1.65 8.35 6.80E-08 uncharacterised 
CRIP1 1.73 10.87 1.58E-07 cysteine-rich protein 1 (intestinal) 
WFDC2 1.84 8.58 1.97E-07 WAP four-disulfide core domain 2 
KRTAP13-2 1.77 7.12 6.40E-07 keratin associated protein 13-2 
SPINK5 1.64 7.50 1.07E-06 serine peptidase inhibitor, Kazal type 5 
MUC12 1.93 10.18 1.19E-06 mucin 12, cell surface associated 
PYY 1.75 8.63 5.02E-06 peptide YY 
TMEM200A 1.52 7.72 2.52E-05 transmembrane protein 200A 
PI3 2.14 8.65 7.83E-05 peptidase inhibitor 3, skin-derived 
GLDN 1.53 6.92 8.54E-05 gliomedin 
GCG 1.73 9.07 0.000255 glucagon 
SLC28A2 1.57 7.45 0.001927 solute carrier family 28 (concentrative 
nucleoside transporter), member 2 
S100P 1.66 9.40 0.004687 S100 calcium binding protein P 
INSL5 1.58 7.12 0.006683 insulin-like 5 
Table 5.8 Genes that are more highly expressed in the distal colon compared to the proximal 
colon, listed in order of adjusted p-value.  Where more than one probe is present for a single 
gene, the probe with the highest p-value is presented. FC=fold change as calculated by 








Figure 5.2. A) Boxplots of PITX2 expression as quantified by the Illumina HT12 microarray 
or qRT-PCR (unpaired t-test, p<2.2E-16). B) Scatterplot demonstrating the relationship 
between the expression of PITX2 as measured by the two different techniques (Spearman 
rho=0.843, p-value=< 2.2e-16). 
 
 















































Correlation between HT12 and qRTPCR measurement of PITX2























Figure 5.3. A) Boxplots of L1TD1 expression as quantified by the Illumina HT12 microarray 
or qRT-PCR (unpaired t-test, p=5.3E-13). B) Scatterplot demonstrating the relationship 
between the expression of L1TD1 as measured by the two different techniques (Spearman 
rho=0.828, p-value=< 2.2e-16). 
 












































Correlation between HT12 and qRTPCR measurement of L1TD1






















Figure 5.4. A) Boxplots of OLFM4 expression as quantified by the Illumina HT12 microarray 
or qRT-PCR (unpaired t-test, p=2.7E-07). B) Scatterplot demonstrating the relationship 
between the expression of OLFM4 as measured by the two different techniques (Spearman 
rho=0.895, p-value=< 2.2e-16). 
 








































Correlation between HT12 and qRTPCR measurement of OLFM4























Figure 5.5. A) Boxplots of PRAC expression as quantified by the Illumina HT12 microarray 
or qRT-PCR (unpaired t-test, p<2.2E-16). B) Scatterplot demonstrating the relationship 
between the expression of PRAC as measured by the two different techniques (Spearman 
rho=0.791, p-value=< 2.2e-16). 
 































Correlation between HT12 and qRTPCR measurement of PRAC









































Figure 5.6. A) Boxplots of CKB expression as quantified by the Illumina HT12 microarray or 
qRT-PCR (unpaired t-test, p=3.6E-07). B) Scatterplot demonstrating the relationship 
between the expression of CKB as measured by the two different techniques (Spearman 
rho=0.759, p-value=< 2.2e-16). 
 





































Correlation between HT12 and qRTPCR measurement of CKB

























     A functional enrichment analysis indicated that genes that were more highly 
expressed in the proximal colon were enriched in gees involved in substrate 
metabolism processes, whereas genes that were more highly expressed in the distal 
colon were enriched for secreted proteins (Table 5.9).
A) 
Category Term FDR adjusted q-
value 
KEGG_PATHWAY Pentose and glucuronate interconversions 1.30E-05 
KEGG_PATHWAY Ascorbate and aldarate metabolism 1.40E-05 
PIR_SUPERFAMILY Glucuronosyltransferase 1.40E-05 
KEGG_PATHWAY Drug metabolism 1.70E-05 
KEGG_PATHWAY Metabolism of xenobiotics by cytochrome P450 2.20E-05 
KEGG_PATHWAY Retinol metabolism 2.90E-05 
INTERPRO UDP-glucuronosyl/UDP-glucosyltransferase 6.00E-05 
KEGG_PATHWAY Porphyrin and chlorophyll metabolism 7.10E-05 
KEGG_PATHWAY Androgen and estrogen metabolism 8.70E-05 
KEGG_PATHWAY Drug metabolism 1.10E-04 
KEGG_PATHWAY Starch and sucrose metabolism 1.10E-04 
KEGG_PATHWAY Steroid hormone biosynthesis 1.20E-04 
GOTERM_MF_FAT glucuronosyltransferase activity 3.60E-04 
GOTERM_CC_FAT extracellular space 4.60E-04 
GOTERM_CC_FAT extracellular region part 2.60E-03 
UP_SEQ_FEATURE signal peptide 2.80E-03 
SP_PIR_KEYWORDS signal 3.20E-03 
GOTERM_CC_FAT extracellular region 1.30E-02 
SP_PIR_KEYWORDS microsome 2.10E-02 
B) 
Category Term FDR adjusted q-
value 
SP_PIR_KEYWORDS Secreted 5.2E-03 
Table 5.9 Functional annotation of pathways, processes and GO terms that are over-
represented in genes that were more highly expressed by >1.5 fold in A) proximal colon; B) 
distal colon. This enrichment analysis was performed using DAVID (as described in 2.6.3) 





     The examination of whole-genome gene expression pr files in relation to clinical 
variables thought to influence gene expression in the colon has detected gender- and 
anatomical site-specific expression differences. There were no detectable age- or 
cancer-related effects, but the power of these analyses are likely to be limited by the 
small numbers and skewed demographics of patients pre enting for non IBD 
(inflammatory bowel disease) -related large bowel resections.  
     The large majority of genes that are more highly expressed in the colorectal 
mucosa of my male subjects are Y-linked. Rather unexpectedly, there is an X 
chromosome gene CD99 that appears to be more highly expressed in males. It is a 
pseudoautosomal gene with a role in innate immunity, and its expression has been 
reported to be higher in the monocytes of males at baseline levels and after in vitro 
lipopolysaccharide stimulation (Lefevre et al, 2012), albeit in a different tissue type. 
The directionality of this reported difference is reassuring and may be of general 
interest, as gender is known to influence the severity and evolution of various 
inflammatory conditions. However, gender-bias is not a general feature of 
inflammatory bowel disease, except in the Asian population where male 
predominance in IBD is typically observed.  
     On the other hand, the majority of the female-biased genes in the colon are X-
linked and are recognised to escape, at least partially, X-inactivation. XIST is the 
obvious exception, as it is a non-coding RNA gene that is the major effector of the 
X-inactivation process and hence only expressed on the inactive X in females. A 
number of these X-linked genes have functionally equivalent Y homologues, and the 
higher expression in females is likely to reflect the mechanism by which dosage 
compensation between males and females are achieved. For instance, RPS4X 
(ribosomal protein S4, X-linked) is more expressed in females, whereas RPS4Y1 
(ribosomal protein S4, Y-linked) is more expressed in males. Other genes similarly 
implicated are EIF1AX, DDX3X, UTX, ZFX, NLGN4X, and PRKX. The other X-
linked genes such as ARSD (Carrel et al, 2005), HDHD1A (Yen et al, 1993), 
TRAPPC2 (Mumm et al, 2001), UBE1 (Carrel et al, 1996), OFD1 (Carrel et al, 
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2005) have previously been reported as escaping X-inactivation in other tissue types. 
The chromosome 19 gene NLRP2 is not known to have gender differences in 
expression. However, it has been reported to be reduced in axial spondyloarthropathy 
(Sharma et al, 2009), which has a marked male predominance, and the authors could 
not exclude a possible effect of gender on the level of transcript expression.  This is 
interesting as firstly, this is in line with the differential expression of NLRP2 
favouring females in the colorectal mucosa, and secondly, NLRP2 is a component of 
some inflammasomes (Church et al, 2008) with inhibitory effects on NF-kB and 
activating effects on caspase 1. This may reflect common aetiological pathways as 
colorectal cancer also sees a male predisposition and the connection between 
inflammation and colorectal tumorigenesis is well-rcognised (as reviewed by Terzić 
et al, 2010). Overall, the gender-specific differential expression detected in the 
colorectal mucosa is largely consistent with known biological processes and 
published literature, providing confidence in the integrity of the samples, the 
microarray platform used and the processing of the data.  It also demonstrates the 
importance of adjusting for gender in any differential gene expression analysis.  
Over half of the site-specific differentially express d genes detected in my samples 
have been previously identified to be differentially expressed, including PITX2, MB, 
ETNK1, SLC23A3, IGFBP2, SLC20A1, MEP1B, ANPEP, OASL, FAM3B, NRIH4, 
OSTalpha, CCL13, CCL8, DEFA5, PRAC, CLDN8, HOXB13, SPON1, CAPN13, 
CKB, MUC17, TFF1, CRIP1, WFDC2, SPINK5, MUC12, PYY, PI3, GCG and 
S100P. Although the fold differences for these genes are not always consistent with 
other published studies, the directionality of the differential expression are in 
accordance with the findings of other similar investigations (Birkenkamp-Demtroder 
et al, 2005; Glebov et al, 2003; LaPointe, 2008).  
Five genes were selected for qRT-PCR validation, of which PRAC, PITX2 and CKB 
have previously been described to have site-specific differences in transcript 
abundance. PRAC is known to be expressed only in human prostate, prostate cancer, 
rectum and the distal colon. Possible co-transcription with HOXB13 and sequence 
analysis suggests a regulatory role in the nucleus (Liu et al, 2001). PITX2 is 
responsible for the establishment of the left-right axis (Logan et al, 1998), 
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asymmetrical development of visceral organs (Shiratori et al, 2006) and gut looping 
(Campione et al, 1999). It is overexpressed in colorectal cancer (Hirose et al, 2011) 
and has been shown to be induced by the Wnt/beta-catenin pathway and required for 
cell-type-specific proliferation (Kioussi et al, 2002). CKB is a cytosolic isoform of 
creatine kinase that is central in cellular energy homeostasis, and has been previously 
shown to promote EMT (Mooney et al, 2011). L1TD1 and OLFM4 are novel genes 
with detectable site-specific expression. Apart from providing technical validation, 
these two novel genes are interesting findings due to their known function in normal 
and diseased tissue. L1TD1 codes for a stem-cell specific RNA-binding protein that 
has a role in the regulation of stemness. It has been shown to be abundantly 
expressed in undifferentiated human embryonic stem c lls (Wong et al, 2011) and 
influences their self-renewal, acting downstream of pluripotent cell-specific 
transcription factors OCT4, SOX2 and NANOG (Narva et al, 2012). OLFM4 is a 
marker for stem cells in the human intestine with restricted expression at the crypt 
base columnar cells (van der Flier et al, 2009). It is a glycoprotein that is selectively 
expressed in inflamed colorectal epithelium and secret d into the mucus in active 
IBD (Gersemann et al, 2012), as well as a candidate biomarker for adenomas and 
non-metastatic colorectal cancer (Besson et al, 2011). There is also evidence that 
OLFM4 exerts an influence on the host defense against H. pylori infection by acting 
through NOD1/NOD2 mediated NF-kB activation (Liu et al, 2010). The site-specific 
expression of these two genes is suggestive of differences in stem cell dynamics and 
self-renewal regulatory properties between the proximal and distal colon, as well as 
the cellular response to inflammatory processes. This may in turn have an influence 
on transformation and the initiation of cancer, particularly as the cancer cell of origin 
is thought to originate from adult intestinal stem cells. Protein quantification and 
localisation within the large intestinal crypt of these site-specific expression 
differences would provide an additional degree of validation, and offer further 
insight into how these site-specific differences are relevant to the aetiology of 
tumourigenic pathways.  
Apart from lending support to the notion that left and right-sided CRC tumours have 
distinctive aetiologies, these findings also suggest that regulatory mechanisms are 
distinctively different between the two segments. Hence, it is important to account 
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for these potentially confounding differences when performing genotype-gene 
expression association analysis in the normal mucosa. Linear regression modelling 
conditional on the sampling site will serve to remove any confounding effects of site-
specific expression, if by chance more of one allele is found in samples taken from a 
certain side of the colon. However, this may be an over-simplistic view as the 
majority of these normal mucosa samples are harvested from surgical specimens 
resected from patients with colorectal cancer/adenomas, and the site of the normal 
mucosa almost always represents the site of the cancer. There is a possibility that co-
segregation of genotype and sampling site (representing the tumour site) are not 
arising by chance, i.e. left- and right-sided tumours have different genetic 
predispositions. GWAS to date have examined genetic predisposition to CRC cancer 
in relation to their location, but this categorisation was limited to the colon versus the 
rectum, with no further subdivision into the proximal or distal colon. For instance, 
the 11q23.1 locus confers risk that was greater for rectal than for colon cancer 
(Tenesa et al, 2008), and one might speculate that there could also be differential 
genetic risk within the colon. Also, there may be sit - pecific eQTL that may not be 
detected even when the modelling is conditioned for site, as any effect in one site 
could be masked by the lack of/opposing effect in the other site. Analysing the 
samples as two distinct tissue types (proximal colon vs distal colon) would be more 
ideal in this regard; however, this will significantly reduce the sample size and 
subsequently the power to detect eQTL. Due to the relatively small sample size 
(n=115) and the targeted nature of my analysis to the 25 colorectal risk variants only, 
it was decided not to analyse the different sites separately to maintain power. This 
will be of more importance in the longer term, when more samples are collected and 
added to this dataset, especially for future whole-genome eQTL studies that are 
already ongoing using this data.  
Overall, the identification of factors that affect global expression in the tissue 
substrate demonstrates the importance of examining and adjusting for them in any 
genotype-gene expression analysis, as this will reduc  the noise within the 
expression phenotype and improve detection. In addition, this analysis has identified 
some novel differentially expressed genes that could potentially inform other studies 




 Chapter 6 
Cis-eQTL analysis of low-penetrance common genetic 
variants associated with colorectal cancer predisposition 
6.1 Introduction 
     At the point of the conception of this study, there was no strong evidence that 
colorectal cancer associated genetic loci exhibits eQTL effects, although two of them 
are in linkage disequilibrium with cis-eQTLs – rs7136702 was in moderate to strong 
LD with four SNPs previously associated with DIP2B expression in lymphoblastoid 
cell lines, and rs492536 was in moderate to strong LD with an eQTL for LAMA5 
expression in the liver tissue (Houlston et al, 2010). This provides some functional 
evidence for these risk variants, as studies have shown that a substantial number of 
eQTLs are shared across diverse tissue types (Bullaughey et al, 2009; Zeller et al, 
2010). Other studies, however, have indicated that eQTLs are likely to be cell- or 
tissue-specific (Cowley et al; 2009, Dimas et al; 2009) – this may explain the lack of 
eQTL associations seen so far with CRC susceptibility loci. Furthermore, it is yet 
unclear how risk alleles exert their causative effect, ither directly within the target 
tissue or by modifying the cellular phenotypes of other cell types that in turn act 
upon the target tissue. Careful deliberation should therefore be given when defining 
the tissue/cell substrate for eQTL studies.  
     Considering that colorectal carcinomas are epith lial in origin, examination of 
eQTLs within the normal non-aberrant colonic mucosa and matched peripheral blood 
mononuclear cells would serve as a useful empirical starting point for the functional 
characterisation of CRC-associated loci in a systema ic manner, with the hypothesis 
that they exert their effect on risk by influencing baseline gene expression. As the 
sample size of my study is relatively small (n=115), I will focus on the possibility of 
their role as cis determinants of gene expression, as polymorphic cis-acting variants 
often have a large effect on the expression level of the target gene and are easier to 




expression of genes within 2Mb upstream or downstream of the tagging SNPs will be 
analysed in relation to the genotype of the tagging SNPs. Any eQTL association will 
be followed-up with fine association mapping, firstly, to identify candidate 
functional variants, and secondly, to identify with better precision where the 
regulatory variants are relative to the target genes. Case-control comparisons of these 
putative eQTL functional variants will then be performed, with the rationale that a 
variant that better explains both target gene expression and CRC risk will be more 



















6.2 Methodological overview 
6.2.1 Study subjects and biological material 
     To explore the effect of risk variants on gene xpression in the normal colonic 
mucosa, 115 fresh normal colorectal mucosa were harvested immediately as 
described in 2.1 after surgical resection of colorectal adenocarcinomas (n=99), 
tubulo-villous (n=8) and villous (n=2) adenomas or n n-neoplastic conditions (n=6). 
Matched PBMC were collected from 60 of the 115 subjects, of which 59 were used 
for gene expression analysis. The characteristics of the study subjects are detailed in 
Table 5.3 in Chapter 5. 
6.2.2 RNA extraction and gene expression quantification of cis-genes  
     RNA was isolated from the tissue samples as described in 2.3.1. The expression 
of the cis-genes within a 2Mb radius of each individual risk locus was derived from 
whole-transcriptome gene expression profiling of the normal mucosa and PBMC as 
described in 2.3.6. 
6.2.3 Genotyping of CRC risk loci 
     Genotypes were obtained by hybridising genomic DNA extracted from EDTA-
venous blood on the HumanOmni5M-4v1_B BeadChip Arrays (Illumina, USA), 
which includes ~5 million SNP markers. Genotypes for 3 SNPs (rs4813802, 
rs10911251 and rs3824999) were not available on the array platform and were 
imputed using IMPUTE2 after phasing with SHAPEIT.1 he 1000 genomes panel 
(Pilot1 Version3 release) was used as a reference. Post-imputation SNPs with an info 
value of <0.3 were excluded. All variants were annotated and presented according to 
the human reference sequence build GRCh37.p12 (hg19). 
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6.2.4 Local eQTL analysis and regional fine-mapping 
     eQTL analysis between genetic variants and level of gene expression was 
performed using linear regression as implemented in the R package “MatrixEQTL” 
using an additive genetic model.2 The analysis of normal mucosa was adjusted for 
age, gender and anatomical sampling site, whereas the analysis of PBMC was 
adjusted for age and gender only. For X-linked SNPs, male hemizygotes were treated 
as homozygotes. For each GWAS SNP, a distance of 2Mb upstream and downstream 
was used as a cut-off for cis-genes. A minimum significance level of nominal p=0.01 
was considered relevant for reporting. To account for multiple comparisons, a 
Bonferroni correction was applied, taking into account the number of genes tested 
within each 4Mb region. The Bonferroni correction method was used based on the 
assumption that each individual test was independent of each other, and was selected 
over the Benjamini-Hochberg FDR procedure as there w r  relatively small numbers 
of cis-genes tested for each locus.  
     For each eQTL identified, fine-mapping of the region in linkage disequilibrium 
with the tagging SNP was performed in relation to the expression of the target gene. 
Regional visualisation of the fine-association mapping was performed using the web 
tool LocusZoom (Pruim et al, 2010; URL6.1) to produce Manhattan plots that 
display the strength of genetic association (-log10 p-value) with target gene 
expression versus chromosomal position. Each dot repres nts a genotyped or 
imputed SNP, and dot colours signify the degree of pairwise correlation (r2) with the 
tagging SNP, as presented in the colour key. Grey dots epict SNPs for which r2 
values are unknown.  
6.2.5 Case-control study of candidate functional SNPs 
     Candidate functional SNPs identified from eQTL fine-association mapping were 
evaluated for their association with CRC in a case-control study (Scotland Phase 1; 
cases=939, controls=945; males=965, females=919).3 Genotypes were obtained by 
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hybridising genomic DNA extracted from EDTA-venous blood on the Illumina 300K 
or Illumina 240K BeadChip Arrays (Illumina, USA), and SNPs not available on 
these arrays were similarly imputed as described in 6.2.3.  Similar to the cis-eQTL 
analysis, male hemizygotes were treated as homozygotes f r X-linked SNPs. 
6.2.6 Technical and biological validation of the Xp22.2 eQTL locus 
     Technical validation of the association between rs5934683 genotype and 
SHROOM2 expression was performed with qRT-PCR using the Taqman® Gene 
Expression assay (ABI) (Table 6.1). The correlation between HT12 microarray 
expression and qRT-PCR was tested statistically with the Spearman correlation test. 
The association between rs5934683 genotype and SHROOM2 expression as 
quantified by qRT-PCR was analysed in R, using linear regression modelling 
corrected for age, gender and anatomical sampling site.  
Table 6.1 A technical comparison between the two methods used for detection of 
SHROOM2 expression.   
     A further level of biological replication was introduced at the level of normal 
mucosa sampling and RNA extraction. In a subset of 37 patients (males=15, 
females=22), 2 further RNA extracts were prepared from the normal mucosa 
harvested at the same time as the first extract but with spatial variation within the 
same colonic site. SHROOM2 was quantified with qRT-PCR, and a nested one-way 
ANOVA was used to statistically account for the multiple levels of replication. 
 ILLUMINA HT12 MICROARRAY  TAQMAN® GENE EXPRESSION 
ASSAY  
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6.3.1 Local eQTL associations of CRC risk loci in normal colorectal 
mucosa and PBMC 
     In the normal colorectal mucosa, 15 SNP-gene expression associations in ten risk 
loci were identified (nominal p-value <0.01) for genes within 2Mb radius of the CRC 
risk variants (Table 6.2). The more stringent Bonferroni correction was performed to 
reduce the number of false positives as any associations will require follow-up with 
validation studies. Five of these associations were significant (adj. p <0.05) after 
Bonferroni correction. In PBMCs, 13 SNP-gene expression associations in seven risk 
loci were identified, of which five were significant (p <0.05) after Bonferroni 
correction (Table 6.3). One eQTL was present in both tissue types (rs7136702-
CERS5), but the association in the normal mucosa did not survive multiple 
correction testing. Several other SNPs had local eQTL effects in both tissue types, 
but the genes that were associated did not overlap and the majority of them were only 
nominally significant in at least one of the tissue types. Two variants, rs11169552 
(12q13.12) and rs16892766 (8q23.3) had local eQTL associations in both tissue 
types that survived multiple testing. rs11169552 is as ociated with the expression of 
SPATS2 in the normal mucosa (adj. p=0.033) and expression of LIMA1 in PBMC 
(adj. p=0.046), whereas rs16892766 is associated with the expression of UTP23 in 










SNP Locus Gene Description p-val Adj. p Beta 
rs3802842 11q23.1 COLCA2 colorectal cancer 
associated 2  
6.85e-14 1.92e-12 -0.16 
rs3802842 11q23.1 COLCA1 colorectal cancer 
associated 1  
2.16e-11 6.05e-10 -0.11 
rs5934683 Xp22.2 SHROOM2 shroom family member 2  4.17e-10 5.00e-09 -0.14 
rs11169552 12q13.12 SPATS2 spermatogenesis 
associated, serine-rich 2  
4.11e-04 3.25e-02 -0.06 
rs16892766 8q23.3 UTP23 small subunit (SSU) 
processome component, 
homolog (yeast) 
8.75e-04 7.88e-03 -0.06 
rs4925386 20q13.33 OSBPL2 oxysterol binding protein-
like 2 
1.73e-03 1.21e-01 0.09 
rs6687758 1q41 HLX H2.0-like homeobox  2.13e-03 6.17e-02 0.04 
rs7136702 12q13.12 CERS5 ceramide synthase 5 2.23e-03 1.85e-01 -0.06 
rs3217810 12p13.32 TEAD4 TEA domain family 
member 4 
2.79e-03 1.12e-01 -0.03 
rs11169552 12q13.12 SMARCD1 SWI/SNF related, matrix 
associated, actin 
dependent regulator of 
chromatin, subfamily d, 
member 1 
2.98e-03 2.35e-01 -0.08 
rs16969681 15q13.3 NOP10 NOP10 ribonucleoprotein 5.31e-03 1.59e-01 0.13 
rs4925386 20q13.33 KCNQ2 potassium channel, 
voltage gated KQT-like 
subfamily Q, member 2 
7.16e-03 5.01e-01 -0.03 
rs16969681 15q13.3 FAN1 FANCD2/FANCI-
associated nuclease 1 
8.22e-03 2.47e-01 -0.12 
rs1321311 6p21.2 FGD2 FYVE, RhoGEF and PH 
domain containing 2 
9.23e-03 4.25e-01 0.15 
rs7136702 12q13.12 PRPH peripherin 9.70e-03 8.05e-01 -0.15 
Table 6.2 CRC risk SNPs that show an association (nominal p-value<0.01) with the 
expression of cis-genes in normal colorectal mucosa (n=115). Associations that are 







SNP Locus Gene Description p-val Adj. p Beta 
rs7136702 12q13.12 CERS5 ceramide synthase 5 1.0e-05 7.66e-04 -0.12 
rs11169552 12q13.12 LIMA1 LIM domain and actin 
binding 1 
6.5e-04 4.63e-02 -0.08 
rs961253 20p12.3 RP11-
19D2.2 
lincRNA 6.7e-04 1.47e-02 -0.05 
rs1321311 6p21.2 MDGA1 MAM domain containing 
glycosylphosphatidylinosito
l anchor 1 
1.1e-03 4.86e-02 0.06 
rs1321311 6p21.2 CMTR1 cap methyltransferase 1 2.8e-03 1.28e-01 0.12 
rs16892766 8q23.3 MED30 mediator complex subunit 
30 
4.2e-03 3.32e-02 0.12 
rs1321311 6p21.2 MAPK14 mitogen-activated protein 
kinase 14 
6.7e-03 3.07e-01 -0.10 
rs11169552 12q13.12 ATF1 activating transcription 
factor 1 
6.8e-03 4.79e-01 -0.04 
rs7136702 12q13.12 SPATS2 spermatogenesis 
associated, serine-rich 2  
9.5e-03 7.10e-01 0.05 
rs11169552 12q13.12 DIP2B DIP2 disco-interacting 
protein 2 homolog B 
(Drosophila) 
9.7e-03 6.92e-01 0.06 
rs3824999 11q13.4 GDPD5 glycerophosphodiester 
phosphodiesterase domain 
containing 5 
5.2e-03 2.36e-01 -0.14 
rs6691170 1q41 DUSP10 dual specificity 
phosphatase 10 
7.8e-03 2.03e-01 -0.03 
rs6691170 1q41 MARC1 mitochondrial amidoxime 
reducing component 1  
9.1e-03 2.35e-01 0.28 
Table 6.3 CRC risk SNPs that show an association (nominal P value<0.01) with the 
expression of cis-genes in PBMC (n=59). Associations that are significant (adj. p<0.05) after 










6.3.2 Identification of putative functional variants underlying individual 
eQTL associations in the normal mucosa 
     In the normal mucosa, the strongest association was seen with rs3802842 which 
tags the locus 11q23.1. This SNP was found to be highly associated with the two 
genes that it is intronic to: COLCA2 (adj. p-val=1.92e-12) and COLCA1 (adj. p-
val=6.05e-10), two uncharacterised genes that appear to be co-regulated and 
transcribed from opposite strands. These 11q23 eQTL associations have recently 
been published by two separate groups (Closa et al, 2014; Peltekova et al, 2014), 
providing independent replication and validation to our findings. The 11q23.1 locus 
corresponds to a 150kb region of LD, and fine associati n mapping of the region 
showed that five SNPs that are in high LD with rs3802842 were more significantly 
associated with the expression of COLCA2 (Figure 6.1), four of which were also 
more significantly associated with the expression of COLCA1 (Figure 6.2). This 
suggests that they may be better functional candidates than the tagging SNP.  In a 
CRC case-control study of 939 cases and 945 controls, only one of these SNPs 
rs11213801 showed a marginally better association with CRC risk (Table 6.4). 
Further genotyping and analysis of the variation within this locus was taken forward 
by fellow PhD student Claire Smillie. 
     The second locus that exhibited eQTL properties was rs59364683 at Xp22.2. This 
SNP is intronic to a putative GPR143 transcript but an association with this gene was 
not observed (nominal p=0.083). Instead, a strong association was observed with the 
expression of neighbouring gene SHROOM2 (adj. p=5.0e-09), which lies 
approximately 3kb downstream from the locus tagging SNP.  Indeed, this cis-eQTL 
association was detectable even in a preliminary analysis of SHROOM2 expression 
in an early subset of these normal mucosa samples (n=42, nominal p=1.3e-07), 
accounting for 55% of the variation in SHROOM2 expression (as reported in Dunlop 
et al, 2012). The SHROOM2 association was also replicated in another study recently 
(Closa et al, 2014), but the authors also predicted an associati n with GPR143 which 
was not observed in my samples. Fine-mapping of this eQTL locus revealed four 
SNPs within the first intron of SHROOM2 that are more highly associated with 




associated with CRC risk with higher odds ratio than the tagging SNP (Table 6.5), 
which is suggestive of a functional role.  
     The two other CRC risk SNPs that exhibited loca  eQTL effects, albeit much 
weaker, were rs11169552 (12q13.12) and rs16892766 (8q23.3). rs11169552 is an 
intergenic SNP that has been recently shown to be an QTL for neighbouring gene 
DIP2B (Closa et al, 2014) but this was not seen in my dataset (nominal p= 0.14 and 
0.86, two expression probes present). Fine-mapping of this region for both DIP2B 
probes did not reveal any eQTL associations in the 500kb region in LD with the 
tagging SNP (Figure 6.4). rs11169552 is, however, associated with expression of 
SPATS2 which is approximately 1.2Mb upstream (adj. p=0.033). It is the best eQTL 
in this region for SPATS2, and is in high LD with four other intronic SNPs within 
neighbouring gene ATF1 (Figure 6.5). These four SNPs appear to be in perfect LD 
with one another, and likely represent a single genetic signal.  
     rs16892766 (8q23.3) is an intergenic variant tha appears to be an eQTL locus for 
nearby gene UTP23 (adj. p=0.008). Fine-mapping of the region revealed 11 other 
SNPs in LD that are more significantly associated with expression of UTP23 (Figure 
6.6); the majority of them are intronic variants within EIF3H and UTP23, with one 
missense variant (rs16888728) that is predicted by SIFT and PolyPhen to be a 
tolerated/benign variant. However, none of these SNPs showed an association with 

























Figure 6.1 A) Boxplot showing the rs3802842 genotype association with COLCA2 (also 
known as C11orf93) expression in normal colorectal mucosa. B) Fine association mapping 




















Figure 6.2 A) Boxplot showing the rs3802842 genotype association with COLCA1(also 
known as C11orf92) expression in normal colorectal mucosa. B) Fine association mapping 















Table 6.4 Variants that are more significantly associated with normal mucosa A) COLCA2, 
and B) COLCA1 expression than the tagging SNP rs3802842, listed in order of their eQTL 
significance values. The tagging SNP is included and highlighted for reference. p-values and 
effect sizes for their eQTL association and CRC risk (case-control comparison) are 
presented.  
SNP SNP position Predicted function p-value beta p-value OR 
rs3087967 chr11:111156836 C11orf53 3’ UTR 
variant 
8.53e-15 -0.165 9.22e-03 1.20 
rs7130173 chr11:111154072 C11orf53 intron 
variant 
8.53e-15 -0.165 1.36e-02 1.20 
rs7103178 chr11:111165009 COLCA1 3’ UTR 
variant 
2.58e-14 -0.159 8.35e-03 1.20 
rs11213801 chr11:111119694 Intergenic 3.86e-14 -0.156 4.50e-03 1.24 
rs3802840 chr11:111171646 COLCA1 and 
COLCA2 intron 
variant 






6.85e-14 -0.161 6.02e-03 1.21 
SNP SNP position Predicted function P-value beta p-value OR 
rs3087967 chr11:111156836 C11orf53 3’ UTR 
variant 
2.35e-12 -0.116 9.22e-03 1.12 
rs7130173 chr11:111154072 C11orf53 intron 2.35e-12 -0.116 1.36e-02 1.19 
rs7103178 chr11:111165009 COLCA1 3’ UTR 
variant 
6.67e-12 -0.112 8.35e-03 1.20 
rs3802840 chr11:111171646 COLCA1 and 
COLCA2 intron 
variant 




























Figure 6.3 A) Boxplot showing the rs5934683 genotype association with SHROOM2 
expression in normal colorectal mucosa. B) Fine association mapping for SHROOM2 










Table 6.5. Variants that are more significantly associated with normal mucosa SHROOM2 
expression than the tagging SNP rs5934683, listed in order of their eQTL significance 
values. The tagging SNP is included and highlighted for reference. p-values and effect sizes 















SNP SNP position Predicted function p-value beta p-value OR 
rs5934685 chrX:9766019 SHROOM2 intron 1 
variant 
1.04e-19 -0.206 1.65e-02 1.296 
rs2521664 chrX:9763429 SHROOM2 intron 1 
variant 
1.62e-13 -0.159 3.52e-02 1.201 
rs2521663 chrX:9761062 SHROOM2 intron 1 
variant 
2.51e-13 -0.158 8.14e-02 1.158 
rs4830657 chrX:9766725 SHROOM2 intron 1 
variant 
5.28e-11 -0.147 6.21e-02 1.185 








Figure 6.4. Fine association mapping for normal colorectal mucosa DIP2B expression 
detailing a 500kb region in LD with rs11169552 (purple). DIP2B expression was detected by 
































Figure 6.5 A) Boxplot showing the rs11169552 genotype association with SPATS2 
expression in the normal colorectal mucosa. B) Manhattan plot demonstrating SPATS2 
location in relation to the peak of the eQTL association. The 4 omitted genes are PRPF40B, 









Figure 6.5 C) Fine association mapping for SPATS2 expression detailing a 500kb region 






























Figure 6.6 A) Boxplot showing the rs11169552 genotype association with UTP23 expression 
in normal colorectal mucosa.  B) Fine association mapping for UTP23 expression detailing a 












SNP SNP position Predicted function p-val beta p-val OR 
rs16892766 chr8:117630683 Intergenic 8.75e-04 -0.060 0.074 1.22 
rs28668628 chr8:117679601 EIF2H intron variant 2.36e-05 -0.086 0.249 1.13 
rs7823271 chr8:117703509 EIF2H intron variant 1.09e-05 -0.087 0.288 1.12 
rs16888695 chr8:117735099 EIF2H intron variant 1.09e-05 -0.087 0.286 1.12 
rs16888699 chr8:117735209 EIF2H intron variant 1.09e-05 -0.087 0.296 1.12 
rs16888728 chr8:117783975 UTP23 missense 
variant 
1.09e-05 -0.087 0.292 1.12 
rs979867 chr8:117791502 UTP23 intron variant 7.30e-05 -0.081 0.269 1.12 
rs1867840 chr8:117799012 UTP23 3' UTR variant 1.09e-05 -0.087 0.257 1.13 
rs7014328 chr8:117799487 UTP23 intron variant 7.30e-05 -0.081 0.265 1.12 
rs200798730 chr8:117799586 UTP23 intron variant 7.30e-05 -0.081 0.263 1.13 
rs7014359 chr8:117799587 UTP23 intron variant 7.30e-05 -0.081 0.280 1.12 
rs6983626 chr8:117802148 UTP23 intron variant 7.30e-05 -0.081 0.288 1.12 
Table 6.6 Variants that are more significantly associated with normal mucosa UTP23 
expression than the tagging SNP rs16892766 are shown in the table, listed in order of their 
chromosomal positions. The tagging SNP is included and highlighted for reference. p-values 













6.3.3 Identification of putative functional variants underlying individual 
eQTL associations in PBMC 
     In PBMC, the strongest association was observed with rs7136702 (12q13.12) and 
expression of CERS5 (adj. p=7.66e-04) that lies 350kb away (Figure 6.7). As alluded 
to before, this association was also observed in the normal mucosa but it was weaker 
and did not survive multiple testing correction (nominal p =2.23e-03, adj. p=0.185). 
Fine-mapping of the region revealed a 700kb region that is in LD with rs7136702, 
with 73 variants showing better association to CERS5 expression. The peak of this 
association is striking, with the best eQTL rs10747573 (chr12:50633839) showing an 
association p-value = 4.80e-13. It is approximately 300kb closer to CERS5 than the 
tagging SNP, and resides within a cluster of highly associated SNPs intronic to the 
upstream neighbouring gene LIMA1. However, none of the SNPs within this cluster 
were associated with CRC risk (Table 6.7). Examinatio  of the wider LD block 
tagged by rs7136702 shows that the majority of these SNPs are intronic variants of 
the genes within this LD block, with a few synonymous variants and missense 
variants that are mostly predicted to be benign/tolerated. Of note, two missense 
variants within FAM186A, rs12303082 (chr12:50754563) and rs6580741 
(chr12:50727706) are predicted by Polyphen to be probably damaging and possibly 
damaging, respectively. However, none of these are better candidates in predicting 
CRC risk. On the other hand, there are 5 other variants within this region that appear 
to be more significantly associated with CRC risk, the best candidate being CERS5 
intron variant rs7398567 (p=0.010). Taken altogether, this evidence is suggestive of 
CERS5 being a candidate gene in CRC common predisposition.  
     For the genotype-gene expression associations rs11169552-LIMA1, rs961253-
RP11-19D2.2 and rs1321311-MDGA1, fine-association mapping did not show any 
other putative functional candidates that are better associated with the target gene 
expression (Figures 6.8 - 6.10). For rs16892766, there was one variant within EIF3H 
intron (rs7825662) that showed a better association w th MED30 expression (Figure 
6.11), but it was not a significant predictor of CR risk (Table 6.8). rs11169552 and 
rs16892766 are also eQTLs in the normal mucosa influe cing different genes 




     Of these eight eQTL loci in the normal mucosa and PBMC, the two associations 
that stood out (11q23.3 and Xp22.2) were selected to be validated technically and 
functionally. Due to the collaborative nature of this project, the 11q23.3 locus and 
COLCA1/COLCA2 expression was investigated by Claire Smillie and further data on 



























Figure 6.7 A) Boxplot showing the rs7136702 genotype association with CERS5 expression 
in PBMC. B) Fine association mapping for CERS5 expression detailing a 1Mb region in LD 










SNP SNP position Predicted function p-val beta p-val OR 
rs7398567 chr12:50551158 CERS5 intron variant 2.56e-06 -0.146 0.010 1.19 
rs3184122 chr12:50570127 LIMA1 3'UTR variant 1.27e-07 -0.160 0.026 1.16 
rs9364 chr12:50570519 LIMA1 3'UTR variant 1.27e-07 -0.160 0.025 1.16 
rs7315690 chr12:50581490 RP3-405J10.3-001 
non coding transcript 
exon variant 
2.41e-07 -0.157 0.058 1.14 
rs7138420 chr12:50583150 RP3-405J10.3-001 
non coding transcript 
exon variant 
2.41e-07 -0.157 0.065 1.13 
rs2302900 chr12:50599709 LIMA1 intron variant 4.01e-07 -0.152 0.073 1.13 
rs12367872 chr12:50607834 LIMA1 intron variant 4.01e-07 -0.152 N/A N/A 
rs12425705 chr12:50610321 LIMA1 intron variant 4.01e-07 -0.152 0.085 1.12 
rs11169322 chr12:50610976 LIMA1 intron variant 4.01e-07 -0.152 0.085 1.12 
rs8181679 chr12:50611020 LIMA1 intron variant 1.95e-12 0.200 0.890 0.99 
rs12424691 chr12:50611477 LIMA1 intron variant 4.01e-07 -0.152 0.085 1.12 
rs1362983 chr12:50614707 LIMA1 intron variant 4.01e-07 -0.152 0.085 1.12 
rs3812825 chr12:50616346 LIMA1 intron variant 4.01e-07 -0.152 0.085 1.12 
rs7314465 chr12:50623658 RP3-405J10.3-001 
non coding transcript 
exon variant 
4.01e-07 -0.152 0.085 1.12 
rs7136648 chr12:50624822 LIMA1 intron variant 2.13e-11 0.196 0.772 0.98 
rs10783342 chr12:50628466 LIMA1 intron variant 1.95e-12 0.200 0.815 0.98 
rs11169332 chr12:50629612 LIMA1 intron variant 4.01e-07 -0.152 0.085 1.12 
rs10747573 chr12:50633839 LIMA1 intron variant 4.80e-13 0.188 N/A N/A 
rs11169335 chr12:50636364 LIMA1 intron variant 4.01e-07 -0.152 0.091 1.12 
rs12828340 chr12:50637295 LIMA1 intron variant 4.01e-07 -0.152 0.085 1.12 
rs7957659 chr12:50638810 LIMA1 intron variant 1.95e-12 0.200 0.862 0.99 
rs7953953 chr12:50647224 LIMA1 intron variant 4.01e-07 -0.152 0.079 1.13 
rs7486747 chr12:50650564 LIMA1 intron variant 4.01e-07 -0.152 0.079 1.13 
rs6580735 chr12:50665227 LIMA1 intron variant 4.01e-07 -0.152 0.068 1.13 
rs11169348 chr12:50665946 LIMA1 intron variant 4.01e-07 -0.152 0.068 1.13 
rs2111988 chr12:50668538 LIMA1 intron variant 4.01e-07 -0.152 0.068 1.13 
rs11169351 chr12:50672214 LIMA1 intron variant 4.01e-07 -0.152 0.068 1.13 
rs7967954 chr12:50673484 LIMA1 intron variant 1.95e-12 0.200 0.768 0.98 
rs10876014 chr12:50674753 LIMA1 intron variant 4.01e-07 -0.152 0.068 1.13 




rs200533278 chr12:50678972 Intergenic 4.01e-07 -0.152 N/A N/A 
rs6580736 chr12:50679418 Intergenic 3.66e-06 -0.140 0.121 1.11 
rs10876017 chr12:50681539 Intergenic 4.01e-07 -0.152 0.068 1.13 
rs11838347 chr12:50687160 Intergenic 4.01e-07 -0.152 0.068 1.13 
rs11169370 chr12:50705872 Intergenic 9.03e-07 -0.147 0.068 1.13 
rs35663729 chr12:50708870 Intergenic 4.01e-07 -0.152 0.068 1.13 
rs7310541 chr12:50725965 FAM186A intron 
variant 
4.01e-07 -0.152 0.074 1.13 
rs6580741 chr12:50727706 FAM186A missense 
variant 
4.01e-07 -0.152 0.080 1.13 
rs7134595 chr12:50730458 FAM186A intron 
variant 
4.01e-07 -0.152 0.073 1.13 
rs4768900 chr12:50734199 FAM186A intron 
variant 
4.01e-07 -0.152 0.068 1.13 
rs4768951 chr12:50739008 FAM186A intron 
variant 
3.66e-06 -0.140 0.112 1.11 
rs7295847 chr12:50743913 FAM186A intron 
variant 
4.01e-07 -0.152 0.068 1.13 
rs7296291 chr12:50744119 FAM186A missense 
variant 
4.01e-07 -0.152 0.068 1.13 
rs7312252 chr12:50744171 FAM186A 
synonymous variant 
4.01e-07 -0.152 0.068 1.13 
rs10506292 chr12:50744753 FAM186A 
synonymous variant 
4.01e-07 -0.152 0.068 1.13 
rs4421818 chr12:50749294 FAM186A 
synonymous variant 
4.01e-07 -0.152 0.068 1.13 
rs12303082 chr12:50754563 FAM186A missense 
variant 
4.01e-07 -0.152 0.068 1.13 
rs11833608 chr12:50757628 FAM186A intron 
variant 
4.01e-07 -0.152 0.068 1.13 
rs10876027 chr12:50763484 FAM186A intron 
variant 
3.66e-06 -0.140 0.124 1.11 
rs12582180 chr12:50767285 FAM186A intron 
variant 
3.66e-06 -0.140 0.114 1.11 
rs7136702 chr12:50880216 Intergenic 1.02e-05 -0.129 0.053 1.14 
rs9788075 chr12:51019171 DIP2B intron variant 3.79e-07 -0.146 0.111 1.11 
rs10876074 chr12:51031817 DIP2B intron variant 3.79e-07 -0.146 0.111 1.11 
rs1316607 chr12:51042890 DIP2B intron variant 3.79e-07 -0.146 0.106 1.11 
rs4768903 chr12:51045449 DIP2B intron variant 2.81e-06 -0.136 0.126 0.90 
rs7309964 chr12:51064064 DIP2B intron variant 4.02e-06 -0.142 0.031 1.16 
rs11169520 chr12:51073523 DIP2B non-coding 
transcript exon variant 
4.02e-06 -0.142 0.029 1.17 
rs12427378 chr12:51074199 DIP2B intron variant 3.79e-07 -0.146 0.121 1.11 




rs2139930 chr12:51089287 DIP2B intron variant 3.79e-07 -0.146 0.113 1.11 
rs11169524 chr12:51089734 DIP2B synonymous 
variant 
3.79e-07 -0.146 0.082 1.12 
rs3742062 chr12:51128832 DIP2B intron variant 7.72e-06 -0.134 0.080 1.13 
rs2280503 chr12:51138687 DIP2B 3' UTR variant 7.72e-06 -0.134 0.074 1.13 
rs61926301 chr12:51157863 ATF1 5' UTR variant 4.05e-06 -0.135 0.100 1.11 
rs12372718 chr12:51171090 ATF1 intron variant 4.05e-06 -0.135 0.112 1.11 
rs10783387 chr12:51180143 ATF1 intron variant 4.05e-06 -0.135 0.112 1.11 
rs7133974 chr12:51184577 ATF1 intron variant 4.05e-06 -0.135 0.112 1.11 
rs1129406 chr12:51203371 ATF1 intron variant 4.05e-06 -0.135 0.116 1.11 
rs4986838 chr12:51203376 ATF1 synonymous 
variant 
4.05e-06 -0.135 0.116 1.11 
rs11169567 chr12:51204938 ATF1 intron variant 4.05e-06 -0.135 0.116 1.11 
rs7306677 chr12:51205763 ATF1 intron variant 4.05e-06 -0.135 0.116 1.11 
rs11169571 chr12:51213765 ATF1 3' UTR variant 4.05e-06 -0.135 0.116 1.11 
rs10876098 chr12:51220373 Intergenic 4.05e-06 -0.135 0.074 1.13 
Table 6.7 Variants that are more significantly associated with PBMC CERS5 expression 
than the tagging SNP rs7136702 are shown in the table, listed in order of their chromosomal 
positions. The tagging SNP is included and highlighted in brown for reference; SNPs within 






































Figure 6.8 A) Boxplot showing the rs11169552 genotype association with LIMA1 expression 
in PBMC.  B) Fine association mapping for LIMA1 expression detailing a 800kb region in LD 































Figure 6.9 A) Boxplot showing the rs961253 genotype association with RP11-19D2.2 
expression in PBMC. B) Manhattan plot demonstrating RP11-19D2.2 location in relation to 







Figure 6.9 C) Fine association mapping for RP11-19D2.2 expression detailing a 100Kb 









































Figure 6.10 A) Boxplot showing the rs1321311 genotype association with MDGA1 
expression in PBMC. B) Manhattan plot demonstrating MDGA1 location in relation to the 






















Figure 6.10 C) Fine association mapping for MDGA1 expression detailing a 50Kb region in 






































Figure 6.11 A) Boxplot showing the rs16892766 genotype association with MED30 























Figure 6.11. C) Fine association mapping for MED30 expression detailing a 200Kb region 





SNP SNP position Predicted function p-value beta p-value OR 
rs16892766 chr8:117630683 Intergenic 4.15E-03 0.122 0.074 1.22 
rs7825662 chr8:117725175 EIF3H intron variant 1.68E-03 0.127 0.755 1.03 
Table 6.8 Variant that is more significantly associated with PBMC MED30 expression than 
the tagging SNP rs16892766 are shown in the table. The tagging SNP is highlighted for 
reference. p-values and effect sizes for their eQTL association and CRC risk (case-control 







6.3.4 Validation of the rs5934683-SHROOM2 expression association 
     Same-sample technical validation of the rs593468  eQTL was performed with 
qRT-PCR, measuring the same mRNA samples (n=115) used for whole-genome 
expression profiling. There was a strong correlation between SHROOM2 expression 
on the Illumina HT12 microarray and expression measured by qRT-PCR (p-
val<2.2e-16, spearman rho=0.66) (Figure 6.12). There was also a highly significant 
association (p-value=2.59e-07) between rs5934683 and SHROOM2 expression 
measured by qRT-PCR (Figure 6.13A), validating the eQTL association seen with 
the Illumina HT12 microarray. The SNP accounted for 22% of the variability in 
SHROOM2 expression, which is indicated by the coefficient of determination R2  in 
the linear model. The risk allele T is associated with lower expression of SHROOM2, 
with a fold difference between the homozygotes/hemizygotes for the risk allele and 
the protective allele of 2.75 (95% CI, 1.96 – 4.36) Interestingly, in this linear 
regression model, gender appeared to have a significa t influence on SHROOM2 
expression (p=0.003).  This was independent of rs5934683 genotype, as there was no 
significant statistical interaction between the SNP genotype and gender (p=0.55). 
This gender-specific difference in SHROOM2 expression will be discussed further in 
the next section.  
     On the other hand, qRT-PCR of the same PBMC samples (n=59) confirmed that 
SHROOM2 was very lowly expressed and there was no detectabl ssociation 
(p=0.37) between rs5934683 genotype and SHROOM2 expression (Figure 6.13B). 











Figure 6.12 Significant correlation was observed between the expression of SHROOM2 as 











































Figure 6.13 A) The association between rs5934683 and SHROOM2 expression in the 
normal mucosa, as quantified by qRT-PCR. Linear regression adjusted for age, gender and 
anatomical site (p=2.59e-07; R2 for rs5934683 = 0.215). B) SHROOM2 relative expression in 
PBMC as quantified by qRT-PCR (normalised to GAPDH). Linear regression adjusted for 






























     To seek further confidence in the rs5934683-SHROOM2 eQTL association, 
further replication was introduced at the level of n rmal mucosa sampling and RNA 
extraction.  In a subset of 37 patients, 2 further RNA extracts were prepared from the 
normal mucosa harvested at the same time as the first extract but with spatial 
variation within the same colonic site. This spatial replication is thought to be of 
particular importance in the females, as heterozygous X-linked polymorphisms are 
functionally mosaic and the progeny of a single X-inactivation pattern are arranged 
together as large patches in the colon.  The association between rs5934683 and 
SHROOM2 was significant (p=3.77e-04) (Figure 6.14), and this remained true whn 
the genders were analysed separately (males, p=1.10e-03; females, p=2.99e-03) 
(Figure 6.15).   
     In summary, the eQTL association between rs593468  and SHROOM2 expression 
in the normal mucosa was technically validated with qRT-PCR, and successfully 
replicated by multiple sampling in a subset of 37 patients. This association was 








Figure 6.14 Biological replication of the association between SHROOM2 and rs5934683 
genotype. SHROOM2 expression was measured with qRT-PCR in 3 different extracts of 













































Figure 6.15 Biological replication of the association between SHROOM2 expression and 
rs5934683 genotype, genders analysed separately with nested one-way ANOVA (males, 











































































6.3.5 Gender-specific differences in SHROOM2 expression 
     In the linear regression modelling for SHROOM2 expression as quantified by 
qRT-PCR, it was observed that gender was significantly ssociated with SHROOM2 
expression (Figure 6.16). Overall, expression appears to be higher in females 
(p=0.003), with a mean fold increase of 1.46 compared to males (95% CI, 1.15-1.89). 
This differential expression was not observed in the Illumina microarray expression 
data. This discrepancy could be a result of the detection of differing transcript 
isoforms, or that of the limitations known to accompany microarray experiments. It 
has been recognised that microarrays tend to have low r sensitivities for certain 
genes (Chuaqui et al, 2002), with a significant decrease in overall accura y of 
differential expression detection at low expression level and relatively poor 
sensitivity in detecting fold changes of less than 2 (Wang et al, 2006). It is plausible 
that the lack of association on the microarray is a false negative, as the fold change is 
small and SHROOM2 is relatively lowly expressed. 
     In view of the gender difference in SHROOM2 expression, I analysed the 
rs5934683 eQTL association separately in males and females (Figure 6.17). 
Although this association was still significant in both genders, it was considerably 
weaker in the females (males, p=3.23e-06; females, p=0.027). Not only was the 
association less significant in females, the variability in expression that was 










qRT-PCR       HT12 microarray 
Figure 6.16 Comparison of SHROOM2 expression between genders. There was significant 
differential expression in SHROOM2 quantified by qRT-PCR. Linear regression adjusted for 
age, anatomical site and rs5934683 genotype (p=0.003, R2 for gender=0.080). SHROOM2 
expression was higher in females with mean fold change=1.46, 95% CI [1.15-1.89]). This 
relationship was not seen in the SHROOM2 expression data from the Illumina HT12 
microarray (p=0.515). 
Figure 6.17 qRT-PCR validation of the association between rs5934683 and SHROOM2 
microarray expression, analysed separately by gender. Linear regression, adjusted for age 








































































































     By using whole-genome expression profiling andeQTL analysis of fresh normal 
mucosa samples and PBMC, I have demonstrated that anumber of CRC risk variants 
are eQTLs that are associated with the expression levels of local cis-genes. For each 
of these loci, fine association mapping to the target ene expression levels and 
colorectal cancer risk was performed. This approach has revealed nearby SNPs in LD 
with the tagging SNP that are more highly associated with expression and risk, which 
makes them more likely to be the causal SNPs. By association, the target genes of 
these risk loci with eQTL activity are candidate susceptibility genes that may 
relevant to the predisposition and development of CRC.  
     The 11q23.1 locus demonstrated the strongest eQTL association, influencing the 
expression of two neighbouring genes, COLCA2 and COLCA1, in the normal 
mucosa. The tagging SNP rs3802842 was one of the early GWAS discoveries 
(Tenesa et al, 2008) with an OR of 1.11, and has been replicated in subsequent 
studies and meta-analyses (Pittman et al, 2008; von Holst et al, 2010; Zou et al, 
2012). The eQTL effects of this locus has recently been reported (Biancolella et al, 
2014; Peltekova et al, 2014, Closa et al, 2014), providing independent validation of 
the data presented here. The rs7130173 SNP has been proposed by these studies to be 
the causal variant, as it explained the highest proportion of variance of the gene 
expression. In agreement with these reports, my findings showed rs7130173 as the 
best eQTL variant, together with a perfect proxy rs3087967. However, they did not 
perform better than the tagging SNP in the case-control analysis; another candidate 
variant rs112138001 was more associated with risk. Further functional studies will 
be required to elucidate the causal variant(s), as well as the allele-specific regulatory 
mechanism that is influenced by the polymorphic variants in this region. The eQTL 
target genes, COLCA1 and COLCA2 have not been characterised in depth, and have 
only recently studied in relation to its association with this CRC risk locus (Peltekova 
et al, 2014). The authors of this study showed via immunohistochemistry that 
COLCA1 is largely expressed in the lamina propria, but not i  normal epithelial cells 




epithelium and the lamina propria. Based on the localisation of these genes in various 
mucosal immune cells of the colon, they proposed an immuno-regulatory role of 
these genes in the predisposition to CRC. However, when tested in our hands, the 
antibody used in this study did not appear to exhibit the level of specificity required 
for localisation via immunostaining, and that there is evidence to suggest that these 
genes are more likely to be long non-coding RNAs intead of protein-coding 
(Smillie, pers. comm.) 
     The Xp22.2 risk locus is the first X-linked locus to be associated with colorectal 
cancer (Dunlop et al, 2012). Here we suggested that it was a very strong colonic 
mucosa-specific eQTL with association to neighbouring gene SHROOM2, and this 
has been validated with qRT-PCR and replicated by repeated sampling in a subset of 
patients. This eQTL association was recently reportd in an independent study (Closa 
et al, 2014), in which the authors also found an associati n with GPR143 which was 
not observed in my data. This discrepancy could be ue to the different microarray 
platform used, where a different probe sequence mayhave detected alternative 
transcripts. Fine-mapping of this region revealed putative functional variants within 
intron1 of SHROOM2, and will require more in-depth functional characterisation.  
     SHROOM2 belongs to the SHROOM family of proteins, which are regulators of 
epithelial morphogenesis, characterized by their ability to bind F-actin and organise 
actomyosin networks (Dietz et al, 2006), which makes it an interesting candidate for 
further study given the contribution of the actin and microtubule cytoskeleton to the 
cell biology of cancer (as reviewed by Hall, 2009). The technical validation of the 
Xp22.2 eQTL effect highlighted a gender-specific differential expression of 
SHROOM2 in the normal mucosa, where expression was overall higher in females. 
Although the eQTL association was significant in both genders, there was 
attenuation of this effect in females, suggesting ivolvement of gender-specific 
factors in the regulation of SHROOM2. This is of interest as it is known that gender 
significantly influences the clinical and pathological characteristics of CRC; not only 
does it impact on the age-standardised incidence and mortality rate (Regula et al, 
2006; Brenner et al; 2007), it also influences where tumours arise within he colon 




than males. The Xp22 locus is rich in genes that normally escape X-inactivation 
(Carrel et al, 2005), hence it is possible incomplete X-activation of SHROOM2 
accounts for the higher expression in females and consequently contribute a 
protective effect against CRC. Escape mechanisms in X-i activation leading to 
disease protection is not unprecedented; X-linked tumour suppressor genes (Zuo et 
al, 2007) and immunomodulatory genes (Anderson et al, 1999) have been identified, 
with skewing and leaky X-inactivation being hypothesis d as mechanisms conferring 
a protective effect in females (Libert et al, 2010;  Chaligné et al, 2014). 
Nevertheless, this is unlikely to be the sole mechanism of gender-specific expression, 
as other factors such as hormonally-driven regulatory elements are almost certainly 
involved too. Without further speculation at this juncture, it is suffice to say that the 
independent association of lower SHROOM2 expression levels with two known CRC 
risk factors (gender = male; rs5934683 = T) makes it a compelling susceptibility 
gene. These observations suggest that SHROOM2 may have a protective or tumour 
suppressive role, with lower expression levels increasing the risk of developing 
colorectal cancer. 
     The other gene that stands out from the local-eQTL analysis is CERS5. Not only 
is it the target gene of the strongest eQTL associati n in PBMC, its expression also 
appears to be weakly influenced by the rs7136702 risk variant in the normal mucosa, 
albeit not surviving the correction for multiple-tes ing. This variant appears to tag a 
very strong eQTL locus for CERS5, and fine-mapping of the wider LD block has also 
revealed several candidate variants that are more highly associated with both CERS5 
expression and CRC risk. CERS5 (Ceramide synthase 5) is involved in the de novo 
synthesis of ceramide, a sphingolipid involved in cell death and proliferation. 
Ceramide synthases have been implicated in cancer and apoptosis, although the 
precise roles of distinct family members have not been fully understood. 
Interestingly, it has recently been demonstrated to be highly expressed in colorectal 
cancer tissue and is associated with poorer clinica outcomes (Fitzgerald et al, 2015).  
     The other candidate genes derived from the cis-eQTL analysis (SPATS2 and 
UTP23 in the normal mucosa, LIMA1, RP11-19D2.2, MDGA1 and MED30 in 




with the respective risk loci, but may still be interesting candidates due to the known 
functions of their protein products. Of these, LIMA1 (LIM domain and actin-binding 
protein 1) is the most interesting candidate. It was previously known as EPLIN 
(epithelial protein lost in neoplasm) when it was first identified to be a human 
epithelial cell protein that is down-regulated or lst in the majority of cancer cell 
lines and xenografts examined (Maul et al, 1999). It was later characterised as a 
cytoskeletal protein with actin-binding properties which links the cadherin-catenin 
complex to F-actin, stabilising the adherens junction in epithelial cells (Abe et al, 
2008). However, the relevance of this gene to colorectal cancer is questionable, as 
the eQTL effect was only observed in PBMC and not in the normal mucosa. 
Although its role in non-epithelial cells is generally not well-studied, there is a recent 
report that LIMA1 is targeted by AP12-MALT1 (juxtaposition of apoptosis inhibitor 2 
to MALT lymphoma translocation gene 1) (Nie et al, 2015), the most frequent 
recurrent chromosomal translocation present in lymphomas involving the mucosa-
associated lymphoid tissue (MALT). The authors also sh wed that depletion of 
LIMA1 in a B-cell derived cell line affected various cancer phenotypes such as 
growth and invasiveness, indicating a possible role of LIMA1 dysregulation in B-cell 
lymphomagenesis. Although this suggestion of a possible role for LIMA1 in 
intestinal immunity is intriguing, it is remains speculative to suggest a link with 
colorectal susceptibility, especially as it is unclear whether peripheral blood 
mononuclear cells are appropriate surrogates for mucosal immune cells. 
     MDGA1 (MAM Domain containing Glycosylphosphatidylinositol Anchor-1) is 
another interesting candidate with potential relevance to cancer biology, as there is 
evidence of its role in cell adhesion. It is a glycoprotein that is localised specifically 
into membrane lipid rafts, and contains structural fe tures found in cell adhesion 
molecules. Cell line over-expression and knock-out st dies suggests that MDGA1 
mediates cell-cell adhesion in a heterophilic manner by affecting adhesion to 
extracellular matrix proteins (Díaz-López t al, 2010). As with LIMA1, the MDGA1 
eQTL was detected in PBMCs and the function of the gene product is not well-




     Potentially more interesting in principle, is the risk variant association with RP11-
19D2.2, an uncharacterised long intervening non-coding RNA. on-coding RNAs 
exhibit cell-specific and developmental dynamic expr ssion patterns capable of 
facilitating a wide repertoire of regulatory functions (Mercer et al, 2009); long non-
coding RNAs (lncRNA) in particular can operate through a variety of mechanisms 
such as chromatin remodelling, transcriptional control, protein inhibition, post-
transcriptional modifiers or decoy elements (reviewed by Cheetham et al, 2013), 
leading to alterations in expression profiles of various target genes involved in cell 
homeostasis and cancer progression. There is accumulating evidence linking the mis-
expression of lncRNA to diverse cancers and implicating a role for them in cancer 
signalling pathways. Interestingly, there is already  report of a papillary thyroid 
cancer risk locus 14q13.3 influencing the transcription of a functional thyroid-
specific lncRNA (PTCSC3) that has tumour suppressor properties (Jendrzejewski et 
al, 2012). The apparent gene desert region that includes the prostate cancer 8q24 
locus have also been shown to produce a lncRNA that may be involved in prostate 
tumourigenesis (Chung et al, 2011). Using a genome-wide approach, another study 
has demonstrated tissue-dependent lncRNA cis-eQTLs, of which a proportion are 
also associated with complex traits and diseases (Kumar et al, 2013). It is likely that 
many more lncRNAs are transcribed from cancer risk loci, but it may require 
targeted interrogation as these low-abundance RNAs may not have been detected or 
annotated.  
     Invariably, there are caveats to consider at various stages of this study, in 
particular with regards to the study design and analytic l methods. The small sample 
size may not be adequately powered to detection subtle cis-regulatory effects, 
particularly in the PBMC where only 59 samples were analysed. Indeed, this may be 
one of the reasons why the eQTL association between rs1321311 (6p21.2) and 
CDKN1A in lymphoblastoid cell lines and T-cells (Dunlop et al, 2012) was not 
replicated in my PBMC samples. PBMC are a heterogenus group of cells that 
consists of lymphocytes, monocytes and macrophages; this cellular heterogeneity 





     The concept that the quality of the study results is only as good as the quality of 
the samples resonated strongly, especially during the early stages of patient 
recruitment and tissue collection. Factors associated with the sampling procedure of 
the colonic tissue and blood can significantly affect downstream observations, and it 
is important to be aware of these at the start to reduce artefactual or confounding 
variability. For example, knowing that cancer field effects may potentially distort 
differential expression (Hawthorn et al, 2014), mucosa samples were harvested from 
the macroscopically normal resection margin furthest away from the tumour to 
reduce any field effects. The variability in tissue post-mortem and ischaemic time is 
another caveat, as this is dependent on several factors including the surgical 
procedure, the timing of the ligation of the vascular supply, and practical issues such 
as the availability of a pathologist. One may also argue whether these samples are 
truly baseline samples, given the inflammatory respon e that accompanies the trauma 
of abdominal surgery. This might be particularly relevant to the PBMC samples as a 
significant proportion of them were collected in the days following the operation, 
when reactive inflammatory responses are likely to peak. Future studies may benefit 
from pre-operative PBMC sampling. Other patient-dependent factors such as 
anaesthetic drugs, medications, diet and even stress levels can potentially affect gene 
expression, and are difficult to control for.  
     From the technical point of view, the use of gene expression microarrays for gene 
expression studies also comes with its own limitations. They are an excellent tool for 
initial target discovery, but the partial coverage, t chnical variability and the 
relatively limited dynamic range, places restraints on the technology with respect to 
sensitivity and specificity. Similarly, although the DNA arrays used in this study 
allows detailed coverage of common SNPs, they do not pr vide information on 
structural variation such as indel polymorphisms and copy number variants. With 
whole-genome and transcriptome sequencing technology becoming more accessible, 
there is huge potential and scope for these samples to be analysed with much more 
depth using an integrative approach, moving beyond eQTL cataloguing to high-
resolution assessment of the transcriptome as a functional phenotype readout of 
genetic variation in the normal colonic mucosa. Recent RNA-seq studies in other 




2011) and variation in mRNA stability (Pai et al, 2012) are influenced by heritable 
genetic variation, and will be of definite interest in future studies. 
     In conclusion, the data presented here has provided evidence that a proportion of 
CRC genetic non-coding variants influence cancer prdisposition, at least in part, by 
affecting the expression levels of candidate genes in two different tissue types – the 
colonic mucosa and peripheral blood mononuclear cells. A though there is evidence 
that there is some overlap of eQTL effects between th  colonic mucosa and blood 
(i.e. rs7136702), this evidence is weak and most of the eQTLs observed in this data 
appears to be tissue-specific. Considering the caveats discussed, the relatively small 
sample size, and the cellular heterogeneity of the tissue substrate, the ability to detect 
eQTL effects is quite remarkable, but may not be entirely surprising, as other 
published studies suggest that eQTLs tend to explain a greater proportion of target 
gene expression variance than is typically seen for risk alleles and clinical traits. It 
should be noted that identification of an eQTL provides only indirect evidence of a 
link between genotype and gene transcription, experimental and molecular 
approaches are necessary for confirming its mechanistic relevance. Methods to 
elucidate the molecular mechanism of polymorphic cis regulation are not easily 
amenable to such high-throughput analyses, and will be the next key challenge in 
validating these eQTL findings. The two best risk loci showing local eQTL effects 
(11q23.3 and Xp22.2) were taken forward for functional studies. Collaboratively, the 
11q23.3 locus was validated and interrogated by another PhD student in the group 
(Claire Smillie) whereas I focused on the characterisation of the Xp22.2 locus and 
SHROOM2, which will be described in the next two chapters.  
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Chapter 7 
Identification of a novel indel polymorphism as the  causal 
variant of the Xp22.2 colorectal cancer risk locus 
7.1 Introduction 
     By using whole genome expression profiling of n rmal colorectal mucosa tissue 
from 115 patients, the X-linked CRC risk SNP rs5934683 has been shown to be a 
strong eQTL governing expression of the neighbouring gene SHROOM2. This was 
initially observed in 42 patients (Dunlop et al, 2012), and subsequently replicated 
when more samples were collected and added into the analysis. To verify this eQTL 
association, the next challenge would be to define th  regulatory mechanism 
underlying this relationship and identify the causal variant. Delineating the functional 
impact of this common, low-penetrance variant will provide tangible understanding 
of the mechanism by which common genetic variation imparts disease risk, which 
















 7.2 Methodological overview 
7.2.1 Targeted resequencing 
     Targeted re-sequencing was performed on blood genomic DNA extracted from a 
subset (n=50) of the 115 patients in the eQTL analysis (Chapter 6). Sanger 
sequencing was performed as described in 2.4.2 for total of 5kb upstream of the 
SHROOM2 TSS. †  
7.2.2 Indel24 genotyping 
     The Indel24 site was amplified with PCR as described in 2.4.2 using the 
following primers‡. The product of the insertion allele is 185bp whereas the product 
of the deletion allele is 161bp. 
Forward primer CACCCACATCCCGCTGATTG 
Reverse primer CCTTACCAAGAGGCGAAGC 
 
     A FAM fluorescent tag was attached to the 5’ end of the reverse primer to allow 
sizing and quantification of the amplified DNA fragments. The products were 
scanned with the ABI PRISM HT7900 (Life Technologies) and analysed with the 
GeneScan® Analysis Software.  
7.2.3 Construction of Manhattan plot and LD plot 
     Manhattan plots of the eQTL fine-association mapping at Xp22.2 was generated 
with the web tool LocusZoom as described in 6.2.4. Linkage disequilibrium plot of 
the Xp22.2 locus was constructed using the Haploview programme from the Broad 
Institute website (Barrett et al, 2005).  
 
                                                            
†
 Sanger sequencing performed by Stuart Reid, technician, MRC Human Genetics Unit, IGMM. 
‡
 PCR and genotyping performed by Stuart Reid, technician, MRC Human Genetics Unit, IGMM. 
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7.2.4 Luciferase reporter assays 
     To study the effects of the Xp22.2 polymorphic variants on transcriptional 
activity, gene elements containing the different alleles of the 3 candidate variants 
were purified and subcloned into firefly luciferase reporter expression vectors (See 
Figure 7.14). Cloning and generation of test plasmid  were performed by Stuart Reid, 
CCGG technician and will not be described in detail here. In brief, genomic blood 
DNA from patients heterozygous for these variants were amplified using proof-
reading Taq Polymerase (Promega) and cloned into the pGEMT Easy vector 
(Promega). After identification and verification by Sanger sequencing, these were 
cloned into the luciferase reporter vectors pGL2 or pGL4 (Promega). The test 
plasmids containing the different alelles were transfected using Lipofectamine™ 
2000 (Life Technologies) in Opti-MEM® I Reduced Serum Medium (Life 
Technologies) into colorectal cancer and retinal epith lial cell lines§ when they are at 
80-90% confluence, according to the manufacturer’s p otocol. Briefly, for each 
transfection sample, the test plasmid DNA (500ng for each well in a 6-well plate) 
and Lipofectamine™ 2000 was diluted separately in Opti-MEM® and allowed to 
stand at room temperature for 5 minutes. The two solutions were then mixed and 
incubated for 30 minutes at room temperature to allw complexes to form, prior to 
addition to wells containing cells in antibiotic-free medium. pCMV-β (generated by 
Laura Boyes and Susan Farrington, CCGG) was co-transfected as a control for 
transfection efficiency. Cells were incubated in antibiotic-free media at 37ºC in a 
humidified incubator (95% O2, 5% CO2), and harvested after 24-48 hours. Cell 
extracts were prepared using Cell Culture Lysis Reagent (Promega), followed by the 
Luciferase Assay (Promega) and β-galactosidase Enzyme Assay (Promega). 
Fluorescence from luciferase activity was measured with the DLRead Lumat 
LB9507 luminometer (EG&G Berthold), whereas β-galactosidase expression was 
quantified by the Multiskan MS microplate reader (Labsystems). The luciferase 
activity in each sample was normalised with β -galactosidase expression. 
 
 
                                                            
§
 Transfections in the retinal pigment cell lines were performed by Andrew McBride, PhD student 
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7.2.5 siRNA gene knockdown in cell lines 
     Cells were plated the day before and grown until 40-60% confluent prior to 
siRNA transfection. SiRNAs used are detailed in Table. Transfections were carried 
out with Lipofectamine™ 2000 (Life Technologies) in Opti-MEM® I Reduced 
Serum Medium (Life Technologies), according to the manufacturer’s protocol. In 
brief, siRNA and Lipofectamine™ 2000 are diluted in the appropriate amount of 
Opti-MEM® I separately and allowed to equilibrate for 5 minutes at room 
temperature. The two solutions were then mixed and incubated for 30 minutes at 
room temperature to allow complexes to form, prior to addition to wells containing 
cells in antibiotic-free medium. Cells were harvested for protein/RNA extraction or 
assayed after 48 hours of incubation at 37ºC in a humidified incubator (95% O2, 5% 
CO2). A dose-response is first performed to determine the lowest effective 
concentration of siRNA for each individual gene and cell line used (usually between 
5-15 nM) before phenotype assays.  
Gene siRNA Oligo ID Sequence (5’ - 3’) 
NF-YA siRNA3 SASI_Hs01_00020331 CGAUGAAGAAGCAAUGACA 
NF-YA siRNA4 SASI_Hs01_00183592 CCAAUGGGACAUUGAUGAU 
NF-YB siRNA1 SASI_Hs02_00341025 GCAUGAAUGAUCAUGAAGA 
NF-YB siRNA2 SASI_Hs02_00341024 GAAGGAAAGACUGGUGAAA 
Negative 
control Scrambled SIC001  
Table 7.1 The IDs and sequence of siRNAs (Sigma) used in this chapter. 
7.2.6 Co-transfection with luciferase reporter plas mid and siRNA  
     For luciferase reporter plasmid and NFY siRNA co-transfections in MCF7 cell 
line, cells were plated the day before to achieve 40-60% confluence. siRNA 
transfections were performed as described in 7.2.5 for 24 hours prior to luciferase 
reporter plasmid DNA transfections as described in 7.2.4. Cells were harvested after 





qRT-PCR was performed on cDNA synthesised from cell line or primary tissue RNA 
as described in Chapter 2. The Taqman® Gene Expression A says used are listed in 
Table 7.2. 
Gene Assay ID Probe sequence                                                         
NF-YA Hs00953589_m1 TCCCCATATGCAGGATCCAAACCAA 
NF-YB Hs01105350_m1 CAACATCATATCAACAGATTTCTGG 
SHROOM2 Hs01113636_m1 CTCCCGGTGATCGGCAATCACTGCT 
CCNB1 Hs01030099_m1 CTGAGCCTATTTTGGTTGATACTGC 
TBP Hs00427620_m1 GCAGCTGCAAAATATTGTATCCACA 
RPL30 Hs00265497_m1 TATCATTGATCCAGGTGACTCTGAC 
Table 7.2 TaqMan® assay IDs of the genes of interest and reference genes quantified in this 
chapter. 
7.2.8 Site-directed mutagenesis of the CCAAT box mo tifs 
     Site directed mutagenesis of the CCAAT box motifs within the insertion allele of 
the 83+Indel24 luciferase reporter vector was performed using QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies) as per manufacturer’s 
instructions.** These vectors were then transfected as described in 7.2.4 into SW480 
and MCF7 cell lines for luciferase reporter assays.  
7.2.9 Case-control analysis 
     Case-control analysis of the rs5934683 tagging SNP and the two putative 
causative variants Indel24 and rs5934685 was performed in 687 cases and 873 
controls from the SOCCS (Scottish Colorectal Cancer Susceptibility) study. The 
putative causal variant Indel24 was genotyped as described in 7.2.2,†† whereas 
                                                            
**
 Site-directed mutagenesis performed by Stuart Reid, technician, MRC Human Genetics Unit, IGMM 
††
 Indel genotyping performed by Stuart Reid, technician, MRC Human Genetics Unit, IGMM. 
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rs5934685 was imputed as described in 6.2.2.‡‡ Subsequently, Indel24 was 
genotyped in a larger dataset derived from samples from across Scotland, England 
and Croatia (cases=8368, controls=6327; males=7846, females=6849).§§ Similar to 
the analysis in 6.2.4, male hemizygotes were treated s homozygotes in this case-
control analysis.***    
7.2.10 Western blotting  
Total protein and subcellular fractions were extracted as described in 2.5. Primary 
antibodies used are listed in Table 7.3. 
Protein Company Catalogue no. Type 
Antibody 
dilution used 
NF-YA (G-2) Santa Cruz #sc-17753 Mouse monoclonal 1:1000 
NF-YB (FL-207) Santa Cruz #sc-13045 Rabbit polyclonal 1:1000 
β-actin Sigma #A1978 Mouse monoclonal 1:5000 










                                                            
‡‡
 rs5934685 imputation and statistical analysis performed by Maria Timofeeva, Statistical Geneticist, 
MRC Human Genetics Unit, IGMM 
§§
 Indel24 genotyping performed by Stuart Reid, technician, MRC Human Genetics Unit, IGMM. 
***




7.3.1 The genomic, epigenomic and regulatory landsc ape of rs5934683 
from publicly available databases 
     The tagging SNP rs5934683 (chrX:9751474) resides within an intergenic region 
between the GPR143 and SHROOM2 genes at Xp22.2, which are divergently 
transcribed on opposite strands (Figure 7.1). The SNP is 3022bp from the 5’ end of 
the SHROOM2 canonical RefSeq gene structure, and is 17,469bp from the 5’ end of 
the GPR143 RefSeq gene structure. There is evidence of longer GPR143 transcripts 
extending into the SHROOM2 promoter, and rs5934683 SNP is within the first intro  
of this transcript (Ensemble transcript model ENST000000447366). The evidence for 
this transcript is weak though, with only a single EST supporting it from the 








Figure 7.1 The genomic context of rs5934683 from Ensembl (Genome assembly GRCh37). 









     The eQTL activity associated with rs5934683 suggests that it may lie within or 
close to tissue specific regulatory elements. To look for evidence of this, regulatory 
data from the ENCODE project was first examined using the UCSC genome 
browser. Tracks examined include chemical modificatons to histone proteins 
(H3K4Me1, H3K4Me3, H3K27Ac), DNase hypersensitivity, methylation and 
transcription factor binding. Bearing in mind that many regulatory elements appear 
to be tissue or cell type specific, it should be noted that the majority of the cell 
lines/cell types used to generate data for the ENCODE project are not of colonic 
origin. However, this information can still be inferential, as cis-eQTL datasets have 
been shown to overlap by more than 50% between cells as diverse as lymphoblastoid 
cells, hepatic cells and monocytes (Zeller et al, 2010).  
     The rs5934683 SNP appears to be encompassed within a DNase hypersensitive 
area of 350bp (chrX:9751266-9751615, Figure 2). Regulatory regions in general and 
promoters in particular, tend to be DNase-sensitive. However, the extent of the 
hypersensitivity is modest with a cluster score of 189/1000, and is only present in 5 
cell types (H9ES, MCF-7, hepatocytes, myometrial cells, osteoblasts) out of the 125 
tested. There are no relevant histone marks in the region; modifications to H3K4me1 
only begin to become apparent ~1kb downstream and nearer to the SHROOM2 
promoter.  
     The closest transcription factor binding site (TFBS) is 972bp downstream and 
closer to the SHROOM2 promoter (Figure 7.2). It is present in all three t sted cell 
lines (GM12878, HeLa-S3 and K562), and binds to the transcription factor NFY-B. 
There is a moderately strong cluster score of 492 (out of 1000), with 3 common 
SNPs within the TFBS. The canonical DNA-binding motif for NFY-B has also been 
identified within the binding site by the Factorbook repository in-silico 
computational analysis (Wang et al, 2012; Wang et al; 2013). The ChIP-seq data 
from the previous ENCODE version (version 2) also sh ws a TFBS for NFY-A that 
overlaps with the NFY-B TFBS, which is not surprising given that the NFY 
transcription factor is a trimeric complex formed by the three subunits, NFY-A, 




Figure 7.2 SHROOM2 promoter region (UCSC browser, Hg19). Tracks displayed include 
transcription levels by RNA-seq, histone marks (H3K4Me1, H3K4Me3 and H3K27Ac), 










     A small, nucleosome depleted region (chrX:9751290-9751339) 135bp upstream 
of rs5934683 is covered by a probe from the Illumina I finium Human Methylation 
450 Bead Array platform (Figure 7.3). This probe appears to demonstrate differential 
DNA methylation, with data from GM12878, Hi-hESC, HeLa-S3, HepG2 and 
HUVEC  indicating this region is fully methylated, and data from K562 indicating a 
lack of methylation. The same region shows evidence of methylation, apparently 
nucleated upon methylated CpG sites, in an independent sequencing based study of 
human frontal cortex (Maunakea et al, 2010). This region also shows evidence for 
association with the nuclear lamina: a chromatin state that is known to include 
regions with methylated CpG sites (Guelen et al, 2008).  
     The presence of rs5934683 within a DNase hypersensitive region suggests it lies 
within the distal promoter of SHROOM2; its presence n ar a TFBS and a 
differentially methylated promoter site is consistent with the eQTL activity of this 
SNP and suggests possible mechanisms underlying this activity. This allele-specific 
regulation may be driven by rs5934683 itself, or any polymorphism that it tags. As 
the linkage disequilibrium of this region is poorly defined (Figure 7.4), this chapter 
will focus on characterising the variation in the region and identifying the causal 
variant by using a combination of expression associati n analysis and functional in-













Figure 7.3 The SHROOM2 promoter region (UCSC genome browser, Hg19). Tracks 
displayed include predicted CpG islands, methylation data from array and sequencing based 








































Figure 7.4. LD plot of the region surrounding rs5934683 derived from 1000GENOMES:phase_1_EUR (Ensembl, Genome assembly GRCh37). LD values 
(r2) between any two variants are graphically displayed using inverted coloured triangles varying from white (low LD) to red (high LD). 
rs5934683 
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7.3.2 Identification of putative causal variants by  targeted 
resequencing and fine-mapping of the Xp22.2 locus 
     Targeted local-resequencing revealed a novel 24bp indel polymorphism 
(henceforth referred to as Indel24) just under 2kb from the start of SHROOM2. This 
was subsequently genotyped in all 115 subjects in the eQTL analysis, with a minor 
allele frequency of 0.24. Due to its location within an ERV1 multiple repeat region, 
the exact origin of the indel polymorphism is ambiguous and may be arising at either 
chrX:9752561 or  chrX:9752545 in hg19 (Figure 7.5). 
     Examination of publicly available sequencing data shows evidence for indel 
polymorphisms close to this site in two independent datasets – Phase 1 data from the 
1000 genomes project and Complete Genomics (Drmanac et al, 2010). ††† In the low 
coverage data (around 3x) from 1000 genomes (URL7.2), a 1bp indel was apparently 
detected at chrX:9752558. Complete Genomics provides higher coverage (around 
80x) sequence for 69 individuals from a variety of human populations (URL7.3), and 
reports detection of a 24bp indel polymorphism at chrX:9752559. No other indels 
were detected in the Complete Genomics data within the ERV1 element or indeed 
anywhere in the extended SHROOM2 promoter region. 
     Alignment of the alleles of the three indel poymorphisms is not straightforward 
as the structure of the repetitive sequence within and flanking the indels makes 
alignments in the region ambiguous. However it appers that all three indel events 
are consistent with a single site of origin (chrX:9752558-9752561) and that the two 





                                                            
†††
Examination of public datasets performed by Colin Semple, MRC Human Genetics Unit, IGMM.  
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          X:9752536                     X:9752584                                                                                       
 
RefSeq    CCACATCCCGCTGATTGGTCCATTT------------------------ACAGAGTGCTAATTGGTCCATTTT 
Indel24   CCACATCCCGCTGATTGGTCCATTTTACAGAGTGCTGATTGGTCCATTTACAGAGTGCTAATTGGTCCATTTT 
 
       
OR 
          
RefSeq    CCACATCCC------------------------GCTGATTGGTCCATTTACAGAGTGCTAATTGGTCCATTTT 
Indel24   CCACATCCCGCTGATTGGTCCATTTTACAGAGTGCTGATTGGTCCATTTACAGAGTGCTAATTGGTCCATTTT 
           
 
 
Figure 7.5 Alignments demonstrating a novel polymorphic variant identified on targeted re-
sequencing - a 24bp insertion at either X:9752561 or X:9752545, where the reference 





          X:9752536           X:9752584 
 
RefSeq    CCACATCCCGCTGATTGGTCCATTT------------------------ACAGAGTGCTAATTGGTCCATTTT 
Indel24   CCACATCCCGCTGATTGGTCCATTTTACAGAGTGCTGATTGGTCCATTTACAGAGTGCTAATTGGTCCATTTT 
 
RefSeq    CCACATCCCGCTGATTGGTCCA------------------------TTTACAGAGTGCTAATTGGTCCATTTT 
CG_Ins    CCACATCCCGCTGATTGGTCCATTTTACAGAGTGCTAATTGGTCCATTTACAGAGTGCTAATTGGTCCATTTT 
 
RefSeq    CCACATCCCGCTGATTGGTCCA-TTTACAGAGTGCTAATTGGTCCATTTT 
1KG_Ins   CCACATCCCGCTGATTGGTCCATTTTACAGAGTGCTAATTGGTCCATTTT 
 
 
Figure 7.6 Alignments of the three indel polymorphisms (Indel24: 24 bp insertion allele 
identified by our local-resequencing; CG_Ins: 24 bp insertion allele from Complete 
Genomics; 1KG_Ins: 1bp insertion allele from 1000 Genomes Phase 1 data). The sequence 








     To investigate whether Indel24 is associated with SHROOM2 expression, Indel24 
genotypes were added to the genotypes for the 115 normal mucosa samples used for 
eQTL analysis and fine association mapping as described in Chapter 6. SHROOM2 
expression as quantified by qRT-PCR was used as the trait phenotype as it is thought 
to be a more accurate and sensitive measurement of transcript abundance than 
microarray signals.  
     A peak of association with SHROOM2 expression was seen at X: 9,740,900 – 
9,766,725 which encompass the tagging SNP rs5934683 (Figure 7.7). Distinctively, 
two variants were more significantly associated with SHROOM2 expression than the 
tagging SNP, with p-values in the order of 1e-10. Closer examination reveals that the 
peak starts from the intergenic region between GPR143/SHROOM2 and extends into 
the first intron of SHROOM2. The variants that were more significantly associated 
with SHROOM2 than the tagging SNP were Indel24 and an intronic SNP rs5934685 
(Figure 7.8) that had previously already been implicated in the fine-association 
mapping to SHROOM2 as quantified on the microarrays (Table 6.5). In a similar 
fashion to the tagging SNP, the minor alleles for bth these variants were associated 












Figure 7.7 Manhattan plot displaying the strength of genetic association (-log10 p-value) to 
SHROOM2 expression versus chromosomal position, representing fine-mapping of a 600kb 
region surrounding the rs5934683 risk locus in 115 patients. The p-values were obtained by 
linear regression analysis with adjustment for age and gender. SHROOM2 expression in the 
normal mucosa was measured by qRT-PCR, normalised to reference genes EIF2B1, TBP 
and RPL30. The peak of association maps to the tagging SNP and a 26kb surrounding 













Figure 7.8 The peak of association with SHROOM2 expression starts at the intergenic 
region between GPR143/SHROOM2 and extends into the first intron of SHROOM2. There is 
no available linkage and recombination data in LocusZoom/HapMap CEU population 



















Figure 7.9 Boxplots for the three variants most highly associated with SHROOM2 
expression. Estimated effect size and p-values are calculated from linear regression analysis 
with adjustment for age, gender and anatomical site. Fold reduction is the ratio of the 
expression means between the homozygotes of the major and the minor alleles. 
 
Variant Alleles MAF Estimate p-value Fold reduction 
rs5934683 C/T 0.36 (T) -1.056 2.59e-07 2.75 (95% CI, 1.96 – 4.36) 
Indel24 Ins/Del 0.24 (Del) -1.410 1.65e-10 6.72 (95% CI, 4.35 – 14.02) 










































































      The linkage disequilibrium structure of the pak region constructed from my 
sample set (n=115) shows that the two variants are in strong LD with each other and 
with the tagging SNP, suggesting that the top signals within the association peak are 
likely to be from a single association rather than two or three independent ones 
(Figure 7.10). To further understand which of these the functional variant is, linear 
regression modelling conditional on all three variants was performed on SHROOM2 
expression, as quantified by qRT-PCR and the Illumina HT12 microarray for 
comparison. The analysis performed on expression data derived from both methods 
indicates that the tagging SNP rs5934683 is not the causative variant, as the effect 
estimate and the test significance were markedly decreased when the two other 
variants were included in the model (Table 7.4). The interpretation of the test 
statistics for Indel24 and rs5934685 is not as straightforward; where expression was 
quantified by qRT-PCR, both Indel24 and rs5934685 bordered on significance, with 
Indel24 being the stronger signal both in terms of effect size and significance. Where 
expression was quantified by the HT12 microarray, rs5934685 appears to be the 
driver signal, attenuating the effect size and significance of Indel24. Although one 
may argue that the analysis based on qRT-PCR is more reliable as it has better 
detection sensitivity and larger dynamic range, it remains speculative at best to 
favour one variant over the other as the functional variant. The possibility of 
independent effects also cannot be excluded. Hence, follow-up with functional 







Figure 7.10 Linkage disequilibrium structure (r2) surrounding the tagging SNP (rs5934683) 
and the 2 candidate functional variants (Indel24 and rs5934685) in my sample set (n=115). 
The D’ reflects the frequency of co-inheritance of alleles, whereas the r2 takes into further 






Table 7.4 Linear regression for SHROOM2 expression (as measured by qRTPCR or Illumina 
HT12 microarray), adjusted for age, gender, anatomical sampling site, the tagging SNP and 




Variant Estimate p-value Estimate p-value 
rs5934683 -0.0943 0.7454 -0.00297 0.908 
Indel24 -0.8381 0.0592 -0.07217 0.066 
rs5934685 -0.6831 0.0679 -0.14280 2.92e-05 
HT12 qRTPCR 
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7.3.3 Evidence of functionality for Indel24 and rs5 934685 in ENCODE 
data 
     Indel24 is encompassed by an ERV repeat element (LTR12B; Family; ERV1; 
Class: LTR; Position: chrX:9752293-9752685) (Figure 7.11). Repeat elements are 
generally associated with increased indel rates (McDonald et al, 2011) and exapted 
ERV repeats have been reported to act as regulatory elements in human promoters 
(Cohen et al, 2009). More compellingly, Indel24 appears to lie within NF-YA and 
NF-YB transcription factor binding sites according to ENCODE ChIPseq data 
(Figure 7.11). As discussed previously (see 7.3.1), these two transcription factors 
bind cooperatively as two subunits of the trimeric NF-Y transcription factor 
complex, and often activate the transcription of cell ycle genes (Müller and 
Engeland, 2010). There is substantial published litrature on NF-Y and it is known to 
have high affinity for the CCAAT box motif. Within known NF-Y binding sites, 
multiple CCAAT binding motifs are often found and the optimal spacing between 
them appears to be 24-53bp (Dolfini et al, 2009), which is similar to the spacing 
between the 3 CCAAT motifs found in this region (Figure 7.12). Remarkably, the 
24bp insert contains a perfect match on the minus strand to the CCAAT box motif. 
This could, in theory, modulate NF-Y binding affinity either by creating/abolishing 









Figure 7.11 Genomic and regulatory landscape around Indel24, UCSC genome browser 
(1KG_Indel: 1bp indel from 1000 Genomes Phase 1 data; CG_Indel: 24 bp indel from 
Complete Genomics; Indel24: 24 bp indel as identified by our local-resequencing). The 




          X:9752536                X:9752594 
                
RefSeq    CCACATCCCGCTGATTGGTCCATTT------------------------ACAGAGTGCTAATTGGTCCATTTT 




          X:9752595                  X:9752657 
 
RefSeq    ACAAACCTCTAGCTAGCCACAGAGCGCTGATTGGTGCATTTTACAATCCTCTTGTAAGACAGAAAAATTCTCG  
Indel24   ACAAACCTCTAGCTAGCCACAGAGCGCTGATTGGTGCATTTTACAATCCTCTTGTAAGACAGAAAAATTCTCG 
 
 
Figure 7.12 Three CCAAT box motifs on the minus strand (appearing as ATTGG on the plus 
strand; pink highlight) are found within the reference sequence of the NFY-B binding site at 
Xp22.2, with 23bp and 42bp spacing between them. The 24bp insert alters the spacing to 
47bp and 42bp, or donates a fourth CCAAT box motif (green highlight), with spacing 





     The other SNP that is a putative causal variant, rs5934685, is a SHROOM2 
intronic variant at chrX:9766019. There is no evidence in the literature to support 
eQTL activity for it, and according to ENCODE it is not associated with DNase 
hypersensitivity, transcription factor binding, histone modifications or methylation. 
The closest transcription factor binding site is situated 324bp upstream from the 
SNP, which binds to YY1(Ying Yang 1) with a cluster score of 180/1000 in H1-
hESC and NT2-D1 cell lines (Figure 7.13). YY1 a multif nctional zinc-finger 
transcription factor that has been associated with cellular proliferation and resistance 
to apoptotic stimuli, and is known to be over-expressed in colorectal cancer 
(Chinnapan et al, 2009). There is also a conserved transcription factor binding site 
196bp upstream of the SNP, which is predicted to bind to VSX2 (visual system 
homeobox 2). This is of possible relevance as VSX2 was originally described as a 
retina-specific transcription factor, with mutations associated with microphthalmia, 
cataracts and iris abnormalities (NCBI gene; URL7.4). It was mutated to create the 
first mouse model of retinoblastoma (Zhang et al, 2004) and has been reported as a 
novel biomarker for CRC (Mori et al, 2011). 
     In summary, local targeted resequencing and fie-mapping strategies have 
identified 2 putative causative variants for the eQTL activity observed at the 
rs5934683 locus. One of these variants, Indel24, is a novel indel polymorphism with 
in-silico evidence of NF-Y transcription factor bind g properties. Statistical 
modelling of SHROOM2 expression accounting for rs5934683 and the 2 candidate 
variants indicates that rs5934683 is a tagging proxy, but is inconclusive in 
determining which of the 2 candidates is the functional variant driving the eQTL 
association. Further evaluation with in-vitro regulatory assays will be necessary to 


















7.3.4 Transcriptional activity assays on putative c ausal variants 
implicates Indel24 as the functional variant 
     To investigate whether the candidate variants po sess allele-specific regulatory 
effects, gene elements containing the different alleles of the 3 candidate variants 
were cloned from human genomic DNA into luciferase reporter vectors (Figure 
7.14). 
     Given the proximity of Indel24 to rs5934683, a 1449bp gene construct (referred 
to as 83+Indel24) containing both variants was tested, with each of the four possible 
haplotypes cloned into a basic transcriptional report r vector (pGL2). All four test 
constructs were transfected into two CRC cell lines (SW480 and DLD1) and two 
retinal pigment epithelial cell lines (RPE1 and ARPE1).‡‡‡ Indel24 shows a highly 
significant allele-specific differential effect on luciferase activity in all four cell lines, 
with the deletion allele showing a stark reduction in transcriptional activity (Figure 
7.15). This is in contrast to the lack of effect between the different alleles of 
rs5934683. There was also no statistical interaction between rs5934683 and Indel24 
in all cell lines, which indicates that the regulatory differences seen with the Indel24 











                                                            
‡‡‡
 The extra-colonic function of SHROOM2 was investigated by PhD student Andrew McBride and 
the reporter assays in non-CRC cell lines were performed by him. This data has been included here 
























rs5934683 and Indel24, 

















Figure 7.14 3 gene constructs containing the 3 eQTL candidate variants (in combination or 
individually, see table) were generated from human genomic DNA. The 83+Indel24 and 
83+Indel24-TSS elements were cloned into pGL2 basic transcriptional vectors, whereas the 








                   
Variant Cell line p-value Fold change 
rs5934683 SW480 0.97 - 
rs5934683 DLD1 0.31 - 
rs5934683 RPE1 0.81 - 
rs5934683 ARPE19 0.67 - 
Indel24 SW480 2.14e-05*** 0.35 (95% CI, 0.26 - 0.47) 
Indel24 DLD1 1.46e-08*** 0.33 (95% CI, 0.26 - 0.42) 
Indel24 RPE1 1.65e-04*** 0.51 (95% CI, 0.38 - 0.68) 
Indel24 ARPE19 6.42e-07*** 0.26 (95% CI, 0.21 - 0.32) 
rs5934683*Indel24 SW480 0.24 - 
rs5934683*Indel24 DLD1 0.12 - 
rs5934683*Indel24 RPE1 0.86 - 
rs5934683*Indel24 ARPE19 0.91 - 
Figure 7.15 Luciferase reporter assays indicating transcriptional activity of the 83+Indel24 
(pGL2) gene construct. The constructs for each allele were transfected into 4 cell lines 
(SW480 and DLD1 are CRC cell lines, RPE1 and ARPE19 are retinal pigment epithelial cell 
lines), and the experiment was replicated at least 4 times in each cell line. Error bars=SEM. 
The allele-specific reporter activity of the rs5934683 SNP and the Indel24 variant was 
analysed separately and together to assess possible interactions. Table shows ANOVA p-
values; where significant, effect sizes were calculated.  
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     To increase the evidence that the transcriptional activity seen with 83+Indel24 is 
reflective of the in-vivo regulation of SHROOM2, the gene element was extended to 
include the core promoter region/transcription start site (TSS) of SHROOM2. The 
experiment was repeated in SW480 with the larger 83+Indel24-TSS gene construct, 
with the shorter 83+Indel24 as a positive control. Although overall activity was 
attenuated and the differential effect was reduced in the larger construct (effect size 
of 0.78 (95% CI, 0.63 - 0.95)), there was still a significant allele-specific effect seen 
with Indel24 that mirrors that seen in the shorter construct (Figure 7.16). Again, this 
effect was not observed between the different alleles of rs5934683. 
Variant Gene element p-value Effect size (ratio) 
rs5934683 83+Indel24 0.92 - 
rs5934683 83+Indel24-TSS 0.49 - 
Indel24 83+Indel24 4.72e-06*** 0.54 (95% CI, 0.43 - 0.67) 
Indel24 83+Indel24-TSS 0.016* 0.78 (95% CI, 0.63 - 0.95) 
Figure 7.16 Luciferase reporter activity for the 83+Indel24 (pGL2) and the longer 
83+Indel24-TSS (pGL2) gene construct. The constructs for each allele was transfected into 
CRC cell line SW480 and the experiment replicated 4 times. Error bars=SEM. Table 
presents unpaired Student t-test p-values; where significant, effect sizes were calculated. 
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     To test if the intronic variant rs5934685 has a regulatory effect, a 421bp gene 
construct (referred to as 85; Figure 7.14) encompassing the rs5934685 SNP was 
cloned into pGL2 as well as pGL4 to maximise detection of enhancer activity. The 
test constructs were transfected into SW480 and DLD1, and appeared to exhibit a 
small degree of allele-specific differential effects on reporter activity (Figure 7.17). 
When the 85 gene element was cloned into pGL2, there appeared to be a reduction in 
reporter activity with the T allele (effect size of 0.86 (CI 95%, 0.82 – 0.90)), but this 
effect was only observed in one of the two cell lines, DLD1. The same gene element 
in the enhancer reporter pGL4 also showed a reduction in reporter activity with the T 
allele (effect size of 0.86 (CI 95%, 0.84 – 0.88)). Again this was only seen in one of 
the two tested cell lines, SW480. Although these eff cts were significant, they were 
relatively small, with a 14% average reduction in transcriptional activity from the C 
allele.    
     In conclusion, this demonstrates that Indel24 has allele-specific regulatory 
function, whereas this is not readily apparent of rs5934683. These results concur 
with ENCODE data where Indel24 is located in known regulatory elements. On the 
other hand, there is some evidence that rs5934685 may have regulatory properties. 
Although the allele-specific transcriptional effect of the 85 gene construct is modest 
in comparison to that seen with the 83+Indel24 construct, the effect sizes and 
confidence intervals of the 85 construct are comparable to that of the longer 
83+Indel24-TSS construct. Overall, these results suggest that Indel24 is most likely 
to be the causative variant driving the SHROOM2 eQTL association, with rs5934683 
tagging the locus signal. However, rs5934685 cannot be ruled out as an independent 









                                    pGL2                                                                 pGL4 
 
Vector Cell line p-value Effect size (ratio) 
pGL2 SW480 0.31 - 
pGL2 DLD1 9.18e-05 0.86 (95% CI, 0.82 – 0.90) 
pGL4 SW480 7.48e-06 0.86 (95% CI, 0.84 – 0.88) 
pGL4 DLD1 0.29 - 
Figure 7.17 Luciferase reporter activity for the 85(pGL2) construct and 85(pGL4) construct. 
The constructs for each allele was transfected into two CRC cell lines (SW480 and DLD1) 
and each experiment replicated 4 times. Error bars=SEM. Table presents unpaired Student 












7.3.5 Indel24 polymorphism alters transcriptional a ctivity of 
SHROOM2 by influencing NF-Y binding affinities  
     The Indel24 polymorphism, defined by the presence or absence of a 24bp gene 
element at chrX: 9752561, appears to have allele-specific transcriptional properties 
that may explain the SHROOM2 eQTL association in colonic normal mucosa. As 
discussed above, this region has been found to bindNFY transcription factor 
subunits A and B in the ENCODE project ChIP-seq data. This suggests that Indel24 
may be modulating transcription of SHROOM2 by altering the DNA-binding affinity 
of NF-Y.  
     To confirm the role of NF-Y in Indel24-mediated transcriptional activity, siRNA 
knockdown of NFY-A and NFY-B was carried out in MCF7 cell line, which was co-
transfected with the 83-Indel24 (pGL2) construct containing the insertion allele. Two 
siRNAs were always used for each gene to enable detection of non-specific or off-
target effects. NF-YA and NF-YB mRNA and protein levels were assessed to ensure 
effective knockdown (Figure 7.18). There was a significant decrease of 30-40% in 
the associated reporter activity upon NF-YA or NF-YB depletion (Figure 7.19). This 
finding is similar between the two NF-Y subunits, which fits in with the knowledge 
that all three subunits of the heterotrimeric complex are required for DNA binding. 
This effect is recapitulated with endogenous SHROOM2, whereby siRNA 
knockdown of NF-YA or NF-YB in DLD1, SW480 and RPE1 cell lines are associated 
with a significant decrease in SHROOM2 mRNA levels (Figure 7.20 and 7.21). 
CCNB1 (Cyclin B1) is measured as a positive control as it has a well-characterised 
NF-Y promoter (Mani et al, 2001) in various cell types including colorectal c ncer 













Figure 7.18. siRNA knock-down of NF-YA and NF-YB in MCF7 as assessed by qRT-PCR 
(top panel) and Western Blotting (bottom panel). Graphs and blots shown are representative 
of 3 replicates. mRNA expression levels of NF-YA and NF-YB were normalised to reference 
gene TBP, whereas β-actin was used as the loading control for Western Blots. (NT=non-
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NT       SC       si 3       si 4   
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Gene siRNA p-val Fold change 
NF-YA 3 0.0017** 0.71 (95% CI, 0.60 - 0.81) 
NF-YA 4 0.0231* 0.72 (95% CI, 0.50 - 0.94) 
NF-YB 1 0.0293* 0.66 (95% CI, 0.37 - 0.94) 
NF-YB 2 0.0043** 0.63 (95% CI, 0.46 - 0.81) 
 
 
Figure 7.19 Luciferase reporter activity of the 83-Indel24 (pGL2) insertion allele, when NF-
YA or NF-YB expression was knocked down with siRNA. MCF-7 cell line was used for the 
co-transfection. p-values reported are of unpaired Student t-tests comparing each siRNA 
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Figure 7.20 Reduction in SHROOM2 expression observed when NF-YA expression was 
knocked down with two different targeting siRNAs (si3 and si4) in three different cell lines 
(DLD1, SW480 and RPE1). The Indel24 genotypes of the cell lines are represented as 
Ins/Ins (homozygote for insertion), Ins/Del (heterozygote) and Del/Del (homozygote for 
deletion). Expression quantified by qRT-PCR, normalised to reference genes TBP or RPL30. 
Error bars=SEM. Experiment replicated 3 times. p-values reported are of unpaired Student t-







Cell line siRNA p-val Fold change 
DLD1 3 0.0389* 0.67 (95% CI, 0.36 - 0.97) 
DLD1 4 0.0079** 0.68 (95% CI, 0.50 - 0.86) 
SW480 3 0.0059** 0.65 (95% CI, 0.47 - 0.83) 
SW480 4 0.1170 - 
RPE1 3 0.0018** 0.62 (95% CI, 0.48 - 0.76) 
RPE1 4 0.0016** 0.71 (95% CI, 0.61 - 0.82) 












Figure 7.21 Reduction in SHROOM2 expression observed when NF-YB expression was 
knocked down with two different targeting siRNAs (si1 and si2) in three different cell lines 
(DLD1, SW480 and RPE1). The Indel24 genotypes of the cell lines are represented as 
Ins/Ins (homozygote for insertion), Ins/Del (heterozygote) and Del/Del (homozygote for 
deletion). Expression quantified by qRT-PCR, normalised to reference genes TBP or RPL30. 
Error bars=SEM. Experiment replicated 3 times. p-values reported are of unpaired Student t-





Cell line siRNA p-val Fold change 
DLD1 1 0.0152* 0.71 (95% CI, 0.51 - 0.91) 
DLD1 2 0.0115* 0.56 (95% CI, 0.29 - 0.84) 
SW480 1 0.0066** 0.47 (95% CI, 0.18 - 0.75) 
SW480 2 0.0018** 0.39 (95% CI, 0.16 - 0.62) 
RPE1 1 0.0007*** 0.53 (95% CI, 0.39 - 0.67) 
RPE1 2 <0.0001*** 0.33 (95% CI, 0.31 - 0.35) 
** ** * * *** *** 
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     The reduction in 83-Indel24 luciferase reporter activity and endogenous 
SHROOM2 with NF-YA or NF-YB knockdown strongly suggests that NF-Y plays a 
regulatory role in SHROOM2 transcription by binding to the DNA region 
encompassing the Indel24 eQTL. This is entirely plausible, as NF-Y is the major 
CCAAT-binding factor (Testa et al, 2005; Ceribelli et al, 2008), and there is an 
ATTGG motif (CCAAT on the minus strand) within the 24bp insertion element with 
three other ATTGG motifs in very close proximity (Figure 7.16). Indeed, CCAAT 
box motifs can be found in promoter regions in either the CCAAT or ATTGG 
orientation, and multiple CCAAT box motifs have been observed for NF-Y 
promoters (Dolfini et al, 2009). However, one potentially confounding caveat to this 
is that there are two other CCAAT box motifs within the reporter gene construct 83-
Indel24 at chrX:9751516 (1kb upstream of Indel24) and chrX:9752716 (150kb 
downstream of Indel24) that could be contributing to NF-Y driven reporter activity. 
To clarify whether the ATTGG motifs at the Indel24 site are the functional motifs, 
these motifs within the 83-Indel24 gene construct were mutated to ATTTC (Figure 
7.22A), which is predicted by JASPAR to have very low NF-Y binding properties. 
The reporter assays performed on the S1,2,3,4 mutant construct demonstrates that 
transcriptional activity was dramatically reduced by ~90% (Figure 7.22B), strongly 
suggesting that the ATTGG motifs at the Indel24 locus are the functional motifs, 
with NF-Y binding at the other two farther sites much less likely.  
     As alluded to previously, it is known that the spacing between motifs in multiple 
CCAAT binding sites is important. To distinguish whet er the insertion element of 
Indel24 improves transcriptional activity by increasing the spacing between S1-S3, 
or by donating an extra binding site in the form of S2, S2 was mutated in the reporter 
construct 83-Indel24 (Figure 7.22A). S2Mut did not reproduce the impact of the 
Deletion allele; its reporter activity was only minimally reduced from the Insertion 
allele (Figure 7.22B). This strongly indicates that Indel24 modifies NF-Y binding by 







Gene construct Cell line p-value Fold change 
Deletion MCF7 3.20e-05*** 0.54 (95% CI, 0.48 - 0.60) 
Deletion SW480 1.72e-05*** 0.50 (95% CI, 0.44 - 0.56) 
S1,2,3,4Mut MCF7 1.90e-08*** 0.09 (95% CI, 0.07 - 0.11) 
S1,2,3,4Mut SW480 6.30e-07*** 0.10 (95% CI, 0.06 - 0.15) 
S2Mut MCF7 8.92e-04*** 0.83 (95% CI, 0.77 - 0.88) 
S2Mut SW480 0.30 - 
Figure 7.22 A) Mutations to the CCAAT box motif (ATTGG on the plus strand) were 
introduced to the insertion allele of the 83-Indel24 gene construct. B) Luciferase reporter 
activity for both alleles of the 83-Indel24 gene construct and the mutant constructs. Error 
bars=SEM, experiment was replicated three times. Table shows p-values for Student 







7.3.6 Case-control studies demonstrates Indel24 as the functional 
variant for CRC risk 
     A CRC case-control logistic regression analysis was performed for all variants 
across the rs5934683 risk locus in 687 cases and 873 controls from the SOCCS 
(Scottish Colorectal Cancer Susceptibility) study. Of the three candidate variants, 
Indel24 appears to be most significantly associated with risk (p =0.05), with the 
Insertion allele conferring an OR of 0.86 (95% CI, 0.75 - 1.00). The tagging SNP 
rs5934683 and the other candidate variant rs5934685 did not reach significance 
(Table 7.5). When the model was conditioned on all three variants, Indel24 again 
stood out as the only significant variant (p=0.02) with an OR of 0.66 (95% CI, 0.46 - 
0.94). 
     Subsequently, the effect of Indel24 on risk was v lidated in the larger dataset 
derived from samples from across Scotland, England and Croatia (8368 cases and 
6327 controls). Indel24 is more significantly associated with the disease phenotype 
(p=0.03, OR=0.92) compared to rs5934683 (p =0.47, OR=0.98) (Table 7.6). 
     Overall, these results strongly suggest that Indel24 is indeed the causative variant 












 Variant p-value Odds Ratio 
rs5934683 0.66 0.97 (95% CI, 0.86 - 1.10) 
Indel24 0.05 0.86 (95% CI, 0.75 - 1.00) 
Individual analysis 
rs5934685 0.11 0.88 (95% CI, 0.76 - 1.03) 
rs5934683 0.16 1.14 (95% CI, 0.95 - 1.37) 
Indel24 0.02 0.66 (95% CI, 0.46 - 0.94) 
Conditional on all 
three putative 
variants 
rs5934685 0.27 1.22 (95% CI, 0.86 - 1.73) 
Table 7.5 Association between putative causal variants and the risk of CRC in SOCCS study 
(687 cases and 873 controls from the Scottish population). p-values and odds ratios were 
derived from the logistic regression model adjusted for age and gender. The top panel shows 
the results for the individual analysis of each of the variants, whereas the bottom panel 






 Variant p-value Odds Ratio 
rs5934683 0.47 0.98 (95% CI, 0.93 - 1.04) Individual analysis 
Indel24 0.03 0.92 (95% CI, 0.86 – 0.99) 
Table 7.6 The CRC association of Indel24 compared to the tagging SNP rs5934683 in 8368 
cases and 6327 controls from Scottish, English and Croatian populations. Each variant was 
analysed separately, with p-values and odds ratios derived from conditional logistic 











     Whole-genome gene expression profiling has ident fi d the colorectal cancer 
(CRC) risk locus at Xp22.2 to be associated with the colonic mucosa expression 
levels of a neighbouring gene SHROOM2, providing a functional mechanism for this 
low-risk genetic locus. Interrogation of the locus with targeted re-sequencing and 
fine-mapping has identified two putative causal variants that appear to drive the 
association with SHROOM2 expression - a novel genetic control element (Indel24) at 
-2203 and rs5934685 within intron 1. Both are signif cantly more associated with 
expression and colorectal cancer risk than the tagging SNP rs5934683. Conditional 
analysis is suggestive that Indel24 is the driver signal in a case-control study, but this 
was not conclusive in the eQTL analysis. Hence, it is crucial that these empirical 
observations are analysed in context with functional studies, as this will help to 
demonstrate the mechanism underlying the eQTL association, and offer insight into 
the aetiology of inherited colorectal susceptibility.  
     The expression of a gene can be influenced in several ways by a genetic variant, 
be it by influencing epigenetic mechanisms such as methylation, altering 
transcriptional activity, or modifying the stability of transcripts to degradation. The 
location of the candidate causal variants at the 5’ nd of SHROOM2 is suggestive of 
an influence on transcriptional activity or possibly promoter methylation. Indeed, 
luciferase reporter assays provided evidence that Indel24 exhibits strong allele-
specific differences in transcriptional activity, whereas the other putative causal 
candidate rs5934685 had only a weak effect, if any. These assays also confirm the 
lack of effect of rs5934683, confirming its role as a tagging SNP. Conversely, whole 
genome and localised methylation analysis performed collaboratively with other 
members of the group did not reveal any evidence of differential methylation in 
region of the tagging SNP and Indel24. 
     The finding that Indel24 has allele-specific regulatory control of transcription is 
consistent with cell line ChIP-seq data from ENCODE which indicates that Indel24 
resides in an NF-Y transcription factor binding site within an ERV1 repeat element. 
Repeat elements are generally associated with increased indel rates (McDonald et al, 
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2011) and exapted ERV repeats have been reported to act as regulatory elements in 
human promoters (Cohen et al, 2009). This repeat may therefore be the source of 
indel polymorphisms in this region, as well as provide a mechanism for the observed 
eQTL effects. Examination of FANTOM5 data, which provides deeply sequenced 
CAGE data over ~2000 human cell types suggests that the ERV1 element is not 
transcribed and is not an alternative SHROOM2 promoter (Semple C, pers. comm.).  
Given the distance of this ERV1 repeat from the SHROOM2 TSS (~1.5 Kb) it would 
seem more reasonable to think of this region as a di t l promoter element rather than 
an enhancer. This is consistent with ENCODE data which does not show the 
characteristic chromatin signature of an enhancer.  
     Further support for Indel24 as the functional v riant was provided by in-silico 
analysis which shows that Indel24 harbours an NF-Y binding motif (CCAAT box), 
with multiple other CCAAT motifs flanking the Indel24 sequence. Depletion of the 
NF-Y subunits as well as mutation of the CCAAT binding motifs was associated 
with a reduction in Indel24 reporter activity, implicating NF-Y as the transcription 
factor that is interacting with Indel24 within the ERV1 repeat element to modify 
SHROOM2 levels. This makes biological sense, as there have been reports of 
intergenic ERV repeats recruiting NF-Y in adult eryth oid cells to assemble a 
complex including RNA polymerase II and thereby affect downstream transcription 
of genes (Pi et al, 2010). Furthermore, the SHROOM2 promoter has two binding 
sites for the E2F1 transcription factor near the SHROOM2 TSS and studies have 
indicated that E2F1 and NF-YA can bind to promoters cooperatively to activate 
transcription (Ru et al, 2006). Biochemical approaches can be adopted to consolidate 
these findings, for example ChIP (chromatin immunoprecipitation) and EMSAs 
(Electrophoretic mobility shift assays) with NF-Y and E2F1 antibodies would be 
useful follow-up studies that can demonstrate endogen us and in-vitro DNA-protein 
binding at the Indel24 site, and can also reveal allele-dependent NF-Y binding 
affinities.  
     Mutation of the CCAAT sites within the region suggests that Indel24 modulates 
NF-Y binding by altering the spacing between the flanking NF-Y binding sites, 
instead of donating an extra CCAAT binding site. The implication that the spacing 
between the CCAAT sites in this region is more critical for NF-Y binding is not 
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unprecedented, as it is known from studies of the triple CCAAT CyclinB2 promoter 
that their precise alignments are required for their function in vivo (Bolognese 1999; 
Manni et al, 2001; Salsi et al, 2003). There is also ChIP-on-chip evidence to suggest 
that no CCAAT sites are closer than 24bp (Dolfini et al, 2009), and in vitro 
biochemical data of dual NF-Y binding to CCAAT boxes indicates that a distance of 
at least 24bp is required for them not to become mutually exclusive (Salsi et al, 
2003; Liberati et al; 1999). This could explain why the extra CCAAT site on the 
Indel24 insertion element does not confer an incremental effect on transcriptional 
activity, as the spacing between S1-S2 and S2-S3 are 24bp and 23bp respectively 
(Figure 22A), and may not be conducive for an extra binding interaction. On the 
other hand, the 24bp insertion element increases th spacing between S1-S3 from 
23bp to 47bp, which bears a closer resemblance to the 42bp spacing of S3-S4. This 
may be functionally more optimal, as it is known that distances between CCAAT 
motifs at NF-Y promoters are enriched at 32bp, 42bp and 53bp, corresponding to 3, 4 
and 5 turns of the double helix, respectively (Dolfini et al, 2009).  
     The involvement of NF-Y is intriguing, as it is well-known to regulate the 
expression of genes involved in cell cycle control and progression (Muller et al, 
2010). Both NF-Y and E2F1 have been linked to the development of multiple 
cancers including CRC (Dolfini et al, 2013; Morris et al, 2008), making SHROOM2 
a compelling candidate as a susceptibility gene. Th functional role of SHROOM2 is 
further investigated in Chapter 8.  
     In summary, the data presented here provides functional mechanistic evidence to 
support the eQTL effect of the Xp22.2 CRC risk locus, whereby a novel indel 
polymorphism can modulate NF-Y binding at the SHROOM2 distal promoter region 
and appears to be the causal variant. The evidence r ported here supports a growing 
number of studies, which highlights the value of functionally characterising disease-
associated common genetic variation in the discovery of novel candidate 
susceptibility genes for complex traits (Moffat et al, 2007; Meyer et al, 2008; 




SHROOM2 as a candidate susceptibility gene for colorectal 
cancer 
8.1 Introduction 
     The association between a colorectal cancer risk locus and SHROOM2 expression 
suggests that SHROOM2 may play a role in the predisposition to colorectal cancer. 
According to published literature, the SHROOM family of proteins are regulators of 
epithelial morphogenesis, characterized by their ability to bind F-actin and organise 
actomyosin networks (Dietz et al, 2006). SHROOM2, previously known as APXL, 
has a PDZ domain, a common structural domain of 80-90 amino acids found in 
signalling proteins. PDZ domain-containing proteins regulate diverse cellular 
processes and many signal transduction pathways (as reviewed by Subbaiah et al, 
2011). More specifically, SHROOM2 has been shown to play a role in cell 
morphogenesis during endothelial and epithelial tissue development (Lee et al, 2009; 
Farber et al, 2011), cytoskeletal organisation (Dietz et al, 2006), tight-junction 
stabilisation (Etournay et al, 2007) and cell contractility and migration (Farber et al, 
2011).  
     SHROOM2 was initially studied as a candidate gene in ocular albinism 
(Schiaffino et al., 1995), and has been shown to regulate melanosome biogenesis and 
localisation in the retinal pigment epithelium (Fairbank et al, 2006; Lee et al, 2009). 
This is intriguing, as abnormal retinal pigmentation, similar to the CHRPE lesions 
that are a component of the familial adenomatous polyposis syndrome, has 
previously been shown to be an extra-colonic feature of non-FAP CRC (Houlston et 
al, 1992; Dunlop et al, 1996) 
     Further suggesting a role in cancer, large-scale screens for mutations in somatic 
cancer have detected missense substitutions in the SHROOM2 coding sequence in 
various tumours including colorectal cancers (Forbes et al, 2010; URL8.1). There is 
also evidence that SHROOM2 is differentially expressed in medulloblastoma (Shou 
et al, 2015), and an intronic SNP within SHROOM2 has been associated with genetic 
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predisposition to prostate cancer (Eeles et al, 2013). SHROOM2 has also recently 
been implicated in non-cancer disease traits; the SHROOM2 gene was found to be 
associated with inherited predisposition to late-onset Alzheimer’s disease (Meda et 
al, 2012), and the authors posited that it may be implicated in the formation of 
pathological tau proteins by mediating actin cytoskeletal changes. 
     SHROOM2’s diverse cellular roles make it an interesting candidate gene for 
colorectal cancer development, although it has not been previously characterised in 
this respect. This chapter presents preliminary functional data that offers insight into 
role of SHROOM2 in colonic epithelial cells, by using a transient siRNA knockdown 


















8.2 Methodological overview 
8.2.1 Transcript-specific reverse-transcription PCR 
     PCR was performed on cDNA synthesised from human primary tissue and cell 
line RNA, as described in Chapter 2. Primers specific for the four different reported 
transcripts of SHROOM2 were used (Table 8.1) 
SHROOM2 
transcripts 
Forward primer Reverse primer 
T-001 GCCTCTTGGAAGGAACAG GACACTGGGCATCTGCTTG 
T-002 GCAGCCCTTGGTATGTG GACACTGGGCATCTGCTTG 
T-201 TGCGTGAGCTTGCCCATC GACACTGGGCATCTGCTTG 
T-003 CTGATCCAGCAAATGTGTGTAG CAAAATAAATAGTGTCTCTTC 
Table 8.1 Primer sequences used to specifically target and amplify the different transcripts of 
SHROOM2.  
8.2.2 SHROOM2 siRNA knockdown 
     siRNA knockdown of SHROOM2 was performed as described in 7.2.5 using 
10nM of siRNAs (Sigma) as detailed in Table 8.2. Transfected cells were incubated 
for 48 hours prior to seeding for phenotypic assays or RNA extraction for gene 
expression analysis. 
Gene siRNA Oligo ID Sequence (5’ - 3’) 
SHROOM2  siRNA1 SASI_Hs01_00205221 GGUAUGUUCCCGAUAAGAA 
SHROOM2  siRNA2 SASI_Hs02_00332240 CAAAGAGAAGACUGUGGAA 
SHROOM2  siRNA3 SASI_Hs01_00205222 GAGACUUCUCCCAUAGCAA 
Negative 
control 
Scrambled SIC001  






8.2.3 Growth assays 
     Growth curves for colorectal cancer epithelial cell lines were performed after 
siRNA knockdown of SHROOM2 for 48 hours. Cells were trypsinised, counted with 
a Coulter Counter (Beckman) and seeded at 2 x 106 in a T25 flasks for each time 
point. At each time point, cells were trypsinised and counted prior to RNA 
extraction. Doubling time was calculated from the cell counts using an online tool 
(Roth V, 2006) (URL8.2).  
8.2.4 Scratch-wound assay 
     Scratch assays for colorectal cancer epithelial cell lines were performed after 
siRNA knockdown of SHROOM2 for 48 hours, when the cell monolayer has 
achieved uniform confluence. For each well, a 200µL pipette tip was used to scratch 
a wound through the centre of the wells. The cells were washed with warm PBS 
gently to remove loose cells, and fresh low-serum media (1% FCS) was added to the 
wells. This is to reduce the effect of proliferation so that the effect of migration can 
be better observed. Cells were then placed in an Axiovert 200 live cell imaging 
system (Zeiss) and three fields of view were selected for each well. Time-lapse 
imaging was carried out every 15 minutes for 24 hours. The area of the wound was 
manually quantified and analysed using ImageJ.  
8.2.5 SHROOM2 siRNA knockdown in cell lines: whole-genome gene 
expression profiling and gene ontology analysis 
     SHROOM2 expression was knocked down with the three different siRNAs in five 
human cell lines from a variety of tissue types - DLD1 (CRC), SW480 (CRC), PNT 
(Prostate epithelium), HEK293 (embryonic kidney) and RPE1 (retinal epithelium). 
Knockdown experiments were replicated twice. After 48 hours, cell line RNA was 
extracted and knockdown confirmed with qRT-PCR. The RNA was then amplified 
and hybridised on the Illumina HumanHT-12 v4.0 Expression BeadChip Arrays 
(Illumina, USA), and gene expression data processed as described in 2.6.2. 
Differentially expressed genes that overlapped between all three siRNAs for each 
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individual cell line were subjected to GO (gene ontology) terms enrichment analysis 
using the web-based tool GOrilla (Eran et al, 2009) (URL2.3). The analyses were 
performed using the running mode that compared the target list of genes to the 
background list of genes (n=14174) that were expressed and detected in the cell lines 
used for the knockdown experiment. Ontologies containing only a single gene were 
omitted.  
8.2.6 Western blotting  
     Total protein and subcellular fractions were extracted as described in 2.5. Primary 
antibodies used are listed in Table 8.3. 
Protein Company Catalogue no. Type 
Antibody 
dilution used 
SHROOM2 Epitomics #S0151 Rabbit polyclonal 1:500 
β-actin Sigma #A1978 Mouse monoclonal 1:5000 
HSP60 Sigma #H3524 Mouse monoclonal 1:500 
E-cadherin Cell signalling #3195 Rabbit monoclonal 1:1000 
Lamin B1 Santa Cruz #SC-6216 Goat polyclonal 1:500 
Vimentin Cell signalling #5741 Rabbit monoclonal 1:500 
Table 8.3 Details of the antibodies and dilutions used in this chapter.  
 
SHROOM2 sera were produced by Dundee Cell Products using peptides1 as listed in 
Table 8.4. Antibodies were affinity purified using cognate peptide bead columns.  
Serum Rabbit Peptide sequence 
CSA 71 71 CSAGAQEPPRASRAEKASQR 
CSA 51 51 CSAGAQEPPRASRAEKASQR 
AQA 71 71 AQAQPRGDRRPELTDRPWRSAH 
AQA 51 51 AQAQPRGDRRPELTDRPWRSAH 
Table 8.4 Details of the customised serum raised against sequences specific to SHROOM2.  
                                                          




8.3.1 Transcript-specific expression of SHROOM2 in cell lines and 
colonic primary tissue 
     To begin studying the function of SHROOM2 in colorectal epithelial cells, the 
SHROOM2 gene and its four transcripts were first examined in a panel of cell lines 
and colonic tissue. This is important as the Illumina HT12 microarray probe detects 
only the largest transcript, whereas the Taqman Gene expression probe for qRT-PCR 
maps to all 3 protein-coding transcripts (Figure 8.1). To investigate which transcripts 
are expressed and relevant in colonic epithelial cells, RT-PCR using transcript-
specific primers was performed on a panel of human CRC cell lines, normal 
colorectal mucosa (NM) and colorectal tumour samples. It appears that colorectal 
cancer cell lines and primary colorectal tissue (normal and tumour) predominantly 
express the canonical transcript T-001 (Table 8.5 and 8.6), which is detected by both 
the Illumina HT-12 gene expression microarray and the qRT-PCR Taqman assay.  
     The transcript-specific primers were also tested against a panel of non-colorectal 
human cell lines (Table 8.7). This served as a positive control experiment showing 
that the primer sets were indeed working, and also demonstrated that there is tissue-
specific expression of SHROOM2 transcript isoforms. SHROOM2 appears to be 
weakly expressed, if at all, in the lymphoblastoid and erythroleukemia cell lines, 
which is similar to what was previously observed in primary PBMCs. The retinal 
pigment epithelial cell line RPE1 appears to lack the canonical transcript and only 
expresses the short T-201 transcript, whereas the prostate epithelial cell line PNT and 
the breast epithelial cell line MCF7 appears to express the shorter transcripts as well 






Figure 8.1 Summary of the SHROOM2 gene (ENSG00000146950) on chromosome X: 
9,754,496-9,917,483 and its 4 transcripts as detailed on Ensembl (GRCh37). Regions 







Name Transcript ID Length 
(bp) 
Protein ID Length 
(aa) 
Biotype 
T-001 ENST00000380913 7447 ENSP00000370299 1616 Protein coding 
T-002 ENST00000452575 2276 ENSP00000406724 375 Protein coding 
T-201 ENST00000418909 3597 ENSP00000415229 451 Protein coding 







rs5934683 T-001 T-002 T-201 T-003 
CACO2 CRC TT Present Absent Absent Absent 
COLO320 CRC CC Absent Absent Absent Absent 
DLD1 CRC CC Present Absent Absent Absent 
HCT116 CRC TT Present Absent Faint Absent 
HT29 CRC CT Absent Absent Absent Absent 
LOVO CRC TT Present Absent Absent Absent 
RKO CRC CC Present Absent Absent Absent 
SW48 CRC CC Absent Absent Absent Absent 
SW480 CRC TT Present Absent Absent Absent 
VACO425 CRC CC Present Absent Absent Absent 
Table 8.5 SHROOM2 transcript-specific RT-PCR using RNA from CRC cell lines.  
Patient Gender rs5934683 Tissue T-001 T-002 T-201 T-003 
CR77 F CT NM Present Absent Absent Absent 
CR90 F CT 
NM Present Absent Absent Absent 
Tumour Present Absent Absent Absent 
CR94 M CC 
NM Present Absent Absent Absent 
Tumour Present Absent Absent Absent 
CR97 F TT NM Present Absent Absent Absent 
CR102 M CC 
NM Present Absent Absent Absent 
Tumour Present Absent Absent Absent 
CR104 M CC 
NM Present Absent Absent Absent 
Tumour Present Absent Absent Absent 
CR142 M TT 
NM Present Absent Absent Absent 
Tumour Present Absent Absent Absent 
CR152 M TT 
NM Present Absent Absent Absent 
Tumour Present Absent Absent Absent 
Table 8.6 SHROOM2 transcript-specific RT-PCR on normal colorectal mucosa and paired 
tumour tissue whenever available. 
Cell line Tissue of origin T-001 T-002 T-201 T-003 
HeLa Cervical cancer Present Absent Absent Absent 
MCF7 Breast cancer Present Faint Absent Absent 
DU145 Prostate cancer Present Absent Absent Absent 
PC3 Prostate cancer Present Absent Absent Absent 
PNT Prostate Present Present Faint Absent 
K562 Erythroleukemia Faint Absent Absent Absent 
CON A Lymphoblastoid  Absent Absent Absent Absent 
CON C Lymphoblastoid Absent Absent Absent Absent 
RPE1 Retinal pigment epithelium Absent Absent Present Absent 
Table 8.7 SHROOM2 transcript-specific RT-PCR on non-CRC cell lines. 
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     Next, the relative expression of SHROOM2 in CRC and non-CRC cell lines was 
assessed by qRT-PCR (Figure 8.2). SHROOM2 gene products were very lowly 
expressed in CRC cell lines COLO320, HT29, SW48 and the blood cell lines K562, 
ConA and ConC, which was consistent with the non-quantitative RT-PCR. The 
colorectal cancer cell lines CACO2, DLD1, HCT116 and SW480 were high 
expressors, and hence selected for siRNA knockdown and phenotypic functional 
studies. The genotypes of these cell lines did not appear to affect SHROOM2 
expression in a consistent manner, which is not surprising given the chromosomal 




Figure 8.2 Relative expression of SHROOM2 in a panel of colorectal cancer cell lines and 
non-colorectal cancer cell lines as quantified by qRT-PCR. SHROOM2 was normalised to 































8.3.2 siRNA knockdown of SHROOM2 
     Having established that the SHROOM2 canonical transcript (T-001) is the relevant 
transcript in colorectal epithelial tissue, transient knockdown of this transcript was 
performed in CRC cell lines using siRNA transfections. Two siRNAs were initially 
used; siRNA1 was chosen to target only the canonical transcript, whereas siRNA2 
targets all four transcripts (Figure 8.1). HCT116 and DLD1 cell lines were initially 
chosen for knockdowns as they are adherent cell lines that transfect well and are 
good expressors of SHROOM2.  
     A transfection with a 48 hour incubation effectively knocked down SHROOM2 at 
the mRNA and protein level, and the level of knockdown was similar when used 
individually or in combination (Figure 8.3 and 8.4). This suggests that the large 
transcript SHROOM2-001 is the main, if not only, transcript expressed in these cell 
lines. It is also indicative that pooling of siRNAs did not appear to function 
synergistically to facilitate further degradation of SHROOM2 mRNA.  
     The SHROOM2 antibody used for Western Blotting appears to detect multiple 
other protein bands of different sizes. However, they are unlikely to be SHROOM2 
isoforms or SHROOM2 degradation products as their intensity does not change with 
knockdown using siRNA2, which targets all three protein-coding transcripts. 
Nevertheless, the non-specificity of this antibody renders it unsuitable for imaging 
and localisation studies. Efforts to obtain an antibody that is specific to SHROOM2 
















































Figure 8.3 qRT-PCR showing SHROOM2 expression normalised to EIF2B1, RPL30 and 
TBP. SHROOM2 was knocked down with the siRNAs individually and in combination for two 
CRC cell lines HCT116 and DLD1. 
 
Figure 8.4 Western blots with a commercial SHROOM2 antibody. The band that was 
reduced with SHROOM2 siRNA knockdown in both cell lines corresponds to the size of 
endogenous SHROOM2. β-actin was used as a loading control.  
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8.3.3 Transient knockdown of SHROOM2 and growth assays in CRC 
cell lines 
     Growth, or increase in total cell number over time, is a good measure of a 
biological response because it is broadly defined and influenced by many different 
factors including mitogens, nutrient levels, changes in transport, membrane integrity, 
attachment factors and so forth. Cell numbers can be affected by death rate, mitotic 
rate, progression through the cell cycle, or even by changing the plateau density. 
Although not specific, growth curves can be used as a general screening tool to 
detect phenotypic changes when a gene product is suppressed.  
     To analyse the growth characteristics of colorectal epithelial cells when 
SHROOM2 is knocked down, growth curves were established for 3 CRC cell lines 
with varying baseline levels of SHROOM2 - SW480 is a high expressor, whereas 
DLD1 and HCT116 have moderate expression of the SHROOM2 transcript. The cells 
were first transfected with siRNA for 48 hours and then trypsinised, counted and 
seeded in fresh media for the growth curves. The population doubling time for the 
cells were then calculated as a measure of cell proliferation. siRNA1 and siRNA2 are 
initially pooled to reduce the number of experiments performed. SHROOM2 mRNA 
level was measured at each time point to ensure that the reduction in expression was 
maintained throughout the experiment, and Western Blotting performed at time point 
0 to confirm depletion of SHROOM2 protein (Figure 8.5). Knock down of 
SHROOM2 appeared effective with a reduction in mRNA expression of >85% at 0 
hours. This effect diminished over time with a residual reduction of >50% at 72 
hours, which is expected of transient siRNA knockdowns.  It is interesting to note 
that SHROOM2 mRNA expression for both the control and knocked down cells 
appeared to increase with the time in culture, which may reflect the confluence or 
density of cells. The high levels at 0 hours (matching that of 72 hours) make this 
more likely - although the number of cells at 0 hours was low, they would have been 
almost confluent prior to trypsin digest and seeding. As RNA was extracted 
immediately after trypsin digest, the levels of cellular mRNA at this time point 
would be representative of that of a confluent phase. This was consistently observed 
in all the cell lines. This apparent relationship between SHROOM2 expression and 
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cell confluence may relate to, and provide support to its reported role in tight 
junction stabilisation. (Etournay et al, 2007). This does not, however, exclude 
confounders such as growth factors and nutrient composition in the growth media, 
which can also change as a function of time.  
     When the growth curves were plotted for the replicates of each cell line 
experiment, the rate of growth for DLD1 appeared to be slower when SHROOM2 
was transiently knocked down. (Figure 8.6). This was not seen with the other cell 
lines. Mann-Whitney U test on the population doubling time confirmed that there 
was a significant difference in doubling time (p-value=0.01) between DLD1 cells 
treated with scrambled siRNA and those treated with the SHROOM2 siRNAs. The 
knockdown cells had a 6.6 hour increase in average doubling time. To rule out off-
target effects, the experiment was repeated with the siRNAs singularly to ensure that 
this effect is specific to SHROOM2. A third siRNA that targets the 3’ end of 
SHROOM2-001 was used (Figure 8.1) for further confidence. All three siRNAs 
appeared to knockdown SHROOM2 mRNA levels to similar degrees (~80%), with 
siRNA1 maintaining the knockdown most effectively (Figure 8.7). The DLD1 
growth curves for the individual siRNAs revealed that the slowing of growth rates 
was only present with siRNA2 and not replicated with siRNA1 and siRNA3 (Figure 
8.8), indicating that this is more likely to be an off-target effect of siRNA2 rather that 
an effect attributable to SHROOM2 specific RNA degradation. 
     In summary, transient depletion of SHROOM2 did not appear to affect the 
population doubling time of CRC cell lines DLD1, HCT116 and SW480. The 
slowing of growth observed in DLD1 when SHROOM2 was knocked down is likely 
to be due to siRNA off targeting, as this effect was not replicable using siRNAs with 







SHROOM2 siRNA 1+2 
  
Figure 8.5 qRT-PCR of CRC cell lines when SHROOM2 was knocked down with siRNA1+2. 
SHROOM2 normalised to ACTB. Western blots of total protein extracted at time point = 0. 
Graphs and blots shown are representative of replicates. SC=scrambled control, 






















































































SHROOM2 siRNA 1+2 
 
 
Figure 8.6 Growth curves of colorectal cancer cell lines when SHROOM2 was knocked 
down with siRNA1+2. Experiments replicated at least 4 times, error bars=SEM. p-values are 
reported for the Mann-Whitney U test.  
Cell line        Average doubling time (hours) 
  Scrambled          SHROOM2 siRNA 1+2 
p-value 
DLD1 20.9 27.5 0.01 
HCT116 19.5 21.5 0.43 






































































Figure 8.7 qRT PCR of DLD1 with SHROOM2 knocked down with three different siRNAs 
singularly. SHROOM2 normalised to ACTB.  
 
 
Figure 8.8 Growth curves of DLD-1 when SHROOM2 was knocked down with three different 
























































8.3.4 Transient knockdown of SHROOM2 and scratch-wound assays in 
CRC cell lines 
     The in vitro scratch-wound assay is a straightforward, reproducible assay 
commonly used to measure basic cell migration parameters. Creation of a “scratch” 
gap in the confluent cell monolayer induces cells on the edge of the gap to polarise 
and migrate toward the opening to close the “scratch” until new cell-cell contacts are 
re-established. It mimics to some extent migration of cells in vivo, and can be useful 
to study the regulation of cell migration by cell-cell interactions.  
     As SHROOM2 appears to regulate endothelial sprouting, migration and 
angiogenesis (Farber 2011), it was hypothesised that SHROOM2 may also play a role 
in colonic epithelial cell migration. To test this hypothesis, in vitro scratch assays 
using time-lapse imaging were performed after siRNA knockdown of SHROOM2 in 
DLD1 cell lines. The closure of wound gap was quantified by measuring the 
remaining area of the gap at multiple time points. The depletion of SHROOM2 did 
not appear to affect the rate of wound closure in DLD1 (Figure 8.9A). This 
experiment was repeated in SW480 and CACO2 cell lines and showed inconsistent 
results. In SW480, SHROOM2 knockdown slowed wound closure, whereas this had 
the opposite effect in CACO2 (Figure 8.9B). SHROOM2 expression levels were 
quantified with qRT-PCR after the final time-point and the knockdown of 
SHROOM2 was >80% for DLD1 and SW480 but was less so at 50% for CACO2 
(Figure 8.10). This experiment has been performed only once in the SW480 and 
CACO2 cell lines, and will require technical replication. 
     In summary, within the remit and limitations of this simple scratch-wound assay, 
SHROOM2 did not appear to have a consistent effect on the rate of wound closure in 









Figure 8.9 A) Scratch wound assay - the remaining gap area over a 24 hour time course 
was quantified as a measure of wound closure in DLD1 cell line monolayer. Transient 
knockdown of SHROOM2 with siRNA was performed prior to introducing the scratch wound. 
Experiments replicated 4 times, error bars=SEM. B) Scratch wound assay similarly 



























































































Figure 8.10 qRTPCR showing depletion of SHROOM2 at the end of the scratch wound time 
course (24hours) for the three cell lines used. SHROOM2 normalised to ACTB. Results 












































8.3.5 Microarray gene expression analysis of normal mucosa and cell 
lines in relation to SHROOM2 expression 
     To gain further insight into the function of SHROOM2, microarray data from 
whole-genome gene expression profiling of normal mucosa were first examined.  
     Of the 21937 genes detected in the normal mucosa, the expression levels of 4570 
genes were correlated with SHROOM2 expression (pers. comm. Grimes). 2390 of 
these were positively correlated, whereas 2180 were negatively correlated. Under the 
working assumption that functionally related genes are more likely to be co-
expressed (Eisen et al, 1998; Hughes et al, 2000; Kim et al, 2001), these genes were 
subjected to gene ontology analysis using GOrilla. The top twenty most significant 
GO terms for all correlated genes, positively correlated genes and negatively 
correlated genes are presented in Table 8.8 – 8.10. There is a striking presence of GO 
terms implicating the cell cycle when all correlated genes are analysed together. The 
positively correlated genes appear to be enriched for metabolic/catabolic processes, 
whereas the negatively correlated genes were predominantly enriched for cell cycle 




















cell cycle process 3.80E-13 4.84E-09 1.82 176 
mitotic cell cycle process 3.01E-12 1.92E-08 1.88 132 
cell cycle 9.51E-10 4.04E-06 1.81 117 
mitotic cell cycle 6.19E-09 1.97E-05 1.96 86 
cell cycle G1/S phase transition 4.72E-08 1.20E-04 2.6 40 
G1/S transition of mitotic cell cycle 4.72E-08 1.00E-04 2.6 40 
cell cycle phase transition 1.83E-07 3.33E-04 2.08 60 
mitotic cell cycle phase transition 2.52E-07 4.02E-04 2.07 59 
regulation of mitotic cell cycle 3.25E-07 4.60E-04 2.05 62 
regulation of cell cycle process 8.06E-07 1.03E-03 1.93 68 
DNA strand elongation involved in DNA 
replication 
8.61E-07 9.97E-04 4.43 16 
regulation of cell cycle 1.02E-06 1.09E-03 1.67 106 
DNA strand elongation 1.46E-06 1.43E-03 4.3 16 
rRNA metabolic process 2.02E-06 1.84E-03 2.39 36 
chromosome organization 4.40E-06 3.73E-03 2 52 
regulation of catalytic activity 5.24E-06 4.17E-03 1.84 69 
regulation of transferase activity 5.49E-06 4.11E-03 2.28 42 
cell division 5.70E-06 4.03E-03 1.86 63 
rRNA processing 5.76E-06 3.86E-03 2.44 35 
DNA metabolic process 8.41E-06 5.36E-03 1.56 113 
Table 8.8 Gene ontology analysis of the genes that are correlated in expression to 
















lipid metabolic process 1.94E-10 2.47E-06 1.54 189 
fatty acid oxidation 8.72E-09 5.56E-05 3.37 25 
cellular lipid metabolic process 1.09E-08 4.62E-05 1.56 149 
lipid oxidation 1.36E-08 4.33E-05 3.31 25 
enzyme linked receptor protein 
signaling pathway 
2.79E-07 7.11E-04 1.49 147 
cellular lipid catabolic process 6.45E-07 1.37E-03 2.29 37 
fatty acid beta-oxidation 6.49E-07 1.18E-03 3.33 19 
lipid modification 1.87E-06 2.98E-03 2.23 36 
phosphate-containing compound 
metabolic process 
4.49E-06 6.36E-03 1.29 259 
fatty acid catabolic process 5.42E-06 6.90E-03 2.72 22 
lipid catabolic process 6.15E-06 7.12E-03 1.89 49 
phosphorus metabolic process 6.76E-06 7.18E-03 1.28 263 
monocarboxylic acid catabolic process 8.48E-06 8.31E-03 2.48 25 
carnitine transport 1.07E-05 9.74E-03 5.49 8 
amino-acid betaine transport 1.07E-05 9.09E-03 5.49 8 
fatty acid metabolic process 1.36E-05 1.08E-02 1.75 57 
regulation of plasma membrane 
organization 
2.01E-05 1.51E-02 2.6 21 
ammonium ion metabolic process 2.31E-05 1.63E-02 2.01 36 
organic hydroxy compound metabolic 
process 
3.22E-05 2.16E-02 1.54 83 
vacuolar transport 4.19E-05 2.67E-02 2.38 23 
Table 8.9 Gene ontology analysis of the genes that are positively correlated in expression to 














cell cycle process 5.09E-35 6.49E-31 2.22 236 
mitotic cell cycle process 1.50E-32 9.56E-29 2.41 186 
mitotic cell cycle 1.53E-31 6.50E-28 2.82 137 
cell cycle 4.92E-26 1.57E-22 2.3 164 
heterocycle metabolic process 7.92E-23 2.02E-19 1.38 629 
nucleobase-containing compound 
metabolic process 
1.36E-22 2.89E-19 1.39 607 
cellular aromatic compound metabolic 
process 
3.10E-22 5.64E-19 1.38 627 
cellular macromolecule metabolic 
process 
1.77E-21 2.82E-18 1.28 835 
cellular nitrogen compound metabolic 
process 
2.76E-21 3.91E-18 1.35 656 
ncRNA metabolic process 2.99E-21 3.81E-18 2.51 112 
gene expression 8.57E-21 9.92E-18 1.98 182 
DNA metabolic process 1.96E-20 2.08E-17 2.05 164 
organic cyclic compound metabolic 
process 
4.95E-20 4.85E-17 1.34 643 
nucleic acid metabolic process 1.03E-19 9.38E-17 1.39 548 
nitrogen compound metabolic process 4.13E-19 3.50E-16 1.31 692 
macromolecule metabolic process 1.11E-18 8.80E-16 1.24 895 
primary metabolic process 3.20E-18 2.39E-15 1.2 1020 
chromosome organization 5.16E-18 3.65E-15 2.76 79 
cellular component organization or 
biogenesis 
4.05E-17 2.71E-14 1.31 627 
cell division 5.39E-16 3.43E-13 2.4 90 
Table 8.10 Gene ontology analysis of the genes that are negatively correlated in expression 






     To evaluate further the role of SHROOM2 in cancer and non-cancer cells, siRNA 
knockdown of SHROOM2 was performed in two CRC cell lines (DLD1 and SW480) 
and three non-cancer cell lines (HEK293, RPE1 and PNT), using three different 
siRNAs (Figure 8.13A). siRNA1 was not effective in RPE1; this was expected given 
that RPE1 expresses only the shorter transcript SHROOM2-201 which lacks the 
target exon of siRNA1, as shown in Table 8.8 and Figure 8.1. 
     Gene expression microarray analysis showed that there were 14174 unique genes 
detected, and the number of genes with differential expression varied between cell 
lines (Figure 8.13B). Gene ontology analysis was performed for genes that are 
downregulated and upregulated upon depletion of SHROOM2, for each cell line 
individually (Table 8. - 8.). Overall, cell-cycle and cell-division related genes appear 
to be overrepresented, most notably within the downregulated genes in DLD1, 
HEK293 and PNT cell lines. This association with cell-cycle genes is consistent with 
the normal mucosa GO analysis, strongly suggesting SHROOM2 has a regulatory 
function of the cell cycle. Interestingly, SHROOM2 has been reported to be a 
centrosome-associated protein in a mouse endothelial cell line, and plays a role in the 
regulation of centrosome duplication (Farber, 2012). Moreover, Xenopus SHROOM2 
has been shown to regulate gamma tubulin (Fairbank et al, 2006), which is found 
primarily in centrosomes and spindle pole bodies. Though speculative, the inference 
that SHROOM2 has a similar role in human colorectal epithelial cells is an attractive 
one, as centrosome defects are known to promote chromosomal instability (Ganem et 
al, 2009), a common and important pathway in the aetiology of colorectal cancer. 
     In the RPE1 cell line, the genes upregulated with knockdown of SHROOM2 are 
enriched with protein localisation and transport genes, which would fit it with 
SHROOM2’s known regulatory function in melanosome biogenesis and localisation 
in the retinal pigment epithelium (Fairbank 2006). In the non-cancer HEK293, RPE1 
and PNT cell lines, the GO analysis also points towards genes with a function in cell 
polarity, morphogenesis and organelle organisation, which could relate to 
SHROOM2’s interaction with the actin-cytoskeleton and cell-junction proteins 
(Etournay et al, 2007). In the DLD1 cell line only, there is enrichment of TGF-
β/SMAD signalling genes in the upregulated genes, which is intriguing given the 
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involvement of this pathway in the pathogenesis of highly penetrable colorectal 
cancer mutational syndromes and colonic crypt homeostasis (Hardwick et al, 2008; 
Bellam et al, 2010; Reynolds et al, 2014). However, this should be interpreted with 
caution as a number of these enriched processes do not survive multiple testing 
correction.  
     The microarray gene expression analysis of these siRNA knockdown experiments 
has also highlighted the well-recognised caveat of the immunostimulatory “side 
effects” of siRNA treatments. There is a component of immune response, viral 
response and cell death genes observed in varying degrees across all cell lines, 
consistent with the knowledge that these effects are cell-type specific. In line with a 
stimulatory effect, these tend to be enriched for within the upregulated genes, 
although in RPE1 there was markedly strong enrichment within the downregulated 
genes. This idiosyncrasy could reflect a stronger immunostimulatory effect of the 
scrambled control siRNA in RPE1 cells. Hence, caution should be exercised when 
interpreting the results of these experiments, and a reduction in the concentration of 
siRNA used should be considered for future experiments, in particular with RPE1 











Figure 8.11 A) qRTPCR of cell lines selected for transcriptomic analysis showing siRNA 
knockdown of SHROOM2. SHROOM2 normalised to RPL30. Graphs are representative of 







Cell line Cell type No. of downregulated 
genes 
No. of upregulated 
genes 
DLD1 Colorectal cancer  792 1015 
SW480 Colorectal cancer 1353 660 
HEK293 Human embryonic kidney 593 759 
RPE1 Retinal pigment epithelium 1518 1542 




































DOWNREGULATED GENES IN DLD1 UPON DEPLETION OF SHROOM2 






cell cycle 3.79E-08 4.79E-04 2.15 57 
mitotic cell cycle 3.52E-07 2.23E-03 2.31 42 
modification-dependent protein 
catabolic process 
4.33E-06 1.82E-02 2.32 34 
cellular macromolecule catabolic 
process 
5.78E-06 1.83E-02 1.88 54 
ubiquitin-dependent protein catabolic 
process 
6.27E-06 1.59E-02 2.32 33 
modification-dependent macromolecule 
catabolic process 
6.42E-06 1.35E-02 2.28 34 
proteasome-mediated ubiquitin-
dependent protein catabolic process 
1.34E-05 2.43E-02 2.47 27 
proteasomal protein catabolic process 2.23E-05 3.53E-02 2.41 27 
proteolysis involved in cellular protein 
catabolic process 
2.32E-05 3.26E-02 2.15 34 
 
UPREGULATED GENES IN DLD1 UPON DEPLETION OF SHROOM2 






negative regulation of response to 
stimulus 
1.58E-04 >0.05 1.48 85 
enzyme linked receptor protein 
signaling pathway 
2.26E-04 >0.05 1.56 65 
transmembrane receptor protein 
serine/threonine kinase signaling 
pathway 
2.27E-04 >0.05 2.3 22 
SMAD protein complex assembly 3.13E-04 >0.05 10.07 4 
transforming growth factor beta 
receptor signaling pathway 
3.14E-04 >0.05 2.56 17 
Table 8.11 Gene ontology analysis of genes that are differentially expressed with depletion 
of SHROOM2 in DLD1 cells. Where FDR q-values are non-significant, the top 5 highest 





DOWNREGULATED GENES IN SW480 UPON DEPLETION OF SHROOM2 






liver development 3.11E-04 >0.05 2.72 15 
mature ribosome assembly 4.08E-04 >0.05 8.94 4 
cardiac septum morphogenesis 6.77E-04 >0.05 3.27 10 
ER-associated ubiquitin-dependent 
protein catabolic process 
8.30E-04 >0.05 3.19 10 
protein folding in endoplasmic 
reticulum 
8.96E-04 >0.05 7.66 4 
 
UPREGULATED GENES IN SW480 UPON DEPLETION OF SHROOM2 






mitochondrial ATP synthesis coupled 
proton transport 
2.80E-04 >0.05 8.02 5 
hydrogen ion transmembrane transport 3.28E-04 >0.05 3.45 11 
positive regulation of molecular 
function 
4.83E-04 >0.05 1.51 66 
transmembrane receptor protein 
tyrosine kinase signaling pathway 
5.94E-04 >0.05 1.76 37 
ribose phosphate metabolic process 6.00E-04 >0.05 2.45 17 
 
Table 8.12 Gene ontology analysis of genes that are differentially expressed with depletion 
of SHROOM2 in SW480 cells. Where FDR q-values are non-significant (>0.05), the top 5 









DOWNREGULATED GENES IN HEK293 UPON DEPLETION OF SHROOM2 






mitotic cell cycle 1.05E-06 1.33E-02 2.57 32 
cell division 2.28E-06 1.44E-02 2.73 27 
chromosome organization involved in 
meiosis 
5.14E-06 2.16E-02 9.57 7 
mitotic nuclear division 1.34E-05 4.24E-02 2.98 20 
cell cycle process 1.37E-05 3.47E-02 1.86 51 
cell cycle 1.51E-05 3.19E-02 2.08 38 
nuclear division 1.88E-05 3.39E-02 2.74 22 
 
UPREGULATED GENES IN HEK293 UPON DEPLETION OF SHROOM2 






protein modification by small protein 
conjugation or removal 
1.47E-04 >0.05 1.73 48 
Golgi vesicle transport 1.80E-04 >0.05 2.34 22 
negative regulation of cell 
communication 
1.86E-04 >0.05 1.56 66 
regulation of cellular respiration 1.92E-04 >0.05 8.36 5 
establishment of cell polarity 2.08E-04 >0.05 4.25 9 
 
Table 8.13 Gene ontology analysis of genes that are differentially expressed with depletion 
of SHROOM2 in HEK293 cells. Where FDR q-values are non-significant (>0.05), the top 5 









DOWNREGULATED GENES IN RPE1 UPON DEPLETION OF SHROOM2 






type I interferon signaling pathway 8.91E-14 1.13E-09 5.11 27 
response to virus 2.27E-10 1.43E-06 2.64 48 
defense response to virus 2.20E-09 9.29E-06 3.03 34 
negative regulation of viral process 6.46E-08 2.04E-04 3.45 23 
negative regulation of viral life cycle 2.28E-07 5.76E-04 3.34 22 
cytokine-mediated signaling pathway 5.03E-07 1.06E-03 1.95 58 
negative regulation of viral genome 
replication 1.27E-06 2.29E-03 4.05 15 
regulation of viral genome replication 1.82E-06 2.87E-03 3.31 19 
response to other organism 2.07E-06 2.90E-03 1.88 57 
response to biotic stimulus 3.60E-06 4.55E-03 1.68 77 
negative regulation of multi-organism 
process 3.87E-06 4.45E-03 2.56 27 
regulation of viral process 4.27E-06 4.50E-03 2.3 33 
response to external biotic stimulus 4.52E-06 4.39E-03 1.69 74 
cellular macromolecule metabolic 
process 7.44E-06 6.71E-03 1.15 576 
regulation of viral life cycle 7.60E-06 6.41E-03 2.27 32 
defense response to other organism 1.07E-05 8.47E-03 2.01 41 
interferon-gamma-mediated signaling 
pathway 2.05E-05 1.53E-02 2.94 18 
regulation of symbiosis, encompassing 
mutualism through parasitism 2.52E-05 1.77E-02 2.12 33 
response to interferon-alpha 3.46E-05 2.30E-02 5.4 8 









UPREGULATED GENES IN RPE1 UPON DEPLETION OF SHROOM2 






multi-organism cellular process 1.45E-09 1.83E-05 1.87 94 
viral process 2.16E-09 1.36E-05 1.86 93 
symbiosis, encompassing mutualism 
through parasitism 2.16E-09 9.09E-06 1.86 93 
interspecies interaction between 
organisms 4.40E-09 1.39E-05 1.78 102 
establishment of protein localization 1.44E-08 3.64E-05 1.55 154 
establishment of protein localization to 
membrane 1.77E-08 3.72E-05 2.37 47 
translation 8.03E-08 1.45E-04 2.14 53 
establishment of localization in cell 1.23E-07 1.94E-04 1.43 187 
single-organism intracellular transport 1.36E-07 1.91E-04 1.57 128 
intracellular transport 1.41E-07 1.78E-04 1.5 152 
protein transport 1.44E-07 1.66E-04 1.52 143 
translational elongation 1.97E-07 2.08E-04 2.4 39 
Golgi vesicle transport 3.76E-07 3.66E-04 2.29 41 
nuclear-transcribed mRNA catabolic 
process 4.34E-07 3.91E-04 2.39 37 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 4.93E-07 4.15E-04 2.77 28 
organic substance transport 6.03E-07 4.77E-04 1.39 192 
protein targeting to ER 6.60E-07 4.91E-04 2.79 27 
protein localization to endoplasmic 
reticulum 7.18E-07 5.04E-04 2.72 28 
cellular component organization or 
biogenesis 7.48E-07 4.97E-04 1.22 420 
intracellular protein transport 8.72E-07 5.51E-04 1.65 92 
Table 8.14 Gene ontology analysis of genes that are differentially expressed with depletion 






DOWNREGULATED GENES IN PNT UPON DEPLETION OF SHROOM2 






organelle assembly 6.20E-09 7.83E-05 2.83 38 
microtubule-based process 3.35E-08 2.12E-04 2.37 47 
cilium organization 3.62E-08 1.52E-04 3.88 22 
cell division 1.25E-07 3.95E-04 2.46 40 
cilium assembly 2.58E-07 6.52E-04 3.76 20 
organelle organization 6.70E-07 1.41E-03 1.45 151 
single-organism organelle organization 8.16E-07 1.47E-03 1.55 115 
mitotic cell cycle process 8.29E-07 1.31E-03 1.9 62 
cellular component assembly involved 
in morphogenesis 1.98E-06 2.79E-03 2.94 24 
cell cycle process 3.05E-05 3.86E-02 1.61 73 
intraciliary transport 3.65E-05 4.20E-02 5.91 8 
 
UPREGULATED GENES IN PNT UPON DEPLETION OF SHROOM2 






regulation of biological quality 4.43E-06 5.60E-02 1.4 154 
cellular component organization or 
biogenesis 3.78E-05 >0.05 1.24 247 




enzyme linked receptor protein 
signaling pathway 5.02E-05 
>0.05 
1.67 62 
cellular component organization 6.05E-05 >0.05 1.23 244 
 
Table 8.15 Gene ontology analysis of genes that are differentially expressed with depletion 
of SHROOM2 in PNT cells. Where FDR q-values are non-significant (>0.05), the top 5 






8.3.6 SHROOM2 protein localisation and function 
     The appropriate localisation of a protein is fundamental as it provides the 
physiological context for their function. SHROOM2 has been showed from the gene 
expression studies in Chapter 6 to be expressed in the colonic normal mucosa. 
However, this is a highly heterogeneous tissue that consists of epithelium, connective 
tissue (lamina propria) and a thin muscle layer (muscularis mucosae) (Figure 8.19). 
They are morphologically distinct yet functionally interdependent, for example, the 
mesenchymal cells of the lamina propria orchestrate the microenvironment of the 
epithelial cells and regulate the stem cell niche within the crypts. The epithelium is 
further divided into more subtypes (e.g. enterocytes and goblet cells), and it is well-
recognised that there is a differential distribution of gene expression along the 
colonic crypt-lumen axis as well as a proliferative and differentiation hierarchy.  In 
the context of cancer, the spatial distribution of this gene product is highly relevant, 
as disruptions in the crypt dynamics and homeostasis is one of the early steps in 
malignant transformation of the colonic epithelium. On a cellular level, the 
eukaryotic cell is organised into membrane-covered compartments that are 
characterised by specific sets of proteins and biochemically distinct cellular 
processes. Hence, the appropriate tissue distribution as well as subcellular 
localisation of endogenous SHROOM2 would provide key insights into its functional 
role. 
Figure 8.12 A cross-section drawing of the colon demonstrating the mucosa layer in the 
luminal surface of the colon.  
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     Immunostaining is a key technique widely used to identify the absence or 
presence of a protein, its tissue distribution, subcellular localisation and changes in 
the expression, and is heavily dependent on a sensitive and specific antibody. As 
demonstrated in previous sections, the commercial antibody to human SHROOM2 
detects a ~170kDa band on Western Blotting that is reduced with siRNA 
knockdown, but also detects multiple other non-specific bands of varying molecular 
weights. Antibodies from other commercial companies were even less effective (data 
not shown),  hence we sought to generate specific antibodies in rabbits with two 
separate antigens consisting of amino acids sequences from distinct regions of 
SHROOM2 (Figure 8.20). Only the AQA sera detects SHROOM2 along with several 
non-specific bands (Figure 8.21A). Dilutions of the AQA sera from rabbit 51 were 
performed but this did not  improve the specificity of the sera (Figure 8.21B).   
 
 
Figure 8.13 A schematic diagram of the human SHROOM2 protein and the protein region 









                     
Figure 8.14 A) Western blots of total cell extracts from DLD1 cells with SHROOM2 
knockdown using siRNA1.  Commercial (Epitomics) and custom antibodies to SHROOM2 
were used for detection of SHROOM2. B) Dilutions of the AQA sera (rabbit 51) with the 







     Without a specific antibody to perform immunostaining, I attempted to 
characterise the subcellular localisation of SHROOM2 by subcellular fractionation 
and Western Blotting. In DLD1 cells, it appears that SHROOM2 is largely expressed 
in the cytosolic compartment and the cytoskeletal compartment (Figure 8.22). 
LS174T is a non-expressing cell line and was used as a negative control. This fits in 
well with published studies of SHROOM2, where it has been reported to associate 
with F-actin and is involved in regulating the cytoskeletal organisation and 
architecture of endothelial cells (Dietz et al, 2006). The markers of various 
subcellular fractions are shown to demonstrate that there is minimal cross-over of the 
compartments, but this is not without caveats and should be interpreted in 
combination. For instance, the nuclear marker Lamin-B stains both nuclear and 
cytoskeletal compartments, as being a nuclear intermediate filament protein it also 
precipitates into the insoluble cytoskeletal fraction. However, staining with the 
cytoskeletal marker Vimentin demonstrates that there is unlikely to be contamination 
of the nuclear fraction with cytoskeletal proteins.  
Figure 8.15 Western blots of subcellular fractions extracted from LS174T cells and DLD1 
cells with SHROOM2 knockdown using siRNA1. The commercial antibody (Epitomics) was 
used for detection of SHROOM2.   
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     To characterise the spatial distribution of SHROOM2 within the colonic normal 
mucosa, I sought circumferential evidence by examining its expression correlation 
with various tissue and cell type markers within the expression microarray data of the 
normal mucosa samples (n=115). Firstly the markers for the three tissue layers of the 
mucosa were examined in relation to SHROOM2 expression (Table 8.8), using 
conventional markers or novel markers recently identified (Pinchuk et al, 2010; 
Powell et al, 2011; Roberts et al, 2014). Endothelial markers were also included to 
account for possible inclusion of the submucosa during the tissue harvesting process. 
Values for each individual probe are shown when there are multiple probes for a 
given gene. Although the different probes for an individual gene are not always 
consistent in expression levels and degree of correlation, it is reassuring that in 
general, they exhibit similar directionality (Figure 8.23). The average gene 
expression (Table 8.8 and Figure 8.23A) suggests that the tissue sampled consisted 
of epithelial cells, mesenchymal stromal cells, smooth muscle cells and endothelial 
cells in decreasing order, which broadly reflects the expected composition of the 
normal mucosa with minimal submucosal contamination. Several marker genes for 
all the different cell types were significantly correlated with the expression of 
SHROOM2, but only CDH1 (E-cadherin), an epithelial cell marker, was positively 
correlated with SHROOM2 (Table 8.8 and Figure 8.23B and C), suggesting that 
SHROOM2 is more likely to be expressed in epithelial cells than other tissue-types. 
Interestingly, SHROOM2 is significantly negatively correlated with the epithelial cell 
marker CD44, which would argue against SHROOM2 being expressed in the 
epithelium. However, this negative correlation may reflect the differential expression 
of SHROOM2 along the colonic crypt vertical axis as CD44 is known to be 
expressed in the crypt base of the murine (Rothenberg et al, 2012) and human colon 














Epithelial CDH1 10.97 0.0006*** 0.311 
 EPCAM 12.63 0.0661 0.171 
 CD44 9.98 0.0145* -0.226 
 CD44 7.40 0.0887 -0.158 
 CD44 7.10 0.1183 -0.145 
Mesenchymal stromal ACTA2 11.69 0.9300 -0.008 
 THY1 7.58 0.2100 -0.116 
 DES 7.07 0.7500 0.030 
 VIM 10.22 0.0400* -0.187 
 VIM 10.98 0.1400 -0.136 
Smooth muscle CALD1 8.08 0.2067 -0.118 
 CALD1 7.82 0.5392 -0.057 
 CALD1 9.21 0.9277 -0.008 
 SMTN 6.59 0.0340* -0.196 
 SMTN 7.64 0.1810 -0.124 
 SMTN 6.71 0.0354* -0.195 
Endothelial PECAM1 7.91 0.0860 -0.159 
 CD34 7.43 0.0031** -0.272 
 CD34 6.58 0.6000 0.049 
 CD34 8.08 0.7300 0.032 
 CD34 6.51 0.7500 0.030 
 MCAM 6.54 0.9800 0.002 
 ENG 7.50 0.0480* -0.184 
Table 8.16 Cell-type specific markers and their correlation with SHROOM2 in the normal 





Figure 8.16 A) The average expression of tissue/cell type specific markers. B) the -log10(p-
value) of the correlation between SHROOM2 expression and marker genes. Dotted line 
represents a p-value of 0.05. C) Spearman rho of the correlation between SHROOM2 and 













































































































































































































































































































     There is increasing evidence of heterogeneity of cells within the human colonic 
epithelium, with different protein markers and transcriptional signatures reflecting 
their lineage, differentiation stage and functional status (Dalerba et al, 2011). By 
inference, SHROOM2’s association with these markers may provide insight into its 
role within the colonic epithelial crypt. Useful markers that are frequently expressed 
in a mutually exclusive way include genes encoding lineage-specific markers such as 
CA1 for enterocytes, MUC2 for goblet cells, and LGR5 for the immature 
compartment. From a differentiation point of view, there are also transcriptional 
programs that characterises “top-of-the-crypt” mature, differentiated enterocytes and 
“bottom-of-the-crypt” cell populations which include compartments characterised by 
genes linked to goblet cells and genes that are expressed in the progenitor cell 
compartment of the mouse small intestine. (Dalerba et al, 2011; Merlos-Suarez et al, 
2011). Functionally, the expression of proliferation markers can also be examined; 
these are generally restricted to the bottom of the crypts.  
     SHROOM2’s appears to be positively correlated with CA1 and not MUC2 or 
LGR5 (Table 8.9 and Figure 8.24), suggesting that it is expressed mainly in 
enterocytes. Overall, there are more significantly positive correlations between 
SHROOM2 and genes that are highly expressed by “top-of-the-crypt” differentiated 
enterocytes, as compared to genes that are expressed by “bottom-of-the-crypt” cells. 
Although there is significant correlation with some of the proliferative markers, these 
correlations are negative and hence consistent with expression in non-proliferative or 
mature differentiated enterocytes. There are also positive correlations with two of the 
genes expressed in the progenitor cell compartment (RGMB and PTPRO), which 
may relate to SHROOM2’s subcellular localisation and function rather than crypt 
distribution, as there was no correlation with the other markers of stem-ness (LGR5 
and ASCL2).  This is rather intriguing as they are both plasma membrane associated 
proteins that have a regulatory role in cellular growth, differentiation and cell cycle 
progression - RGMB is a glycosylphosphatidylinositol (GPI)-anchored protein that 
potentiates BMP signalling (Halbrooks et al, 2007), whereas PTPRO is a protein 
tyrosine phosphatase localised to the apical surface of polarised cells that interferes 
with cell cycle progression (Motiwala et al, 2004). Alternatively, these could be false 














Crypt-top Mature enterocytes SLC26A3 13.19 0.0001*** 0.351 
  CA1 12.32 0.0248* 0.208 
  CA2 12.96 0.0331* 0.197 
  CA2 12.35 0.1256 0.142 
  MS4A12 10.82 0.0047** 0.260 
  AQP8 11.20 0.0008*** 0.307 
  CD177 7.12 0.0067** 0.250 
  CD177 7.53 0.0069** 0.249 
  KRT20 9.05 0.0171* 0.220 
  KRT20 11.94 0.0501 0.182 
Crypt-
bottom 
Goblet MUC2 11.52 0.7838 0.026 
  TFF3 13.23 0.2982 -0.097 
  SPDEF 8.04 0.0703 -0.168 
  SPINK4 10.38 0.1295 -0.141 
 Stem/Progenitor LGR5 6.56 0.9477 0.006 
  OLFM4 11.16 0.0605 -0.174 
  OLFM4 7.52 0.0552 -0.178 
  ASCL2 7.80 0.6126 -0.047 
  RGMB 6.64 0.1243 -0.143 
  RGMB 7.87 0.0242* 0.209 
  RGMB 6.58 0.0181* 0.219 
  PTPRO 7.41 0.0365* 0.194 
  PTPRO 7.39 0.0330* 0.197 
 Proliferative MKI67 6.76 0.0115* -0.233 
  TOP2A 8.65 0.0227* -0.211 
  BIRC5 6.49 0.1166 -0.146 
  BIRC5 7.20 0.5412 -0.057 
Table 8.17 Genes characteristically expressed by subpopulations of epithelial cells and their 
correlation with SHROOM2 in the normal colorectal mucosa. Values are shown for each 
probe when there are multiple probes for a gene. 
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Figure 8.17 A) The average expression of genes characteristic of colonic epithelial 
subpopulations. B) the -log10(p-value) of the correlation between SHROOM2 expression and 
marker genes. Dotted line represents a p-value of 0.05. C) Spearman rho of the correlation 
between SHROOM2 and marker genes. Values are shown for each probe when there are 






























































































































































































































































































































































































     In summary, by Western Blotting of subcellular fractions, SHROOM2 appears to 
be a cytosolic protein that associates with the cytoskeleton in DLD1 colorectal 
cancer cell line. By examining the correlation of SHROOM2 with gene-expression 
markers of the different cell populations within the colonic mucosa, it was deduced 
that SHROOM2 is mainly expressed in mature enterocytes of the epithelial layer at 
the top of the colonic crypts. An effective antibody to SHROOM2 would provide the 
























     The data presented in Chapter 6 and 7 has shown that the Xp22.2 CRC risk locus 
demonstrates eQTL activity targeting the cis-gene SHROOM2, with evidence to 
suggest that the causal indel variant at the distal promoter region influences 
SHROOM2 transcription by modulating NF-Y transcription factor binding. By 
association, SHROOM2 is implicated as a candidate susceptibility gene and this 
chapter presents preliminary data on the function of SHROOM2 in human colonic 
epithelial cells.  
     Prior to any functional assays of SHROOM2, it is important that the presence of 
transcript isoforms are first identified in the tissue type of interest, as it has been 
reported that non-coding genetic variation may influence disease risk by altering 
levels of expression and splicing architecture of mRNA transcripts (Graham et al, 
2006; Zhang et al, 2009). Furthermore, characterisation of the relevant transcript 
isoforms will ensure that any observed phenotype is accurately attributed to a 
specific transcript isoform. This is particularly important for SHROOM2 as there are 
four reported transcripts and the HT12 microarray probe used for the eQTL analysis 
only detects the large canonical transcript T-001. Hence, it is reassuring that it is the 
only transcript that is expressed in the primary normal mucosa and tumour tissue and 
most of the cell lines used for functional assays (8.3.2). There is some evidence of 
tissue-specific alternative splicing as the other protein coding transcript isoforms are 
present in cell lines derived from other tissue types such as the retinal pigment 
epithelium, breast cancer and prostate tissue, suggesting different or additional 
functional roles for SHROOM2 in extra-colonic tissue. 
     The data presented in the next part of the chapter focuses on the transient 
knockdown of SHROOM2 in tumour cell lines with RNA interference, and the effect 
on tumourigenicity assays such as growth curves and scratch-wound assays. 
Traditional cancer cell lines have the advantage of being accessible, easily 
manipulated and replicable, hence ideal for in-vitro cell biology experiments where 
near-complete control of the environment and the existence of a single cell type are 
desirable. However, not only do these cell lines harbour genetic aberrations, they 
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have been subjected to gross manipulation during the process of creating cell lines 
and are kept under artificial conditions, therefore are not necessarily an accurate 
representation of the natural cellular state in vivo. The preliminary work presented 
here did not show a detectable change in the growth curves and scratch-wound 
assays with transient RNAi of SHROOM2, however, these negative results may 
reflect the major caveat that accompanies tumour cell lines, where overbearing 
mutator phenotypes in proliferative signalling and cell-cycle check points would 
displace or override any subtle effect of a lower-risk gene. Alternatively, it may 
represent a requirement for further experimental optimisation. For example, cell 
counting is a rough-and-ready technique and more specific readouts such as viability 
assays, proliferative and apoptotic markers, cell cycle phase markers may be more 
informative. With regards to the scratch wound assay, the cell line controls used only 
closed the scratch-wound gap minimally, with a closure of only ~25% after 24 hours. 
This suggests there may be factors impeding the migration of the cells in general, and 
any effect of gene depletion may have been masked. Further optimisation of this 
system will be required to robustly demonstrate the role of SHROOM2 in cell 
migration, for instance, knockdown of a positive control such as FAK, titration of 
serum in the growth medium and/or cell confluence, a longer time-course, or use of 
chemoattractants and gradient chambers. An experimental design utilising repeated 
measures analyses could also be used in future experiments to allow longitudinal 
monitoring and analysis. This will improve the power of detecting changes and order 
effects, and may reveal more subtle changes in cellular phenotypes associated with 
SHROOM2 depletion. 
     A further consideration for future functional work is stable knockdown/knockout 
of SHROOM2 or overexpression vectors, as certain cellular phenotypes may not be 
easily observed and quantified within the short time frame of transient siRNA 
depletion. Alternative models such as mouse models, ex-vivo three-dimensional 
organoid culture or normal colonic epithelial cell lines would offer a relatively 
normal physiological platform investigate gene functions, albeit more challenging 
and costly/labour-intensive. Stable genome editing using CRISPR-Cas9 technology 
has recently been successfully performed for driver pathway mutations in human 
colonic organoids as a model of colorectal cancer (Matano et al, 2015), and may 
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ultimately allow more definitive phenotype characterisation for candidate 
susceptibility genes such as SHROOM2 before progressing to dissect the subtle 
phenotypes associated with gene dosage. 
     Co-expression analysis implicates that SHROOM2 is expressed in the mature 
differentiated enterocytes at the top of the colonic epithelial crypts, and gene 
ontology analysis of cell line RNAi and correlated genes in the normal mucosa is 
suggestive of a role in cell cycle regulation. It is known that the transcription factor 
implicated in its transcriptional control, NF-Y, also regulates transcription of various 
genes related to the cell cycle (Elkon et al, 2003; Caretti et al, 2003) and that co-
regulated genes often share biological functions.  This indirectly lends further 
support to the suggestion that SHROOM2 may exert its tumour suppressive effects 
by influencing the cell cycle progression, which can in turn, influence proliferation, 
differentiation and apoptosis. It would therefore be of considerable interest to design 
and perform experiments that would directly implicate SHROOM2 in the regulation 
of cell cycle, such as flow cytometry cell cycle analysis or FUCCI (Fluorescence 
Ubiquitin Cell Cycle Indicator) cell cycle reporter vectors.  
     The expression of many genes as well as eQTLs effects appear to be tissue- or 
cell-type specific. As demonstrated in 6.3.2, not only is SHROOM2 lowly expressed 
in PBMCs compared to normal mucosa, the rs5934683-SHROOM2 eQTL is also not 
detectable. Given the heterogeneity of cell-types within the normal mucosa as well as 
the expression gradient along the epithelial crypt axis, it is conceivable that 
SHROOM2 expression and/or the eQTL effect are selectively present in a similar 
fashion. Risk alleles and their target genes may act in a non-cell autonomous fashion 
and therefore may exert their effect through other cell types that act upon the target 
cells, it is therefore crucial to further understand the spatial distribution of 
SHROOM2 within the colonic mucosa. This is particularly so as it is well-recognised 
that the mesenchymal stroma plays a key paracrine signalling role in maintaining the 
epithelial crypt architecture, and that cancers are thought to arise from the 
dysregulation of the crypt-base stem cell niche which harbours the cell of origin of 
colorectal cancer - the ‘bottom-up’ hypothesis. The co-expression analysis of 
SHROOM2 and cell-specific marker genes in the normal mucosa indicates that 
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SHROOM2 expression is correlated with markers of crypt-top mature enterocytes, 
suggesting that SHROOM2 is mainly expressed in this cell sub-type. This may or 
may not be representative of the eQTL effect. As there is rapid cell turnover and the 
majority of differentiated cells are shed into the lumen within 5days, perturbations in 
this crypt compartment are in theory less likely to initiate neoplasia. Interestingly, a 
recent mouse model study of hereditary mixed polyposis syndrome (HMPS) 
demonstrated evidence for the alternative ‘top-down’ hypothesis of tumour 
formation, where aberrant epithelial expression of GREM1 promoted the persistence 
and/or reacquisition of stem cell properties in LGR5-negative cells that have exited 
the stem cell niche, allowing cells outside the crypt-base stem cell niche to form 
ectopic crypts and act as tumour progenitors (Davis et al, 2014). Sporadic traditional 
serrated adenomas, which are characterised by ectopic crypt foci, were also shown 
by the authors to express epithelial GREM1, suggesting a similar underlying 
mechanism. In another study, activated NF-κB induced mucosal inflammation in 
combination with constitutive epithelial Wnt signalling was shown to promote the 
initiation of neoplasia from cells situated outside the crypt base stem cell niche 
(Schwitalla et al, 2013). Given that these studies demonstrate that the top-down 
model of tumourigenesis may indeed fit some subtypes of inherited and sporadic 
colorectal cancers, it would be of great interest to refine the tissue localisation of 
SHROOM2 and the eQTL effect. Apart from immunostaining techniques, RNA-
FISH could be used to demonstrate the spatial distribution of SHROOM2 transcripts. 
Alternatively, disaggregation of the intestinal epithelial crypts from the underlying 
stromal tissue using enzymatic or non-enzymatic methods can be performed on 
freshly sampled colonic mucosa prior to extraction of RNA/protein. During the 
process of normal mucosa sampling, tumour tissue has also been collected and fresh 
frozen, and may shed light on the role of SHROOM2 in tumourigeneis. SHROOM2 
expression and the eQTL effect could be examined, as well as any associations with 
driver pathway mutations, chromosomal abberations, microsatellite instability and 
epigenetic changes (e.g. CIMP phenotype). 
     In the context of human case-control studies, the study that would cement 
SHROOM2’s role in CRC risk is to quantify SHROOM2 expression in the normal 
mucosa of cases versus controls, ideally in a prospective manner. This is challenging 
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to say the least, but is possible in the longer term with the increasing realisation that 
normal tissue repositories are a vital resource in understanding disease mechanisms. 
In the larger scheme, this would also be an invaluable resource in facilitating the 
amalgamation of genetics, transcriptomics and proteomics of normal tissue states that 
would complement the ongoing work in disease states, and to discover and study 
biomarkers of disease predisposition and clinical outcomes.  
     In summary, this chapter presents preliminary data on the functional role of 
SHROOM2, the target gene of a GWAS-associated common variant that is 
implicated as a colorectal cancer susceptibility gene. Subcellular localisation studies 
and co-expression analysis of the normal mucosa suggests that it is a cytoplasmic 
protein that associates with the cytoskeleton, and is likely to be mainly expressed in 
the crypt-top mature enterocytes. RNA interference studies suggests a role in the 
regulation of cell cycle progression, and further understanding of role of SHROOM2 
would prove invaluable in understanding the contributory pathways to CRC 
carcinogenesis, and ultimately inform the rational development of 











Functional characterisation of the gene-environment (plasma 
25-hydroxyvitamin D) interaction at the 16q22.1 risk locus 
9.1 Introduction 
     The eQTL analysis of colorectal mucosa and PBL has provided evidence of 
regulatory function for approximately half of the CRC risk SNPs (Chapter 6). Further 
functional studies of the Xp22.2 locus validates this eQTL association (Chapter 7), 
providing proof of principle on a molecular level. However, there is still a large 
proportion of risk variants whose functions and target genes are unaccounted for.  
There is emerging evidence of gene-environment interactions on cancer risk in the 
context of low-penetrance genetic susceptibility polymorphisms, for instance, parity 
and alcohol consumption influencing breast cancer genetic risk conferred by 
common alleles (Nickels et al, 2013), and common genetic variation modifying the 
protective effect of NSAID/aspirin use in colorectal cancer (Nan et al, 2015). 
Although the underlying molecular mechanisms have yet to be identified, these 
studies are suggestive that the function of common variants may also be modified by 
non-genetic factors. Hence, it is conceivable that the eQTL effects of CRC risk 
variants may not be fully appreciable under steady-state conditions, in other words, 
their association with the expression of target genes may be modifiable by 
perturbations of cellular pathways that are influenced by lifestyle/environmental 
factors.  
     A recent study by the Colon Cancer Genetics Group (Zgaga et al, unpublished) 
investigated whether vitamin D levels modified the risk conferred by the 25 common 
variants associated with CRC. This investigation stemmed from the implication of 
vitamin D deficiency as a possible risk factor in the aetiology of colorectal cancer, 
where higher vitamin D intake, higher serum 25-hydroxyvitamin D (25-OHD) and 
residence in regions with strong UVB radiation were associated with lower CRC risk 
(Gorham et al, 2005; Giovannucci 2009; Gandini et al, 2011) and cancer mortality 
238 
 
(Robsahm et al, 2004, Tretli et al, 2012). Interestingly, this study demonstrated a 
statistically significant 2-way interaction between plasma 25-OHD and rs9929218 at 
the 16q22.1 locus (p=0.004) (Figure 9.1). In other words, the effect of rs9929218 on 
CRC risk was modified by the levels of plasma 25-OHD (Table 9.1).  This is the first 
study to implicate an interaction between a known CRC risk variant and an 
environmental factor; if true, this could have a significant impact on public health 
strategies in CRC risk stratification, screening and prevention. Hence, there is much 
value in pursuing an understanding of the functional mechanism that mediates this 
gene-environment interaction observed in population studies. 
     The rs9929218 SNP (chr16:68820946) resides within intron 2 of CDH1 that 
codes for E-cadherin, a protein that plays a crucial role in epithelial cell-cell adhesion 
and tissue architecture maintenance. It has been previously implicated in colorectal 
cancer (as reviewed by Tsanou et al, 2008), and its reduced expression is known to 
be associated with invasive potential and poor prognosis in various cancers. 
Although intron 2 of CDH1 is known to contain cis-regulatory elements for its 
transcription (Stemmler et al; 2005), the expression analysis of CRC risk variants in 
normal mucosa and PBMC (Chapter 6) did not reveal any evidence to suggest a 
relationship between rs9929218 genotype and CDH1 expression. Similarly, ChIP-seq 
studies of the vitamin D receptor (VDR) does not show vitamin D response elements 
at this locus (Ramagopalan et al, 2010;) and independent bioinformatics analysis 
does not support VDR binding at this locus (Zgaga et al, unpublished). Instead, the 
in-silico analysis strongly suggests a putative FoxO binding site at rs9929218, with a 
10-fold increase in FoxO binding affinity associated with the A allele. This is 
intriguingly as there is evidence in the literature to indicate that VDR associates 
directly with FoxO proteins and their regulators, and that vitamin D treatment 
induces post-translational modification of FoxO proteins, enhancing their binding to 
the promoters of target genes (An et al, 2010). There is also evidence suggesting that 
FoxO3a is involved in the regulation of E-cadherin expression in urothelial cancer 
cells (Shiota et al, 2010).  
     From this, it can be postulated that the observed interaction between 25-OHD and 
rs9929218 on CRC risk is mediated by VDR’s ligand-dependent non-genomic 
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actions, whereby it modulates the activity of FoxO proteins on cis-regulatory 
elements of CDH1. This chapter aims to investigate this hypothesis by utilising the 
expression data derived from the human colonic mucosa and PBMC, as well as 
measurements of matched serum 25-OHD. To investigate further whether the 
rs9929218 genotype influences the induction of CDH1 expression, the in-vivo 
expression analysis will be complemented by the in-vitro vitamin D treatment of 
CRC cell lines and human colonic organoids. 
     One of the biggest limitations of studies utilising single 25-OHD measurements in 
observational studies of cancer incidence and mortality is that 25-OHD is frequently 
measured after the diagnosis. Determining the direction of causality is challenging as 
25-OHD levels may have decreased as a result of illness or treatment. Indeed, 
decreased circulating 25OHD concentration has been reported after elective knee 
surgery (Reid et al, 2011) and cardiopulmonary bypass (Krishnan et al, 2010). As the 
majority of vitamin D measurements used in this chapter were taken post-operatively 
at varying intervals (ranging from 1to 468 days), they may not accurately reflect the 
vitamin D status at the point of mucosa sampling given the reported changes that 
accompany major surgery. Therefore, it is of importance to characterise these 
changes after abdominal surgery for large bowel resections. Understanding how 
circulating 25-OHD fluctuates peri- and post-operatively will not only contribute 
towards robust statistical analysis of its association with disease and expression 
phenotypes, it will also offer insight into the regulation and homeostasis of vitamin D 
and inform the design of future studies investigating its role in the development of 













  GA vs. AA   GG vs. AA 
N OR 95% CI p   OR 95% CI P 
1 1357 0.92 0.61-1.41 0.71 
 
0.97 0.64-1.46 0.87 
2 1449 1.27 0.85-1.9 0.24 
 
1.49 1.01-2.21 0.044 
3 1410 1.83 1.15-2.91 0.01  2.35 1.49-3.7 0.0002 
Table 9.1 Association between rs9929218 and colorectal cancer for different tertiles of May-
standardised 25-OHD. The cut-offs for the 25-OHD tertiles (T1, T2 and T3) were: 0-8.3, 8.4-




Figure 9.1 The proportion of colorectal cases in subgroups based on rs9929218 genotype 

































9.2 Methodological overview 
9.2.1 Study subjects and biological material 
     To investigate the factors influencing CDH1 expression in-vivo, normal colonic 
mucosa (n=115) and matched PBMC (n=59) were collected from patients 
undergoing large bowel surgery as described in 6.2.1. In a subset of these patients 
(n=83), blood was also collected post-operatively for the quantification of circulating 
25-OHD. Plasma was isolated from peripheral blood as described in 2.1.2.  
     A different cohort of patients undergoing large bowel surgery for CRC were 
recruited for the serial sampling study of serum 25-OHD (n=40) (Table 9.2). Six 
serum samples were obtained from these patients at the following time points – pre-
operatively (3-19 days before surgery), 1-2 days post-op, 3-5 days post-op, 6-8 days 
post-op, first outpatient follow-up (30-120 days post-op), and second outpatient 













MD AGE GENDER AJCC STAGE OPERATION 
11015 74 M 2 Laparoscopic 
11028 82 M 1 Open 
12692 63 M 1 Laparoscopic 
12755 76 F 2 Open 
12777 73 F 3 Open 
12781 81 F 3 Laparoscopic 
12785 57 F 1 Open 
12788 73 F 1 Laparoscopic 
12789 88 M 3 Open 
12794 86 F 3 Laparoscopic 
12796 76 F 2 Laparoscopic 
12797 75 M 2 Laparoscopic 
12798 61 M 1 Laparoscopic 
12800 65 F 2 Laparoscopic 
12802 71 F 1 Laparoscopic 
12804 46 M 1 Laparoscopic 
12805 49 F 2 Laparoscopic 
12807 68 M 2 Open 
12808 69 M 1 Open 
12811 78 F 3 Laparoscopic 
12812 52 M 1 Open 
12813 78 M 1 Open 
12815 65 M 2 Laparoscopic 
12822 73 F 3 Open 
12824 65 F 1 Laparoscopic 
12826 83 F 2 Open 
12857 71 F 1 Laparoscopic 
12873 64 M 2 Laparoscopic 
12874 65 M 2 Laparoscopic 
12876 76 M 2 Laparoscopic 
12882 81 M 2 Open 
12887 65 M 1 Open 
12890 85 M 2 Open 
12893 81 M 2 Laparoscopic 
12897 52 M 1 Laparoscopic 
12898 85 M 3 Laparoscopic 
12903 78 M 2 Open 
12904 60 F 1 Laparoscopic 
12906 49 M 1 Open 
12919 76 M 2 Laparoscopic 
Table 9.2 Characteristics of the 40 study subjects – age, gender, AJCC stage of CRC and 
the type of large bowel surgery (open or laparoscopic).  
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9.2.2 Gene expression levels and variant genotypes  
     The expression of the genes of interest was extracted from the microarray data 
after normalisation, batch correction and log transformation as described in 2.3.6. 
Genotypes of the SNPs of interest were obtained from the HumanOmni5M-4v1_B 
BeadChip Arrays (Illumina, USA) as described in 6.2.3.  
9.2.3 Calcitriol treatment of cell lines 
     Cell lines were cultured as described in 2.2 until 50% confluence prior to 
calcitriol treatment. Calcitriol (Sigma-Aldrich) was reconstituted in 100% ethanol 
and a final concentration of 100nM were used. The equivalent volume of 100% 
ethanol was used as the negative control, which equates to 1% v/v ethanol. 10% 
charcoal-stripped fetal bovine serum (Life Technologies) was used during calcitriol 
treatment to eliminate lipophilic material that contain vitamin D metabolites that may 
mask or falsely elevate the effect of calcitriol treatment.  
9.2.4 Calcitriol treatment of human organoids 
     Human colonic organoid culture was carried out as described in Sato et al, 2011 
using epithelial crypts dissociated from the colonic tissue harvested from fresh 
surgical specimens.  In brief, epithelial crypts are dissociated from the stroma using 
25mM EDTA and mechanical pipetting. After washing, the crypts were resuspended 
in Matrigel (BD Bioscience) at 200 crypts per 50µL of Matrigel in each well (24-
well plate). 500µL of culture medium was placed in each well after the Matrigel has 
solidified, and culture medium was replaced every 2 days. The organoids were 
incubated at 37ºC in a humidified incubator (95% O2, 5% CO2). At day 5 in culture 
when crypt budding started to occur, the organoids were treated with 100nm 
calcitriol (Sigma-Aldrich) or the 1% v/v ethanol negative control for 16 hours.  








Advanced DMEM/F12 Invitrogen™, Life Technologies 1x 
Glutamax Invitrogen™, Life Technologies 2mM 
Hepes Invitrogen™, Life Technologies 10mM 
Bsa Sigma-Aldrich 0.1% 
Penicillin/Streptomycin In-house technical services 100U/130µg per ml 
N-acetylcysteine Sigma-Aldrich 1mM 
N2 Invitrogen™, Life Technologies 1x 
B27 Invitrogen™, Life Technologies 1x 
Gastrin I Sigma-Aldrich 10nM 
Nicotinamide Sigma-Aldrich 10mM 
A83-01 Tocris 500nM 
SB202190 Sigma-Aldrich 10µM 
Noggin 
(mouse recombinant) 
Peprotech 100 ng/ml 
Epidermal Growth Factor 
(mouse recombinant) 
Invitrogen™, Life Technologies 50ng/ml 
R-Spondin 
(mouse recombinant) 




Table 9.3 Details of the reagents used for the human organoid culture medium.  
 
9.2.5 qRT-PCR 
     RNA from cell lines and human organoids was extracted using the Ambion® 
RiboPure™ RNA extraction kit (Life Technologies) as per the manufacturer’s 
protocol. DNAse treatment, cDNA synthesis and qRT-PCR of the genes of interest 
were performed as described in 2.3, using the Taqman® Gene Expression assays 







Gene Assay ID Probe sequence 
CDH1 Hs01023895_m1 AAGGTGCTCTTCCAGGAACCTCTGT 
VDR Hs01045844_m1 TGAAGGAGTTCATTCTGACAGATGA 
CYP24A1 Hs00167999_m1 GCGGTGGAAACGACAGCAAACAGTC 
CYP3A4 Hs00604506_m1 ATTTTGTCCTACCATAAGGGCTTTT 
ACTB Hs99999903_m1 CCTTTGCCGATCCGCCGCCCGTCCA 
Table 9.4 Taqman gene expression assays used in the quantification of gene expression in 
the calcitriol-treated cell lines and human organoids. 
 
9.2.6 Measurement of circulating 25-OHD  
     Circulating 25-OHD was quantified as a measure of vitamin D status. Total 
plasma or serum 25-OHD (25-OHD2 and 25-OHD3) was measured by the liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method by the Clinical 
Biochemistry department, Glasgow Royal Infirmary, following standard protocols 
and quality control procedures (Knox  et al. 2009). More details about this method 
can be found elsewhere (Knox et al. 2009; Wallace et al. 2010). Levels <8nmol/L 
were undetectable and randomisation was performed based on the distribution of the 
other samples in the cohort (Figure 9.2). May-adjusted 25-OHD concentrations were 
used as described in Zgaga et al, 2011. To minimise the confounding effects of the 
season and subsequently daylight length, 25-OHD levels were standardised to the 
month of May, to remove the effect of the month when blood was sampled on 25-
OHD levels (adjusted values of <0nmol/L were re-coded as 0nmol/L). As the 
majority of samples were considered clinically deficient in 25-OHD (<30nmol/L), 
the levels were categorised in tertiles for the gene-environment analysis. The cut-offs 







9.2.7 Statistical analysis 
     All models were adjusted for age, gender and site of sampling. To test for two-
way interactions, linear regression analysis was performed, modelling both the main 
effects and the interaction for the selected SNPs, genes or serum 25-OHD. Where 
more than one probe was present for a gene, the expression of each probe was 
analysed individually. Correlation between individual gene expression in the normal 
mucosa was performed using Spearman correlation as a non-parametric measure of 





























Figure 9.2 Distribution of serum/plasma 25-OHD used in this study (top panel). Samples 
<8nmol/L (highlighted in purple, n=71) were undetectable by LC-MS/MS and imputation was 
performed. The distributions of imputed and subsequent May-adjusted values for these 




9.3.1 Expression of CDH1 is independently associated with VDR, 
CYP3A4 and FOXO transcription factors 
     Vitamin D exerts its biological effects primarily by activating the vitamin D 
receptor (VDR). Upon ligand activation, this nuclear hormone receptor forms a 
heterodimer with the retinoid-X receptor and binds to vitamin D response elements 
(VDRE) on DNA, facilitating the recruitment of protein complexes that are essential 
for transcriptional modulation. There is also evidence of transcriptional 
autoregulation of VDR by the active vitamin D metabolite calcitriol (1,25-
dihyroxyvitamin D3) using ChIP anlaysis (Zella et al, 2006). Hence, its expression is 
useful as a marker of vitamin D transcriptional activity and by extension, a proxy of 
cellular vitamin D status. CYP3A4 is used as an alternative marker of vitamin D 
transcriptional activity, as it is a ligand-induced VDR-mediated target gene in 
intestinal cells (Pavek et al, 2009). 
     In primary human normal colonic mucosa (n=115), expression of CDH1 was 
found to be associated with both VDR and CYP3A4 (Table 9.5). As a total of 11 
probes were tested in this analysis, the significance threshold was set at 0.0045 to 
correct for multiple testing. Although one of the two probes for VDR did not survive 
multiple testing, the probe that did (ILMN_2319952) was very highly significant 
p=5.44E-15) and explained a remarkable 51% of the variance in CHD1 expression. 
As there are 7 reported protein-coding transcripts for VDR, of which 5 are poorly-
supported transcript models according to the Ensembl genome database (URL9.1), it 
is reassuring that the ILMN_2319952 probe captures the two well supported protein-
coding transcript models VDR-002 and VDR-004. On the other hand, expression of 
FOXO1, FOXO3 (two out of three probes) and FOXO4 are also very significantly 
associated with the expression of CDH1 (Table 9.5), of which FOXO4 appears to be 
the most significantly associated gene (p=1.62E-13).  
     Taken altogether, these results lend support to the hypothesis that the expression 
of CDH1 is regulated by VDR and FOXO proteins. However, these associations are 
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only suggestive of a mechanistic link, and do not shed light on the nature of this 
relationship and the direction of regulation, if any. 
Illumina probe 
ID 
Gene Spearman correlation 
with CDH1 
Linear model adjusted for 
age, gender and sampling 
site 
  rho p-value Estimate p-value 
ILMN_2319952 VDR 0.714 < 2.2e-16*** 1.025 5.44E-15*** 
ILMN_1666203 VDR 0.235 0.011 1.282 0.015 
ILMN_1772206 CYP3A4 0.375 3.73E-05*** 1.023 3.96E-05*** 
ILMN_1738816 FOXO1 0.381 2.67E-05*** 0.648 1.29E-05*** 
ILMN_1681703 FOXO3 0.528 1.34E-09*** 0.578 1.23E-11*** 
ILMN_1712515 FOXO3 0.213 0.023 0.947 0.063 
ILMN_1844692 FOXO3 0.429 1.67E-06*** 0.558 3.30E-09*** 
ILMN_1712095 FOXO4 0.578 1.38E-11*** 0.734 1.62E-13*** 
ILMN_3307977 FOXO6 -0.074 0.432 -0.516 0.255 
ILMN_3311135 FOXO6 -0.098 0.299 0.054 0.907 
ILMN_3311155 FOXO6 -0.008 0.936 -0.139 0.804 
Table 9.5 The association between expression of CDH1 and the expression of implicated 









9.3.2 CRC risk variant rs9929218 modifies the association between 
FOXO4 and CDH1 
     To gain insight into the direction of regulation, a two-way interaction analysis 
was performed with the CDH1 variant, rs9929218. A statistically significant two-
way interaction (p=0.0057) was observed between rs9929218 and FOXO4 
expression on the expression of CDH1 (Table 9.6), suggesting that FOXO4 
influences the expression of CDH1 and not vice-versa. Interaction analysis with 
rs9929218 was also carried out for VDR and the other FOXO family members, but no 
other further interactions were observed to be present.  
     The negative estimate of the interaction term between the main variables FOXO4 
and rs9929218 implies that there is negative synergy between them, i.e. their 
presence at the same time dampens their effect on CDH1. To illustrate this, the 
association between FOXO4 and CDH1 expression was analysed separately for each 
rs9929218 genotype (GG, GA and AA) (Figure 9.3). The relationship between 
FOXO4 and CDH1 appears to be modified by the rs9929218 genotype, where the 
gradient of the positive linear relationship between FOXO4 and CDH1 expression 
decreased with the number of A alleles. Although there is the possibility of a false 
positive result due to the small numbers of the AA genotype, this statistical 
interaction makes biological sense given that rs9929218 has been predicted to 
modify FOXO binding affinity, and offers a plausible mechanism for the plasma 











 Estimate p-value 
Age 0.003 0.15 
Gender -0.085 0.11 
Sampling site -0.079 0.19 
FOXO4 0.878 1.77E-14*** 
rs9929218 3.383 0.0053** 
FOXO4*rs9929218 -0.404 0.0057** 
 
Table 9.6 The multivariate linear regression modelling for expression of CDH1 in the normal 


















Figure 9.3 The association between expression of CDH1 and FOXO4 in the normal mucosa, 
analysed separately for each rs9929218 genotype (the major allele G is associated with a 




rs9929218 N Estimate p-value 
GG 76 0.863 4.05E-12*** 
GA 29 0.557 6.51E-03** 

























9.3.3 VDR expression and a VDR polymorphism independently 
modifies the association between FOXO4 and CDH1 
     A further analysis was carried out to examine the possibility of VDR influencing 
the relationship between FOXO and CDH1 expression. A statistically significant 
two-way interaction (p=0.00617) was observed between VDR and FOXO4 
expression as determinants of CDH1 expression (Table 9.7). The association 
between FOXO4 and CDH1 expression was analysed separately for each tertile of 
VDR expression (Figure 9.4). The relationship between FOXO4 and CDH1 appears 
to be modified by levels of VDR, where the influence of FOXO4 on CDH1 appears 
to decrease as VDR levels increased. 
     To find further supporting evidence for the interaction between VDR and FOXO4, 
two-way interaction analyses was carried out between FOXO4 and VDR 
polymorphisms that have been reported to have a bearing on VDR function (as 
reviewed by Uitterlinden et al, 2004) and the risk of colorectal adenomas and cancer 
(Touvier et al, 2011; Bai et al, 2012) (Table 9.8). Interestingly, the FokI 
polymorphism that is located in the start codon showed a significant two-way 
interaction with FOXO4 (p=0.0076), where the influence of FOXO4 expression on 
CDH1 expression increased with the number of the major allele G (Figure 9.5). The 
major allele produces a protein that is shorter by three amino acids (Whitfield et al, 
2001), and could conceivably influence the modulatory effect of VDR on FoxO4.   
     The independent effect of VDR expression and a VDR polymorphism on the 
FOXO4-CDH1 association is strongly supportive of a direct association between 
VDR and FoxO4 that enhances FoxO4 binding to regulatory elements and the 
consequent transcription of CDH1.  
     In view of these significant two-way interactions implicating a functional 
relationship between VDR, FOXO4 and rs9929218 on CDH1 expression, a three-way 
interaction analysis was performed for these three variables. No significant three-way 
interaction was found (p=0.644) but the power of detection may be limited by the 




 Estimate p-value 
Age 0.003 0.11 
Gender -0.070 0.11 
Sampling site -0.024 0.63 
FOXO4 6.912 3.29E-03** 
VDR 7.800 2.60E-03** 
FOXO4*VDR -0.848 6.17E-03** 
 
Table 9.7 The multivariate linear regression modelling for expression of CDH1 in the normal 




















Figure 9.4 The association between expression of CDH1 and FOXO4 in the normal mucosa, 























VDR expression tertile 1
VDR expression tertile 2
VDR expression tertile 3
VDR expression N Estimate p-value 
Tertile 1 (7.0 – 7.49) 38 0.838 2.06E-07*** 
Tertile 2 (7.49 – 7.67) 38 0.205 0.178 





Table 9.8 Two-way interaction analyses between VDR polymorphisms and FOXO4 
expression in the linear regression modelling of CDH1 expression. Model adjusted for age, 







VDR polymorphisms MAF Estimate p-value 
FOXO4*ApaI (rs7975232) 0.46 -0.218 0.11 
FOXO4*FokI (rs10735810) 0.40 0.393 7.60E-03** 









Figure 9.5 The association between expression of CDH1 and FOXO4 in the normal mucosa, 



























FokI genotype N Estimate p-value 
AA 12 1.541 0.025* 
GA 53 0.836 1.16E-07*** 
GG 50 0.487 3.90E-04*** 
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9.3.4 Tissue-specific effects of VDR, FOXO4 and rs9929218 on CDH1 
expression 
     In a subset of matched PBMC (n=59), CDH1 is not detected on the HT12 
microarray and is only detectable at low levels by qRT-PCR. This is not surprisingly 
as it is well-established that E-cadherin is an adherens junction protein 
predominantly expressed in epithelial cells. However, recent studies have uncovered 
a role for this adhesion molecule in mononuclear phagocyte functions, where it 
regulates the maturation and migration of Langerhans cells, as well as the interaction 
between various immune cells and dendritic cells (as reviewed by Van den Bossche 
et al, 2013). Hence, it was thought to be of interest to investigate whether the genes 
and two-way interactions associated with CDH1 expression are also present in 
PBMCs.  
     Similar to that in the normal mucosa, rs9929218 is not significantly associated 
with the expression of CDH1 (p=0.67). The expression of CDH1 is also not 
associated with the FOXO family members (p>0.43) or VDR (p=0.066). The two-
way interactions between FOXO4 and rs9929218, VDR and FokI individually were 
not present in PBMC. This suggests that the postulated effect of VDR modulating the 
activity of FOXO4 on cis-regulatory elements of CDH1 is specific to the normal 











9.3.5 Analysis of the effect of serum 25OHD on normal mucosa CDH1 
expression  
     In view of the gene-environment interaction of plasma 25-OHD and rs9929218 on 
colorectal cancer risk, matched serum 25-OHD was retrospectively collected for a 
subset (n=83) of the normal mucosa used for the above analysis. Serum 25-OHD was 
not significantly associated with CDH1 expression, and neither was there a 
statistically significant interaction between serum 25-OHD and rs9929218, VDR, 
FokI or FOXO4 on the expression of CDH1 in the normal mucosa or PBMC. This is 
not surprising, as serum 25-OHD was collected at variable time points post-
operatively, and may not accurately represent the intracellular vitamin D status of the 
normal mucosa tissue collected during the surgical procedure. It has been reported 
that that circulating 25-OHD is affected in patients undergoing cardiopulmonary 
bypass (Krishnan et al, 2010) and elective knee arthroplasty (Reid et al, 2011). 
Krishnan et al reported that plasma 25-OHD returned to baseline pre-operative levels 
by post-operative day 5, whereas Reid et al observed that 25-OHD remained 
significantly lower at 3 months post-operatively. Hence, it is possible that any 
association between vitamin D and CDH1 expression may have eluded detection due 










9.3.6 Serial sampling of circulating 25-OHD in patients undergoing 
large bowel surgery 
     To address the fluctuations of circulating 25-OHD that may result from large 
bowel surgery, serial samples of serum were prospectively collected from patients 
undergoing elective large bowel resections for colorectal cancer (n=40) that 
consisted of one pre-operative sample and five post-operative samples. There was a 
significant reduction in circulating 25-OHD levels at the first four post-operative 
time points (Figure 9.6). The reduction was observed to be largest at 1-2 days post-
op, with a diminishing effect as the number of days from surgery elapsed. At the 
final time-point (>162 days from surgery), the reduction was no longer significant, 
suggesting that circulating 25-OHD returned to baseline levels after approximately 
5.5 months.  
     Interestingly, for each individual person, the levels of 25-OHD at every post-
operative time point was very significantly associated with their pre-operative 
baseline levels (Figure 9.7). This indicates that although an operation impacted on 












Figure 9.6 Boxplots demonstrating serial circulating 25-OHD levels in patients undergoing 
large bowel resections for colorectal cancer. Each post-operative time point was compared 

























N 40 40 32 32 40 40 
p-value  8.38e-07*** 8.64e-09*** 2.32e-04*** 8.26e-03** 0.075 














































Figure 9.7 Scatterplots demonstrating the association between pre-op and post-op 25-OHD 
levels. Each post-op time point was analysed separately using a linear regression model 
adjusted for age, gender, AJCC stage and type of surgery (open or laparoscopic).  
 
 
Days after surgery p-value 
1-2 days 3.50e-08*** 
3-5 days 2.83e-10*** 
6-8 days 5.61e-09*** 
30-120 days 4.99e-12*** 
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9.3.7 Vitamin D treatment of human cell lines and colonic organoids 
     The two-way interactions influencing CDH1 expression in the normal mucosa 
implicates the vitamin D signalling pathway in the regulation of CDH1, and suggests 
that the rs9929218 SNP modifies this regulation by altering the binding of VDR-
interacting transcription factor FOXO4. To experimentally investigate these 
observations, six colorectal cancer cell lines that are homozygotes for the rs9929218 
polymorphism (AA=3, GG=3) were selected for treatment with calcitriol (1α,25-
dihydroxyvitamin D), which is the active metabolite of vitamin D. It was 
hypothesised that firstly, CDH1 expression would be induced by calcitriol, and 
secondly, this response will vary according to the rs9929218 genotype.  
     Baseline VDR, CDH1 and CYP24A1 expression were first checked for each of 
these cell lines (Figure 9.8). Triplicate time courses were carried out for each cell 
line, and the CDH1 response was calculated by the fold change from controls treated 
with the ethanol carrier at each time point (Figure 9.9). CYP24A1, a well-known 
target gene of VDR, was measured as a positive control for calcitriol-dependent 
transcriptional response (Figure 9.9). Overall, the induction of CYP24A1 appears to 
peak at 16-24 hours, with the exception of COLO205 that had a relatively small fold 
change. Baseline levels appeared to influence the magnitude of the calcitriol-induced 
fold change i.e. cell lines with higher baseline levels of CYP24A1 demonstrated 
smaller fold changes. 
     Of the six cell lines, SW480 showed the most convincing response in CDH1- a 
six-fold change was observed after 16 hours of calcitriol treatment and this persisted 
up to 48 hours (Figure 9.10). The response after 24 and 48 hours was variable 
between the replicates and hence not statistically significant, but a minimum of a 
four-fold change was still present. This large differential response may be partly due 
to the fact that baseline CDH1 levels are very low in SW480 (Figure 9.8) and the any 
absolute increase in CDH1 levels will be reflected as a large fold change. Two other 
cell lines, LS174T and SW48 also showed a significant induction of CDH1 at 16 
hours of treatment, albeit of a lesser magnitude (>two-fold change). There was no 
obvious influence of the rs9929218 genotype on the CDH1 response. However, there 
were large differences in baseline levels of CDH1 and VDR, both of which could in 
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theory influence the effect of calcitriol stimulation on CDH1 expression fold change, 
hence displacing any effect of rs9929218. Nevertheless, the induction of CDH1 
expression in three out of six colorectal epithelial cell lines supports a link between 
vitamin D and the regulation of CDH1 expression in the normal mucosa. 
     As discussed in previous chapters, the use of cell lines for assessing SNP function 
is challenging and suboptimal at best due to the cellular genomic and karyotypic 
abnormalities that they have accumulated. To address this limitation, the culture of 
colonic organoids derived from primary human large bowel epithelium was 
instigated as a non-aberrant in-vitro model system (Figure 9.11). It has to be noted 
that the organotypic culture used in this thesis is at its preliminary stages, and the 
methods are still in need of optimisation for the organoids to proliferate in a robust 
and reproducible manner. Presently, these organoids do not survive for more than 10 
days, hence, they were treated at day 5 for a comparison of CDH1 expression in 
response to calcitriol treatment. Based on the time course studies in cell lines, the 
organoids were treated for 16 hours to elicit a maximal response. A baseline level of 
gene expression was also quantified at day 0 for comparison.  
     Unfortunately, there were recurring issues with fungal infections of the organoid 
culture, and only three of the five organoid cultures survived until calcitriol treatment 
at day 5. Hence, no meaningful statistical analyses were able to be performed. Two 
of these organoid cultures were of the rs9929218 (GG) genotype, whereas one was of 
the rs9929218 (AA) genotype (Figure 9.12). Firstly, it can be observed that the two 
positive control genes, CYP24A1 and CYP3A4, have very low baseline levels. In fact, 
CYP24A1 was undetectable in two out of the three samples, which concurs with the 
expression data of the normal mucosa. Treatment with calcitriol induced a response 
in all three organoid cultures, which is reassuring of calcitriol penetration through the 
Matrigel scaffold and a vitamin D-dependent transcriptional response. Baseline 
levels of CDH1 and VDR appears to be closely matched, which again is in 
concordance with the normal mucosa expression where these two genes are very 
significantly correlated. Calcitriol treatment appears to induce a 1.5 fold increase in 
VDR expression in one of the organoid cultures, but this was not observable in the 
other two. Rather interestingly, calcitriol treatment appears to induce a small increase 
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in CDH1 in the organoids with the rs9929218-AA genotype (n=1), which was not 
seen in organoids with the rs9929218-GG genotype (n=2). However, this sample had 
higher baseline CDH1 levels at day 0, which had reduced by almost half at the point 
of calcitriol treatment at day 5  
     These preliminary results suggest that normal mucosa derived-organoids could 
serve as an effective model system to demonstrate common allele-specific effects 
that are only apparent under cellular perturbations such as a ligand-dependent 
regulation, but will require replication before a suggestion of an allele-specific 
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Figure 9.8 Baseline expression of VDR, CDH1 and CYP24A1 in cell lines selected for 






















































































Figure 9.9 CYP24A1 induction by calcitriol treatment for a series of time points in six 
colorectal cancer cell lines. A) Relative expression of CYP24A1 in LS174T is presented 
individually for the ethanol control and calcitriol treatment as fold changes cannot be 
calculated from an undetectable baseline. B) Log fold change of CYP24A1 expression 
between calcitriol treatment and ethanol control in the other five tested cell lines. Error bars 
are not presented when fold changes are calculable for only one replicate due to 














































































































Figure 9.10  CDH1 expression fold change with calcitriol treatment for a series of time points 
in six colorectal cancer cell lines, performed in triplicates. Error bars=SEM. Student unpaired 
t-tests were performed on the fold change compared to the ethanol-treated controls, * 


















































Figure 9.11 Human normal colon organoids. A) Colon crypts disaggregated from 
surrounding stroma. B) Crypts disrupted and seeded. C) Crypt like structures budding at day 












Figure 9.12 Relative expression of CYP24A1, CYP3A4, VDR and CDH1 in human colonic 
organoids derived from the normal mucosa of three patients. Each MD number represents 
crypts derived from an individual patient, with their rs9929218 genotype indicated. A baseline 
measurement was taken at day 0 after the colonic crypts were dissociated from the stroma. 
Organoids were treated at day 5 in culture with 1% ETOH (negative control) or 100nM 
calcitriol for 16 hours. Relative expression was measured by qRT-PCR, using ACTB as a 




















































































































     The chemopreventative role of vitamin D in colorectal cancer has been the focus 
of many recent studies. Various approaches have been used to estimate vitamin D 
status, including direct measures of circulating 25-OHD, surrogates or determinants 
of vitamin D such as dietary intake and sun exposure estimates (as reviewed by 
Giovannucci, 2010). Although confounding factors cannot be entirely excluded, the 
consistency of these associations with CRC are highly suggestive of a causal 
association. There have been two randomised controlled trials investigating the effect 
of vitamin D supplementation on colorectal cancer risk, both of which failed to 
demonstrate an effect on CRC incidence (Trivedi et al, 2003; Ding et al, 2008). 
However, these studies are limited by the small number of participants, low doses of 
vitamin D and inadequate trial duration to demonstrate an effect. Hence, the gene-
environment interaction between 25-OHD and a known CRC susceptibility variant at 
the CDH1 gene (rs9929218) (Zgaga et al, unpublished) is of significant interest, as 
not only does it lend weight to the suggestion of causality, it may also explain a 
proportion of the missing heritability of colorectal cancer. It is critical to identify the 
molecular mechanism underlying this relationship, as it will provide validation to the 
epidemiological findings and consequently inform the rational development of 
targeted preventative and therapeutic strategies. Given that the role of CDH1 (E-
cadherin) in cancer is well-established, it was hypothesised that this gene-
environment interaction manifests its effects on the regulation of its transcription, 
particularly as its expression has previously been shown to correlate with VDR 
expression in colorectal tumours (Pena et al, 2005).  
     The correlation of CDH1 expression in the normal colonic mucosa with VDR and 
CYP3A4, an intestinal VDR target gene, is suggestive of CDH1 regulation by vitamin 
D activity in the large bowel epithelium. The strong correlation of CDH1 expression 
with the FOXO transcription factors also implicates a role for them in the regulation 
of CDH1. The regulatory relationship suggested by these correlations have been 
previously demonstrated in-vitro using various cell line models – calcitriol-
dependent VDR regulation of CDH1 in the colorectal cancer cell line SW480 (Palmer 
et al, 2003), and FOXO-mediated regulation of CDH1 in urothelial cells (Shiota et 
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al, 2010) and kidney epithelial cells (Carew et a, 2011). A recent study demonstrated 
that ligand-bound VDR induce the dephosphorylation and activation of FoxO 
proteins to regulate common VDR/FoxO target genes in a squamous cell carcinoma 
cell line (An et al, 2010). Hence, the finding of multiple two-way interactions 
between FOXO4 levels-rs9929218, FOXO4 levels-VDR levels and FOXO4 levels-
FokI is exciting, as it alludes to a biologically plausible in-vivo co-regulatory 
relationship between VDR and FOXO4 on the expression of CDH1 that is modified 
by an established risk SNP, and provides support to the hypothesis driven by the 
epidemiological and bioinformatics analysis. However, the number of samples in this 
study is very small and must be validated independently in larger studies.    
     Circulating 25-OHD is the most frequently used biomarker of vitamin D status in 
clinical settings and epidemiological studies, as it accounts for both endogenous 
synthesis in the skin and vitamin D intake, and has been shown to vary widely in 
human populations (as reviewed by Jacobs et al, 2011). Although there is a lack of 
association between CDH1 expression and circulating 25-OHD (singularly or as a 
factor in two-way interaction analysis), it should be recognised that there are 
limitations inherent to the use of 25-OHD in associative studies, which is especially 
pertinent to the study presented in this chapter. Firstly, circulating 25-OHD may not 
effectively capture intracellular vitamin D status due to the dynamics and variability 
in local tissue-level conversion of 25-OHD to the active metabolite 1,25(OH)2D, and 
secondly, the sampling of serum 25-OHD was carried out post-operatively at varying 
time points from the treatment for cancer. As shown in the serial samples of 25-OHD 
of patients undergoing large bowel surgery, the procedure impacts on circulating 25-
OHD levels with effects lasting well beyond the hospital stay (approximately a 
week). This could be due to a combination of various factors such as re-distribution 
of vitamin D metabolites induced by a general anaesthetic, IV fluids, inflammatory 
responses, and the lack of sun exposure during the rehabilitation period. For the 
normal mucosa gene expression study, patients undergoing adjuvant chemotherapy 
were not excluded and it is also possible that this may also have an influence on 25-
OHD levels. Hence, it is very likely that 25-OHD levels used in the gene expression 
correlation study do not accurately reflect the vitamin D status of the tissue harvested 
from the surgically resected large bowel specimens. Interestingly, the results from 
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the serial samples of 25-OHD indicate that the impact of surgery on absolute 25-
OHD levels did not affect the relative levels of 25-OHD at all the time points 
examined, suggesting that sampling at a consistent time from the operation could be 
an acceptable substitute for pre-operative sampling. In other words, the time from the 
operation to sampling could be included as a variable in the regression model to 
account for the effects of surgery, which is potentially important in association 
studies of cancers where surgery is the mainstay of treatment and patients are 
recruited at varying time periods after surgical treatment. Future work should include 
further assessment of the serum 25-OHD serial sampling data using repeated 
measures analysis, as this would remove between-subjects variability and could 
improve the power of the test in detecting significant differences between means.   
     The calcitriol treatment of CRC cell lines and human colorectal organoids provide 
preliminary evidence that CDH1 is up-regulated by vitamin D activity. Going 
forward, more detailed functional studies are now required to robustly elucidate the 
mechanism of this regulation, as well as any allele-specific effect of rs9929218. 
Using cell lines that have shown a CDH1 transcriptional response to calcitriol 
treatment, immunoprecipitation and western blotting will be able to demonstrate any 
post-translational modifications of the FoxO proteins that are mediated by VDR, 
ChIP will reveal DNA-protein binding at the rs9929218 locus, and gene depletion of 
VDR and FOXO will establish the role of these transcription factors on CDH1 
transcription. EMSAs and luciferase reporter plasmids are also useful in-vitro assays 
that can show an allele-specific effect of rs9929218. Replication with the human 
organoid culture will consolidate the functional relevance in the non-transformed 
tissue state, but this may not always be technically feasible due to the limited amount 
of tissue available for the set-up of culture and the large amounts of cellular extract 
required for some of these assays. Hence, it is of interest to optimise the viability of 
the colonic crypts and the growth conditions for allow adequate expansion of the 
culture for parallel functional experiments. 
     In summary, the data presented in this chapter has demonstrated an approach 
using gene expression data derived from colorectal primary tissue, cell lines and 
human organoids to gain insight into the molecular mechanisms underlying a gene-
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environment interaction involving a common CRC susceptibility variant and vitamin 
D status. Although the evidence is largely observational and preliminary, it suggests 
that there is scope for further discovery and sets the groundwork on which further 
functional studies can be built. There is enormous potential and value in pursuing the 
molecular mechanism underlying this gene-environment interaction as the level of 
vitamin D is modifiable with supplementation, which has a relatively safe side-effect 
profile. Informed, appropriate selection of those that would benefit most from an 
improvement in vitamin D levels can potentially lead to a large impact on the 



















Summary and Discussion 
10.1 Summary 
     In the last decade, the use of GWAS on large, well-characterised case-control 
cohorts of colorectal cancer has facilitated the identification of greater than 25 
common genetic variants that carry with them an increased predisposition to 
colorectal cancer. As the majority lie within non-coding regions, the underlying 
causal mechanism is to-date poorly understood for the majority of these loci. The 
work presented in this thesis has demonstrated that a number of these genetic 
variants also influence gene expression levels, strongly suggesting that they confer 
risk, at least in part, by modifying regulatory mechanisms.  
     The hypothesis that CRC-associated genetic variants influence gene expression 
was tested by two approaches - an agnostic approach that utilised eQTL analysis, and 
a hypothesis-driven approach that specifically examined the expression of target 
genes and regulatory pathways of an established risk locus. It was thought that these 
heritable influences on gene expression are likely to be subtle, hence there was a 
strong emphasis on the methodology and production of robust data to minimise 
experimentally-induced non-biological variations and consequent erroneous 
conclusions. Chapter 3 described the development of a reproducible protocol that 
ensures the extraction of high-quality RNA from primary colorectal mucosal tissue 
for reliable gene expression profiling, whereas Chapter 4 focused the selection and 
validation of context-specific reference genes for qRT-PCR. The detection of 
differential expression profiles in relation to clinicopathological features (Chapter 5) 
allowed internal validation of the sample and data processing, and also highlighted 
the importance of accounting for these potential confounders in the subsequent 
expression analysis.  
     The systematic analysis of the association between 25 established risk loci and 
expression of cis-genes (Chapter 6) provides evidence to support the hypothesis that 
these risk loci exert their effects on CRC risk by having tissue-specific eQTL effects 
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on gene expression. Expression fine-mapping of these eQTL associations identifies 
putative functional variants, some of which are also better at predicting CRC risk, 
thus making them likely to be the causative variants. Chapter 7 follows up the 
Xp22.2 eQTL/risk locus with functional assays, validating the experimental rationale 
of cis-eQTL analysis and expression fine-mapping. By association, the target gene of 
this locus, SHROOM2, is a candidate in the predisposition to CRC. Little is known of 
SHROOM2 in the context of CRC, and Chapter 8 outlines an investigative approach 
with preliminary functional data suggesting that SHROOM2 has a possible role in 
cell cycle regulation and is likely to be expressed at the top of colonic epithelial 
crypts. 
     Although the eQTL analysis has produced risk loci-expression associations, the 
functional effects of many of the loci remain unexplained. Chapter 9 takes an 
alternative hypothesis-driven approach to understand the mechanism underlying the 
16q22.1 locus, which has recently been shown in a gene-environment interaction 
analysis to modify the protective association of vitamin D levels on CRC risk. 
Variant-expression and expression-expression interaction analyses support a role for 
the vitamin D signalling pathway in the modulation of the heritable variation in 
CDH1 expression, demonstrating a candidate-based approach in deciphering the link 
between genetic locus and CRC susceptibility.   
10.2 A hypothesis-free discovery of candidate causal 
variants and genes: utility of tissue-specific eQTL 
analysis 
     It has been established that common genetic variants contribute to the risk of 
colorectal cancer, and the post-GWAS challenge is to elucidate how these risk 
variants specifically influence the development of colorectal cancer. By examining 
the expression of cis-genes neighbouring these CRC risk variants in normal 
colorectal mucosa and matching peripheral blood, I have demonstrated at least five 
local eQTL associations for these risk variants in each of the tissue types (Chapter 6), 
agreeing with the published observation that trait-associated SNPs are more likely to 
be eQTLs (Nicolae et al, 2010). The majority of these associations were tissue-
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specific; even when the risk variants were eQTLs in both tissue types, their target 
genes did not overlap, consistent with reports in the literature that disease-associated 
variants tend to exert more cell-type specificity (Fu et al, 2012; Brown et al, 2013). 
The presence of CRC-associated eQTL in colonic and extra-colonic tissue, as well as 
the tissue-specificity they exhibit, is interesting. Assuming that the cell-type that 
harbours the intermediate phenotype of transcript abundance contributes to the 
transformation of the cell of cancer origin, the extra-colonic eQTLs suggest that 
alterations in extra-colonic cells may indirectly modify CRC susceptibility in a non-
cell autonomous fashion. This tissue-specificity also emphasizes the importance of 
selecting the relevant target tissue for the examination of eQTLs, particularly as 
previous examination of publically available LCL eQTL databases did not reveal 
convincing eQTL effects, with the exception of the 6p21.2 (Dunlop et al, 2012) and 
18q21.1 (Broderick et al, 2007), where there was some evidence of association to the 
expression of neighbouring genes. In view of the heterogeneity of cell-types and 
transcriptional signatures within the intestinal epithelial crypts, risk eQTLs could in 
fact be specific to a particular crypt compartment or a particular epithelial cell-type, 
and it would be of interest to test this hypothesis with single-cell gene expression 
analysis.     
     The two best associations were seen in the colorectal mucosa, at 11q23.1 and 
Xp22.2, with adjusted association p-values in the order of 10e-09, which fits in with 
the expectation that eQTL associations observed in the originating tissue giving rise 
to the tumour are likely to be more informative (Freedman et al, 2011). The target 
genes COLCA1, COLCA2 and SHROOM2 lie adjacent to the risk loci, and have not 
been previously known to be associated with cancer, possibly representing novel 
pathways/molecular networks that are involved in cancer initiation and progression. 
eQTL analysis of susceptibility loci in other tissue types such as the liver and 
prostate have been shown to be of value in identifying target genes that influence 
disease susceptibility (Musunuru et al, 2010; Pomerantz et al, 2010). The other three 
risk/eQTL loci identified in the colorectal mucosa were 12q13.12 (SPATS2), 8q23.3 
(UTP23) and 1q41 (HLX), but their effects were much weaker and validation studies 
will be required.  
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     In the PBMC, the eQTL effects of risk variants were also weak, but it should be 
noted that not only were the sample size considerably smaller, peripheral blood was 
obtained at inconsistent time points after the operation, increasing the variation 
‘noise’ and reducing the power to detect eQTLs. Despite this, there were significant 
cis-associations even after multiple-testing correction, targeting genes that have been 
previously implicated in cancer biology such as CERS5 (Ceramide synthase 5) and 
LIMA1 (LIM domain and actin-binding protein 1). Although eQTLs in PBMCs 
may not be as directly relevant to those detected in colorectal mucosa, they could be 
of interest as they may reflect indirect effects in immune cells that induce changes in 
the colorectal epithelium by modulating the stromal microenvironment, particularly 
as inflammatory processes are known to contribute to the development of CRC. 
Nevertheless, further study is required as it is unclear whether peripheral blood 
mononuclear cells are appropriate surrogates for mucosal immune cells. The 
association of the risk locus 20p12.3 with RP11-19D2.2, an uncharacterised long 
intervening non-coding RNA transcript is interesting in principle. Together with the 
evidence suggesting that COLCA1 and COLCA2 are also long non-coding RNAs 
(Smillie, pers. comm.), this lends support to the notion that low-abundance 
unannotated lncRNAs are transcribed from cancer risk loci and mediate risk by 
facilitating a wide repertoire of regulatory functions. Deep sequencing of transcripts 
derived from targeted regions with techniques such as RNA- CaptureSeq (Mercer et 
al, 2011) will allow targeted interrogation of different populations of RNA in relation 
to risk loci genotypes. More generally, RNA-Seq techniques have increased coverage 
over microarrays, providing the ability to look at alternative gene spliced transcripts, 
post-transcriptional modifications, gene fusion and allele specific expression. This 
would allow better definition of the transcriptome and ultimately be of greater value 
in detecting changes associated with risk alleles. 
     After the initial identification of eQTL associations, expression fine-mapping of 
these individual risk loci was performed using data from high-density genotyping 
arrays. For each eQTL loci, candidate functional variants for expression were 
compared for their effects on CRC risk, with the rationale that variants that better 
explain both target gene expression and CRC risk are more likely to be causal. Using 
this approach, candidate variants for the 11q23.1 (COLCA1 and COLCA2), Xp22.2 
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(SHROOM2) and 12q13.12 (CERS5) loci were identified. Functional assays are 
required to hone in on the causal variant – this was demonstrated for the Xp22.2 
locus in Chapter 7, where gene reporter assays showed marked differential 
transcriptional activity with Indel24 which was not seen with the tagging SNP, nor 
matched by the alternative candidate SNP rs5934685.   
     During the progress of this research, two reports of CRC risk variants exhibiting 
eQTL effects on cis-genes in colorectal tissue were published independently (Loo et 
al, 2012; Closa et al, 2014), however, not all the results were in agreement with my 
findings. Loo et al identified four genes (ATP5C1, DLGAP5, NOL3 and DDX28) at 
three risk loci with differential expression levels as a function of genotype, none of 
which were nominally significant in my samples. Closa et al’s findings matched 
more closely to those of mine, implicating the 11q23.1, Xp22.2 and 12q13.12 loci as 
local eQTLs that similarly affected COLCA1, COLCA2 and SHROOM2 expression, 
as well as additional target genes GPR143 and DIP2B. Although the independent 
replication of part of my findings is reassuring validation, the discrepancies in the 
others suggest that the eQTL analysis are subjected to errors induced by non-
biological factors such as sample sizes and study power, genotyping and imputation 
methods, microarray platforms utilised and the sampling procedure (surgery or 
colonoscopy biopsies). Both studies also examined tumour tissue as well as normal 
tissue, which could have harboured large regulatory aberrations masking the subtle 
eQTL effects associated with germline variation. Closa et al also examined trans-
eQTL effects of CRC risk loci on genome-wide gene expression, and found that two 
of the loci with cis-eQTL activity (11q23.1 and 12q13.12) also exhibited trans- 
associations with the expression of multiple genes, albeit weaker than the cis- 
associations.  Although this is suggestive that the trans- associations are related to 
common transcriptional networks, this does not exclude the possibility that trans-
eQTL activity could account for the yet unexplained function of other risk loci, as 
trans- associations tend to be indirect and hence weaker. Hence, it would still be of 
interest to examine for trans- associations in the normal colorectal mucosa, but a 
larger sample size may be required to increase the power of detection.  
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10.3 Identification of a novel causal variant and candidate 
cancer susceptibility gene at the Xp22.2 locus 
     To verify the eQTL associations identified at CRC risk loci, it is important that 
the causal variant is defined and the underlying regulatory mechanism delineated. 
The identification of the molecular mechanisms underlying the Xp22.2 eQTL locus 
is validation of the experimental rationale of examining expression as an 
intermediate phenotype. By using a combinatory approach of targeted resequencing 
and fine-mapping of the Xp22.2 risk locus with SHROOM2 expression, two 
candidate functional variants (rs5934685 and the novel Indel24) were identified to be 
more strongly associated with both expression and risk than the tagging SNP 
rs5934683 (Chapter 7). Although conditional modelling of SHROOM2 expression 
cannot exclude the possibility of independent association signals, conditional 
analysis of a case-control study supports Indel24 as the driver signal. Indeed, in vitro 
luciferase gene reporter assays indicates that the novel Indel24 is the most likely 
functional variant modulating regulatory control of transcription. In silico data from 
ENCODE ChIP-seq studies indicates that Indel24 resides within the binding sites of 
NF-YA and NF-YB, two transcription factors that bind cooperatively as two subunits 
of the trimeric NF-Y transcription factor complex. siRNA depletion of NF-YA and 
NF-YB singularly was associated with a reduction in transcription as observed by 
gene reporter activity, as well as endogenous SHROOM2 levels in CRC and RPE cell 
lines, indicating that Indel24 may be modulating transcription of SHROOM2 by 
altering the DNA-binding affinity of NF-Y. Indeed, on the minus strand, the NF-Y 
consensus binding motif CCAAT is present within the insertion allele of Indel24 
with three other CCAAT motifs flanking Indel24. The introduction of mutations to 
the CCAAT motifs in a series of reporter constructs s provided further evidence that 
NF-Y is involved in the Indel24 modulation of differential transcriptional control, 
and that Indel24 modifies NF-Y binding affinities by altering the spacing between its 
functional binding motifs and not by donating an extra binding site. Aside from 
demonstrating the function of the causative eQTL variant at the Xp22.2 risk locus, 
this work also exemplifies how structural variation at non-coding regions can 
influence the activity of control elements.  
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     The target gene of Xp22.2 eQTL, SHROOM2, is an interesting candidate for 
colorectal tumourigenesis, as it has previously been shown to have a role in cell 
morphogenesis during endothelial and epithelial tissue development (Lee et al, 2009; 
Farber et al, 2011), cytoskeletal organisation (Dietz et al, 2006), tight-junction 
stabilisation (Etournay et al, 2007) and cell contractility and migration (Farber et al, 
2011), all of which are aspects often implicated in cancer biology. SHROOM2 co-
expression analysis in the normal colorectal mucosa is suggestive of a role in cell 
cycle regulation, which is also corroborated by the transcriptomic analysis of cell 
lines with siRNA depletion of SHROOM2 (Chapter 8). Furthermore, the transcription 
factor implicated in SHROOM2’s transcriptional control, NF-Y, is known to activate 
the transcription of various cell cycle genes (Muller and Engeland, 2010), indirectly 
adding support to the postulation that SHROOM2 exerts its tumour suppressive 
effects by influencing cell cycle progression. It would therefore be of considerable 
interest for future work to include experiments that would directly implicate 
SHROOM2 in the regulation of cell cycle. The availability of compelling new tools 
recently reengineered within the unit, such as the bicistronic Fucci2a system and the 
R26Fucci2aR mouse model (Mort et al, 2014), provides an attractive collaborative 
opportunity with local expertise for the investigation of SHROOM2’s role in cell 
cycle dynamics, both in cell culture and during mouse embryonic development. In 
the planning and design of such functional assays, consideration should be given to 
the fact that aberrant gene activity of the inactive X-chromosome are often seen in 
neoplastic processes leading to perturbed dosage of X-linked factors. This is 
particularly relevant as some of these genes are known to be involved in cancer 
promotion and could confound functional phenotypes thought to be related to 
SHROOM2.      
     In the same vein as the considerations about the cell-type specificity of eQTLs, 
the localisation of SHROOM2 expression within the colorectal epithelial crypt is of 
interest as it sheds light on protein function and its role in the development of cancer. 
As a specific antibody to SHROOM2 was lacking, indirect evidence from SHROOM2 
co-expression analysis with cell-specific marker genes in the normal colorectal 
mucosa pointed towards expression in the crypt-top mature enterocytes, suggesting 
that SHROOM2 may contribute to their tumour-initiating capacity via a ‘top-down’ 
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mechanism where dysregulated cells outside the crypt-base stem cell niche 
dedifferentiate and act as tumour progenitors (Schwitalla et al, 2013; Davis et al, 
2014). RNA-FISH could be used to demonstrate the spatial distribution and tissue 
localisation of SHROOM2 transcripts, but may not be of similar utility for subcellular 
localisation. Future work should continue to focus on the generation of suitable 
antibodies, as it will be crucial in the investigation of SHROOM2 function. In 
conjunction with this, further stable loss-of-function studies in cell lines or animal 
models (e.g. mice) will be beneficial, allowing more definitive phenotype 
characterisation before ultimately progressing to dissect the more subtle phenotypes 
associated with gene dosage and eQTL effects. 
10.4 A hypothesis-driven approach: the genetic and non-
genetic modulation of target gene (CDH1) expression 
may underlie gene-environment interactions in the 
predisposition to CRC 
     Although the eQTL analysis of colorectal mucosa and PBL has provided evidence 
of regulatory function for approximately half of the CRC risk loci (Chapter 6), there 
is still a significant proportion of risk variants whose functions and target genes are 
unexplained. The reasons for this could be many; in view of the gene-environment 
interaction (Zgaga et al, unpublished) between circulating vitamin D levels and the 
16q22.1 risk locus, Chapter 9 outlines a hypothesis-driven approach which 
demonstrates that the tagging SNP rs9929218  modifies the influence of the VDR-
interacting factor FOXO4 on the target gene CDH1. By using expression levels 
derived from gene expression microarrays of the normal colorectal mucosa, multiple 
two-way statistical interactions were observed between rs9929218-FOXO4 
expression, FOXO4 expression-VDR expression, and FOXO4 expression-VDR 
polymorphism (FokI), which is in agreement with the in silico prediction that 
rs9929218 alleles possess differential FOXO-binding affinity.  It implicates a 
biologically plausible in-vivo co-regulatory relationship between VDR and FOXO4 
that is modified by an established risk SNP within intron 2 of CDH1, providing 
functional support to an epidemiological gene-environment interaction. 
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     The vitamin D active metabolite (calcitriol) treatment of CRC cell lines and 
human colonic organoids provided preliminary evidence that CDH1 expression is 
can be induced by vitamin D activity (Chapter 9). Going forward, more detailed 
functional studies are required to directly demonstrate the biological interactions 
postulated from the observations derived from static gene expression profiles. 
Having now identified cell lines with a CDH1 transcriptional response to calcitriol 
treatment, ligand-dependent immunoprecipitation, co-localisation, western blotting 
can be performed at optimal time-points to reveal post-translational modifications of 
FOXO4 that are mediated by VDR, as well as ligand-dependent ChIP to study DNA-
protein binding at the rs9929218 locus. Additionally, gene depletion of VDR and 
FOXO4 will establish the role of these transcription factors on CDH1 expression, and 
gene reporter assays will be useful to show a ligand-dependent allele-specific 
differential effect of rs9929218 that mirrors the epidemiological gene-environment 
interaction.  
     To further substantiate the link between vitamin D activity, rs9929218 and CDH1 
expression, serum 25-OHD was retrospectively collected from a subset of patients 
who had donated colorectal tissue for gene expression profiling. There was no 
association with CDH1 expression, nor were there any statistical interaction between 
circulating 25-OHD and rs9929218 or markers of vitamin D activity. Given that 
serum 25-OHD was collected at variable time points post-operatively, it may not 
have accurately represented the intracellular vitamin D status of the normal mucosa 
tissue collected during surgery. Indeed, a peri-operative time series of circulating 25-
OHD examined in a prospective cohort of patients undergoing large bowel resection 
for CRC demonstrated a post-operative reduction of 25-OHD which did not return to 
pre-operative levels for at least ~5.5 months (Chapter 9). Interestingly, the time 
series also showed that although absolute levels of 25-OHD decreased with the 
surgery, relative levels were maintained at all time-points, suggesting that the 
inclusion of the time interval, from treatment to sampling, as a co-variate may 
improve statistical modelling. This finding is of importance in the wider scheme of 
scientific study into the effects of circulating 25-OHD and CRC outcomes, as one of 
the limitations of such observational studies is that the time period between surgery 
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for the treatment of cancer and 25-OHD sampling was not constant (Zgaga et al, 
2014).  
10.5 Gender- and site-specific differential gene expression in 
the normal colorectal mucosa 
     Gene expression profiling of the normal mucosa samples used in this research 
revealed differences in gene expression that are influenced by gender and the 
anatomical site of the large bowel (Chapter 5). The gender-specific and site-specific 
differential expression detected in the colorectal mucosa is largely consistent with 
known biological processes and published literature, providing internal validation of 
the integrity of the samples, the microarray platform used and the processing of the 
data.  It also demonstrates the importance of including gender and anatomical site as 
co-variates in the eQTL analysis to optimise the detection of subtle effects that are 
associated with inherited variation of gene expression.  
     There are known epidemiological, clinical and molecular differences between 
proximal and distal colon tumours, suggesting that the risk factors and 
transformation pathways of sporadic colorectal cancer may differ according to the 
anatomical location within the colon. The analysis in Chapter 5 confirms the findings 
of previous studies that there are widespread expression differences between the 
normal mucosa of the proximal and distal colorectum. Hence, it would be of interest 
to design future studies to analyse the proximal and distal large bowel separately (as 
different target tissue), in relation to heritable variation in expression (eQTL), as well 
as the heritable risk of CRC (GWAS). Although this will compromise the sample 
size, the power of the study may not necessarily suffer if there are site-specific 
effects that are opposing in directionality. A pilot analysis utilising the microarray 
data available from the samples used in this research here may inform the utility and 





10.6 Concluding remarks 
In conclusion, the work presented in this thesis has demonstrated a functional 
approach to discover and validate the molecular mechanisms underlying the common 
predisposition to colorectal cancer, and offers promise for new levels of 
understanding on how CRC risk variants mediates risk. The revelation that some of 
these common genetic variants impart risk by influencing the intermediate phenotype 
of transcript abundance in a tissue-specific manner adds further complexity to the 
study of CRC susceptibility genes and pathways. Further identification of the 
intermediate phenotypes for all of the risk loci will be critical in order to fully 
appreciate the contribution that common genetic variation makes to the development 
of cancer. Some of this may be achieved by examining eQTLs in specific segments 
of the large bowel, specific compartments/cell-types within the colonic epithelial 
crypt, or other tissue types altogether. Alternative intermediate phenotypes such as 
trans-eQTLs, long non-coding RNA, alternative transcripts and influences on the 
epigenome are also potential areas for future investigation. The knowledge that some 
of these effects may only be unveiled when analysed in relation to environmental 
factors highlights the need for more research into gene-environment interactions, 
particularly on a molecular level. Detailed understanding of the molecular 
consequences of inherited predisposition to this common complex disease can only 
have a positive impact on understanding how CRC develop and ultimately be of 
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